MONOGRAPH ABOUT GREEN SAP, NATURAL MEDICAMENT BASED ON THE UNION OF ORIGINAL MEDICINAL HERBS’S CONCENTRATED FROM URUGUAY

 

 

 

 

 

 

 

 

 

Dr. Bernardo Udaquiola

(Oncologist, Ex  Coordinator Chief of Semiology and current Chief of Auto valid Department from the National Institute of Oncology of Uruguay, member of the expert group in introducing tunnel central venous catheters for chemotherapy and fluid perfusion)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Edited in March, 2003.

 


Contents

Dr. BERNARDO UDAQUIOLA´S CURRICULUM.. 4

INTRODUCTION. 7

DESCRIPTION OF GREEN SAP COMPONENTS. 8

MEDICAMENT´S USES AND TYPE OF ACTION. 8

Malignant prostate pathology. 12

Malignant prostate pathology: Mr. Eber Paiva. 12

Malignant prostate pathology: Mr. Héctor Tanco. 29

Malignant prostate pathology: Mr. Raúl Smith. 32

Glandular hyperplasia with atypical focuses with PIN III: Mr. Luis Mohana. 55

Malignant prostate pathology: Mr. Pablo Cordero. 57

Conclusions on anti-tumor GREEN SAP action on malignant prostate neoplasies. 63

Kidney cancer 65

Light cell kidney adenocarcinoma pathology with metastasis: Mr. Jorge Lindh. 65

Pathology: Light cell adenocarcinoma and hypernefroma: Mr. Jorge Suárez. 68

Kidney cancer: Mrs. Irma Renoldi 82

Pathology: Wilms’ tumor: María Tabares. 87

Conclusions on GREEN SAP action on Kidney Neoplasies. 91

Malignant Ependimoma. 93

Malignant Ependimoma Pathology: E. Benegas. 93

Malignant Ependimoma Pathology: Mauricio Ruiz. 106

Oligodendroglioma-glioblastoma Pathology: Sirvart Doganian. 109

General conclusions on the GREEN SAP anti-tumor action in the Central Nervous System. 127

Rectum cancer 129

Rectum cancer: Mr. Luis Peralta. 129

Conclusions on GREEN SAP action on malignant neoplasies of colon and rectum. 131

Lung Cancer 144

Lung Cancer with Brain Metastasis: Mrs. Liliana Calzada. 144

Lung epydermoid cancer: Mr. Honorio Pereira. 163

Conclusions on GREEN SAP Action on Lung-Bronchium Carcinomas and its Metastasis. 165

Pancreatic Cancer 167

Pancreatic cancer: Mrs. Herminia Andarnello. 167

Conclusions on GREEN SAP Action on Pancreatic tumours. 176

Thyroid Cancer 177

Thyroid Cancer: Mrs. María Pilani 177

Conclusions on GREEN SAP Action on Thyroid tumours. 189

Vulva-vaginal Carcinoma with  Metastasis. 190

Conclusions on GREEN SAP Action on vulva-vaginal neoplasms. 193

Conclusions on GREEN SAP Action on skin neoplasms. 194

CONCLUSIONS. 195

OPINION OF SOME HEALTH PROFESSIONALS WHO HAVE EXPERIMENTED THE USE OF THE MEDICAMENT IN THEIR PATIENTS. 197

Dra. Araceli Tashjian. 197

Dra. María del Carmen García. 197

Dr. Joaquín Velarde. 198

Dr. Miguel Aristy. 200

Dr. Carlos Eduardo Medina. 200

Some E-Mails received from patients treated with GREEN SAP. 202

HYGIENIC-DIETETIC RECOMMENDATIONS - Special for patients being treated with GREEN SAP: 288

 

 


Dr. BERNARDO UDAQUIOLA´S CURRICULUM

 

      NCP: 55497

·         Medicine doctor withdrawn from the University of the Republic of Uruguay on April 28th., 1992.

·         Oncology postgraduate from Medicine University, December 22nd., 1999.

·         Oncologist doctor from the Oncology National Institute from January, 1994 until present.

·         Doctor of Preventive Policlinics of the Oncology National Institute from 1994 until present.

·         Collaborator doctor of the Breast Cancer National Program from 1992 until present.

·         Retainer doctor (hospitalization floor, radio, policlinics, emergency and Special Care Unit) in Uruguay-Spain Hospital from March 23rd., 1993 to May 17th., 1995.

·         Substitute doctor in Uruguayan Medical Hospital from 1995 to 2000.

·         Oncologist doctor in National Civil Employees Association, afterwards COMAEC, from 1994 to 2001.

·         Interviewer doctor in the World Health Organization (1992)

·         Doctor with largest casuistic in the last 5 years in the PRONACAM (National Program against Breast Cancer)

·         Scientific search on GREEN SAP drops action in the treatment of malignant neoplasies, from April, 2000.

 

PUBLISHED SCIENTIFIC RESEARCHES.

 

  • Spleen carcinomatose metastases. Communication of a pathological clinical case and revision of the splenectomies at Clinics Hospital in a 10 years period (1982-1991), research presented at the Medical and Pediatric Oncology Society of Uruguay on March 17th., 1993.
  • Results of the survey on the situation of the opportune detection of breast cancer, presented on the Second Journey of PRONACAM, November 18-19th., 1993.
  • Study on descriptive epidemiology regarding 6170 breast exams, presented on the Second Journey of PRONACAM, November 18-19th., 1993.
  • Evaluation on the impact of PRONACAM in the INDO for the 4 years of its establishment, presented on the IV Journeys of PRONACAM, October 27- 28th., 1995.
  • External Jugular central venous via with standard catheter, presented in the Uruguayan Surgery Society on September, 4th.,1996, and in a round in the 5th. Oncology Uruguayan Congress.
  • Evaluation on the impact of the PRONACAM in the INDO, at the V Journeys of the PRONACAM, October 25-26th., 1996.
  • External Jugular venous via with standard catheter, published in the Uruguayan Surgery Magazine, 1997; 67 (1): 40-42.

 

Abroad clerkships.

  • Curie Institute in Paris, France, April 1999.
  • Saint Louis Hospital in Paris, France, April 1999.

 

Distinctions.

  • Special Distinction to the Doctor with the largest casuistic at the II Journeys of PRONACAM, November 19-20th., 1993.
  • Special Distinction to the Doctor with the largest casuistic at the III Journeys of the PRONACAM, September 9th., 1994.
  • Special Distinction for the scientific research presented at the III Journeys of the PRONACAM, September 9th., 1994.
  • Special Distinction for the Doctor with the largest casuistic at the IV Journeys of the PRONACAM, October 27-28th., 1995.
  • Special Distinction for the Doctor with the largest casuistic at the V Journeys of the PRONACAM, October 25-26th., 1996.
  • Special Distinction for his activity in the PRONACAM, occupying the third place among more than 1.000 technicians adhered, VII Journeys of the PRONACAM, November 20th., 1998.

 

Congresses and symposiums participation.

 

  • II Regional Symposium of arterial hypertension of U.S.C.As. II Symposium of the hispano-american society of arterial hypertension, I.M.M., Montevideo, June 27-29, 1985.
  • First Uruguayan Oncology Congress, Montevideo, October, 1986.
  • II Oncology Journeys of the interior of the Republic, Salto, October 1-4th., 1987.
  • Clinic Symposium of clinic-therapeutic actualization of MUCAM, Montevideo, April 23rd., 1988.
  • Actualization Journey about mitral valve prolapse, SUC, Montevideo, June 3rd., 1988.
  • First River Plate Encounter, Fourth Argentinean Encounter of mediastine lymphatic group “Lung Cancer”, Punta del Este, November 10-12th., 1989.
  • Actualization course on child-young endocrinology, Montevideo, July 25-26th., 1991.
  •  VIII Pan american Congress of Neurology, Satellite Symposium about brain ischemia, therapeutic criteria, I.M.M., Montevideo, October 10th., 1991.
  • Fifth Actualization Course of Internal Medicine, Montevideo, June 26th., 1992.
  • Course on Medical Mycology, INDO, Montevideo, July 29-30th., 1992.
  • First Journeys of the PRONACAM, UTE Holliday Park, November 13-14th., 1992.
  • Oncology actualization journey, Head and Neck Cancer, Breast Cancer, Montevideo, April 1st., 1993.
  • V Journeys of Oncology actualization, Montevideo, June 11th., 1993.
  • Journey about the heterogeneity of breast cancer II stage, sub-clinic breast cancer, man breast cancer, epidemiology, diagnoses and treatment, Montevideo, July 16th., 1993.
  •  French-Uruguayan Journeys of Cancerology, Montevideo, September 20th.-October 15th., 1993.
  • III Actualization Journeys and perfectionism on colon-rectum-anal pathology and surgery, Montevideo, November 1993.
  • II Journeys of the PRONACAM, UTE Holliday Park, November 19-20th., 1993.
  • III Journeys of the PRONACAM, Public Health Ministry, September 9th., 1994.
  • III Oncology Uruguayan Congress, Montevideo, December 5-9th., 1994.
  • First International Symposium on oncology research advances, INDO, Montevideo, April 27-28th., 1995.
  • IV Journeys of the PRONACAM, Solis Resort, October 27-28th., 1995.
  • Informative Meeting Post-ASCO, Buenos Aires, 1996.
  • V Journeys of the PRONACAM, Solis Resort, October 25-26th., 1996.
  • Oncology Congresses in Uruguay, Montevideo, December 9-12th., 1996.
  • VII Journeys of the PRONACAM, Public Health Ministry, November 20th., 1998.
  • V Oncology Uruguayan Congress, Montevideo, November 26-29th., 1998.
  • XIX Work Meeting of the AAOC, XIV Clinical Oncology Argentinean Congresses, XV Clinical Oncology River Plate Journeys, Buenos Aires, June 24-27th., 1999.
  • XI Clinical Oncology Brazilian Congress, Florianópolis, September 27th.-October 1st., 1999.
  • II Oncology Meeting ESMO, American South Cone, Punta del Este, December 3rd., 1999.
  • Integrated Oncology congress 2000, Buenos Aires, April 15th., 2000.
  • Second Argentinean Conference on Cancer, Buenos Aires, April 17-19th., 2000.
  • 36th. Annual Meeting of the American Society of Clinical Oncology, New Orleans, L.A., U.S.A., May 20-23rd., 2000.
  • New perspectives on the management of respiratory infections, Montevideo, June 29th, 2000.
  • IX Journeys of the PRONACAM, Montevideo, November 25th., 2000.
  • X Journeys of the PRONACAM, Paysandú, November, 2001.

 


INTRODUCTION.

 

GREEN SAP medicament is  100% natural, elaborated in base of  3 herbs, BACCHARIS ARTICULATA, PLANTAGO MAJOR, ROSMARINUS OFFICINALIS, without side effects and medicaments interactions so it can be administered together with allopathic and/or homeopathic treatments.

    As a Oncologist I was interested in searching any natural therapeutic that could help my patients to pass this awful experience that is to have cancer.

    In spite my allopathic formation my conduct is to treat not to private the oncological patient any therapeutic resource, just be traditional or product of alternative medicine.

    I dedicated myself to search in nation and interantional bibliography and pharmacopeas about medicinal plants that have antitumoral, antioxidatives and inmunemodulator properties, to develop a product, wiht natural origin, non agresive, to treat the cancer searching improve the quality of life of oncological patient, knowing that not only must attack the tumor but only must contemplate the patient.

So I  conformed a multidisciplinary team integrated by profesionals of differents areas between them we find veterinarians, Pharmaceutical Chemist, Agronomus Engineer, Biochemical Licenciated and Biology, as others investigators of different countries so as to joint efforce to follow this objective.

It starts so the selection of herbs’s stage, choising the ones that have tumoral action. According to its formulation this one has caracteristics of an homeopathic complex, in relation to Schwabe’s pharmacopea.    

 

The active principles act from the interior of the organism, having in some opportunities local action when it’s necessary.

It’s of easy absorption, being its molecules integrables to huma plasma quickly which is one of the elements that give its therapeutic versality and its action’s perfile, following differents phases that improves the delicate human homeostatic system to obtain the excellency of its action in differents diseases and also the optimisation of health till to  recover previous levels of it or directly improve it; to levels that the body in this case ill didn’t get in, reaching it by the administration of this product so natural as the soil where developpe its components.

 

 

 

 

 

 

 

 

HERBS’S PROPERTIES THAT COMPOSE GREEN SAP:

 

 

BACCHARIS ARTICULATA

 

Baccharis Articulata (Carqueja) has antioxidative property (1), antiviral propertyl (2), antiulcerative property (3), hepatoprotective and colague property (4), as cytotoxic (5) (6) (7)(8) and antimicrobial (9).

 

ROSMARINUS OFFICINALIS

 

Rosmarinus Officinalis (Romero) has also antiproliferative activity (10) (11) (12)

 

 

PLANTAGO MAJOR

Plantago Major has cytotoxic and inmunomodulative activity (13) (14) (15) (16) (17), also has an antialergenic action (18) (19), as antitumoral property (20)(21). Besides has an antiviral activity. (22)

 

 

 

DESCRIPTION OF GREEN SAP COMPONENTS

Thriterphenal Steroids, Steroidal Glycosids, Crisosaponic Acid, Santonine, Absintine, Resinic Acid, Luteoline, Quercetine, Acacetine, 7,4-dimetil-Apigenine, Cirsimaritine, Salvigenine, Jaceidine, Esculetine, jaceosidine, Oleanolic Acid, Lupeol, Chonodrillasterol, Arabionogalactan, Ramnogalacturonana, Grucomanan, Tanines, Fenocarboxilic Acids. Flavonoids: Apigenol, Luteolosid, Reductant Sugars.

Mineral saults (Zn, Si, K). Iridoid Heterosids: asperulosids, aucubosids, catalpol.

Solvent and Excipients.

 

DEVELOPMENT OF THE INVESTIGATION

 

In vitro studies were made, toxicity studies at Biochemical Catedra of Chemist Faculty of Buenos Aires University, where was demonstrated its inocuity.

Besides were made stability studies at Pharmacognosy Catedra at Chemist Faculty of Uruguayan University, that showed the viability of the product in time.

After the obtaining of this formulation were started “in vivo” proofs in animals that made by a Veterinarian Doctor Carlos Rodríguez, who obtained  results with the one, in this cases were injected peritumoral and sometimes intratumoral.

This way with the results obtained the patients of my private activity opted to proove this product, obtaining very good results, as other collegues from more than 14 countries.

Due these ones, it’s why we decide to make scientific studies in a Official Institute, that guarantee these properties.

For this reason  “in vitro” studies at CEFYBO, dependent of Ministry  of Education, Science and technology dependent of Argentine Republic Presidence.

 

 

 

 

 

 

INFORM ABOUT THE EVALUATION OF EXTRACT NAMED GREEN SAP AND OF ITS INDIVIDUAL COMPONENT ON CELLS BW5147 PROLIFERATION.

 

 

I. DESCRIPTION:

 

The anti proliferate action of GREEN SAP product was evaluated on lymphoma murine cells BW5147 in vitro by dosage-answer curves and at different times of exposition to these products, in cultures of them in presence and absence of this herbal extract, of its individual components or the vehicle.  The proliferate answer was determined by the technique of [3H]-timidine ([3H]-TdR) incorporation to cellular DNA and later evaluation  of the nuclear radioactivity by spectrometry of liquid twinkle.

 

 

II. METHODOLOGY’S ESPECIFICATION :

 

1- Herbal Extracts :

 

The herbal extracts evaluated correspond to the following description:

 

1-     Mother Tincture (MT): Correspond to a tincture made by the mixture of three individuals tinctures, to know: Baccharis articulata’s tincture 40 % v/v; Rosmarinus officinalis’s tincture 40 % v/v and Plantago major’s tincture 20 % v/v. The alcoholic content of mother tincture is of 50 %. 

 

2-     Final Product  1 (FP1) or GREEN SAP: Correspond to a dilution  1/10 of mother tincture in water (Baccharis articulata’s tincture 4 % v/v; Rosmarinus officinalis’s tincture 4 % v/v ,  Plantago major’s tincture 2 % v/v and alcoholic content of 5 % v/v).

 

3-     Final Product 3 (PF3): Correspond to a dilution  1/10 of mother tincture, with an alcohol aggregate till a final concentration of 15 % v/v.

 

 

2- Lymphoma murine line:

 

The line used correspond to a lymphoma murine T, denominated BW5147, proceeding from a spontaneous tumor of mouse AKR/J adapted to culture, originated in the Jackson Laboratories, USA.  The one is sensible to cortisol (10-6 M) and express the haplotype H-2k and the following markers: CD3+, receptor T ab and Thy 1.1, these one are routinely checked by cytometry of flux with specific monoclonal antibodies.

 

 

3-Conditions of culture and evaluation of cellular proliferation:

 

The cells BW5147 (3-5 X 105 cel/ml) were cultured in medium RPMI 1640 supplemented with 10% of bovine fetal serum and 2 mM of glutamine in presence of antibiotics penicillin (100U/ml) and  streptomycin (100µg/ml), in plates of 96 cups (final volume  0.2 ml), in  conditions of sterility (laminar flux, Sterilized Guard Hood class II, Type a/B3; mark: Baker Company, model: SG-400m), and in gasified ambient with 5% of CO2 (gasified stove of CO2; mark:  Scientific form; model: 3111). It have been made cultures with increased concentrations of the herbal extracts already mentioned for 24, 48 and 72 hs of incubation. The cells were pulsed with 0.75 µCi/cup de [3H]TdR (S = 25 Ci/mmol) 16 hs before the sacrifice of cultures (by freezing at -20 ºC).

Later the cultures were unfreezed and filtered by glass fiber’s filters, Whatmann GF/A. The [3H]-TdR  incorporated to nuclear DNA and stopped in these filters was quantified by spectrometry of liquid twinkle using cocktails of commercial twinkles. The results (obtained in dpm) were expressed as Percentage of inhibition (% Inhib) considering as 100% a the dpm obtained in absence of extract and/or in presence of vehicle.

 

 

4-    Determination of cellular viability:

 

The cellular viability in different times in presence or absence of MT and FP was evaluated by microscopic cellular count in Neubauer’s camera, using a colorant of exclusion, the Blue  Tripan. The correspondents % of viability were calculated taking into account the quantity of alive cells (that don’t include the exclusion colorant) with respect to the total cells (Alive + Death, just to say the cells that incorporate the colorant and are seen blue colored at microscopic observation).

 

 

5- Statistic analysis of results:

 

The results were analyzed by the Student’s Test and Varianza Analysis followed by Dunnet’s  test to determine the significant differences between groups. The values were considered  statistically significant when p £ 0.05.

 

III. RESULTS

 

 

1.       Action anti-proliferate dosage-answer of herbal extracts on cells BW5147 at 24 hs’s culture:

 

TABLE 1: Percentage of proliferate inhibition of lymphoma T cells induced by increased concentrations of GREEN SAP, of its mother tincture and of FP3, at 24 hs of culture.

 

DILUTIONa

MT

DILUTIONa

FP1

FP3

% Inhibb

% Inhibb

%  Inhibb

1/25

93.3 ± 2.9*

1/2.5

N.D.

N.D.

1/100

79.5 ± 5.9*

1/10

84.7 ± 3.6*

85.3 ± 3.9*

1/250

60.3 ± 2.5*

1/25

71.4 ± 3.1*

71.1 ± 7.7*

1/500

51.5 ± 3.4*

1/50

44.4 ± 5.2*

45.0 ± 4.0*

1/1000

30.8 ± 3.5*

1/100

23.7 ± 5.1*

49.0 ± 2.5*

1/2000

22.2 ± 3.7#

1/200

17.0 ± 2.5#

28.7 ± 2.4*

1/4000

10.7 ± 1.1

1/400

5.1 ± 0.9

22.7 ± 2.6#

1/8000

6.0 ± 0.7

1/800

1.1 ± 0.8

5.2 ± 0.5

a  There were used correlatives dilutions of MT and FP according to its proportion in MT. The total volume of dilution of herbal products added was  0.02 ml, maximum volume  that can be added without diluting the contribution of nutrients in the culture medium. It must be remarked that for this reason hasn’t been evaluated (N.D. = not determined) the dilution FP1 and FP3 (1/2.5) is equivalent to dilution 1/25 of MT.

b The percentages of inhibition were calculated considering as 100% the radioactivity of [3H]-TdR incorporated in basal cultures  (to say, in absence of herbal product): 24024 ± 1206 dpm.  It’s remarkable that the presence of 1.5 and 2 % of alcoholic vehicle (alcoholic content of the dilution 1/25 of FP3 and of MT respectively) stimulates cellular proliferation in about 25 % . All the others dilutions of herbal extracts were made maintaining a constant final concentration of alcohol of 0.5% that didn’t affect basal proliferation. The results showed are the average ± E.S. of n=5 experiments made by triplicate.

* Defers significantly from the basal with p £ 0.01

# Defers significantly from the basal with p £ 0.05

 

 

 

2.       Action dosage-answer of individuals tinctures on the proliferation of BW5147 cells at  24 hs of culture:

 

 

TABLE 2: Effect of increased concentrations of individuals tinctures on BW5147 cells.

 

 

DILUTIONa

PLANTAGO (P)

CARQUEJA (C)

ROMERO (R)

%  Inhibb

%  Inhibb

%  Inhibb

1/25

26.0 ± 0.8#

56.8 ± 6.5*

92.0 ± 2.8*

1/50

         13.8 ± 8.6

38.5 ± 2.5*

85.8 ± 5.1*

1/100

1.5 ± 0.3

         24.8 ± 7.2

70.0 ± 8.5*

1/500

1.4 ± 0.1

1.6 ± 0.1

1.6 ± 0.1

 

a Each extract of individual tincture was diluted in culture’s medium containing a final concentration of alcohol of 50% and in the same proportions that are contained in MT. In the plate was made a positive control correspondent to the dilution 1/25 of MT with the one was obtained in all the cases a  % Inhib ³ 94%.

b The percentages of inhibition showed are the media ± ES of n=2 determinations made by triplicate and were calculated as was explained previously.

* Defers significantly from the basal with p £ 0.01

# Defers significantly from the basal with p £ 0.05

 

 

 


 

3.       Action anti-proliferate dosage-answer of herbal extracts on BW5147 cells at  48 hs of culture:

 

 

 

TABLE 3: Percentage of inhibition of lymphoma T cells induced by increased concentrations of GREEN SAP, of mother tincture and FP3, at 48 hs of culture

 

DILUTIONa

MT

DILUTIONa

FP1

FP3

% Inhibb

% Inhibb

%  Inhibb

1/25

99.4 ± 0.1*

1/2.5

N.D.

N.D.

1/100

99.4 ± 0.4*

1/10

98.8 ± 0.9*

99.5 ± 8.0*

1/250

91.2 ± 0.8*

1/25

97.4 ± 6.4*

98.8 ± 7.0*

1/500

80.0 ± 0.5*

1/50

86.4 ± 2.7*

87.5 ± 6.0*

1/1000

38.8 ± 0.9*

1/100

31.0 ± 0.4*

73.7 ± 1.2*

1/2000

25.1 ± 1.1*

1/200

13.8 ± 1.1#

30.6 ± 2.0*

1/4000

9.7 ± 0.2

1/400

    11.5 ± 3.8

24.0 ± 2.1*

 

a  There were used correlatives dilutions of MT and FP as was described in Table 1.

b The percentages of inhibition were calculated taking as 100% the radioactivity of [3H]-TdR incorporated in basal cultures: 32360 ± 1165 dpm.  At 48 hs of culture weren’t observed significant differences with con 1.5% and 2 % of alcoholic vehicle (dilution 1/25 of FP3 and MT, respectively) respect to basal proliferation. All the other dilutions of herbal extract were made maintaining a constant final concentration of alcohol of 0.5% that didn’t affect the basal proliferation. The results showed are the average ± E.S. of n=5 experiments made by triplicate.

* Defers significantly from the basal with p £ 0.01

# Defers significantly from the basal with p £ 0.05

 

 

4.       Action anti-proliferate dosage-answer of herbal extracts on BW5147 cells at 72 hs of culture:

 

TABLE 4: Percentage of inhibition dosage-answer induced by GREEN SAP, its mother tincture and FP3 on the proliferation of  lymphoma T cells at 72 hs of culture.

 

DILUTIONa

MT

DILUTIONa

FP1

FP3

% Inhibb

% Inhibb

%  Inhibb

1/500

54.1 ± 6.8*

1/50

61.2 ± 6.8*

64.5 ± 5.1*

1/1000

49.0 ± 4.0*

1/100

40.1 ± 2.8*

46.0 ± 4.6*

1/2000

39.3 ± 3.1*

1/200

20.6 ± 1.1#

26.1 ± 3.0*

1/4000

29.0 ± 4.8#

1/400

    19.4 ± 1.7

28.8 ± 1.7*

 

a There were used the correlatives dilutions of MT and FP as was described previously.

b The percentages of inhibition were calculated taking as 100% the radioactivity of [3H]-TdR incorporated in basal cultures: (16781 ± 1188) dpm. In all the dilutions was maintained a 0.5% of alcoholic content that didn’t modified the basal proliferation.

The results shown are the average  ± E.S. de n=5 experiments made by triplicate.* Defers significantly from the basal with p £ 0.01#. Defers significantly from the basal with p £ 0.05

 

 

5.       Action of herbal extracts on the viability of BW5147 cells at different times of culture:

 

TABLE 5:  Effect of MT and FP3 on the viability of cultures cells at different times of the study

 

TIME

(hours)

% VIABILITYa

MT

FP3

1/500

1/2000

1/4000

1/50

1/200

1/400

24

61.3 ± 10.9#

  84.7 ± 5.1

  71.7 ± 2.0

72.5 ± 11.4

  72.0 ± 6.6

  85.6 ± 4.5

48

 50.3 ± 11.3*

  80.3 ± 4.1

  76.7 ± 0.6

49.0 ± 9.8*

  77.0 ± 3.3

76.7 ± 2.9

72

 34.3 ± 1.0*

76.7 ± 1.9*

84.3 ± 2.8#

24.3 ± 1.2*

60.4 ± 2.3*

80.6 ± 2.8*

 

 

a  The % of viability at each time (average ± ES of n=3 experiments) were calculated taking into account the quantity of alive cells (that not include the exclusion colorant Blue Tripán) respect to the total cells (alive + death: cells that incorporate the colorant and are seen of color blue at microscopic observation). The results are compared with the averaged values correspondent to the basal and to the incubated cells by the same times in average with 0.5% of alcohol, which are detailed at continuation:  (95.3 ± 1.2) %, (94.0 ± 1.4) % and (94.3 ± 1.0)% at 24, 48 and 72 hs, respectively.

* Defers significantly from the basal values with p £ 0.01

# Defers significantly from the basal values with p £ 0.05

 

 

CONCLUSIONS:

 

1-    It’s observed an inhibitory effect (Fig. 1-3, Tables1, 3 y 4) of the proliferation of lymphoma T murine BW5147 cells induced by herbal products MT, FP1 and FP3. This effect is concentration dependent. It’s observed in the 3 times studied, 24, 48 and 72 hs of culture. It’s maximum at 48 hs of culture to the highest dosage and it’s seen a potency action at 72 hs of culture of the effects induced by the bigger dilutions. In this time it must be considered however the possible contribution to inhibition mechanisms by contact between the cells in culture, that duplicate every 12-14 hs (Cremaschi et al, J. Neuroimmunol, 2000, 110: 57).

2-    It’s been found concordance between the effects exercised by FP and MT, in the three times studied.

3-    The evaluation of the effects of the extracts of individual tinctures diluted and tested in the same proportions that the ones contained in MT, permit to verify a synergic effect of the three components (Table 2, Fig. 4).

4-    The microscopic observation with an exclusion colorant permit infer that also FP as MT has a cytostatic effect at 24 hs that didn’t modified significantly cellular viability, however with the time it seems to occur a cytotoxic effect that can’t be discharge the participation of inherent factors to cellular culture (Table 5, Fig. 5 y 6).

 

Final Conclusion: Also MT as its FP exercise an anti proliferate effect overwhelming on lymphoma T BW5147 that justify to prosecute with the evaluation of their action on the biological behavior in lymphoma.

 

 

 

Figure 1: Percentage of inhibition of the proliferation of lymphoma T cells dosage-answer induced by mother tincture at different times of culture.

 

 

 

Figure 2: Percentage of inhibition of lymphoma T cell’s proliferation  dosage-answer induced by final product 1 (FP1) at different times of culture.


Figure 3: Percentage of inhibition of lymphoma cell’s proliferation dosage-answer induced by final product 3 (FP3) at different times of culture.

 

 


Figure 4: Percentages of inhibition of BW5147 cell’s proliferation induced by individuals tinctures.

 



Figure 5: Effect of mother tincture on the viability of BW5147 cells at different times of culture.

 

 

 

 

Figure 6: Effect  of final product 3 (FP3) on the viability of BW5147 cells at different times of culture.

 
 


 

 

 


GREEN SAP MECHANISM OF ACTION

 

The synergism of the 3 components of GREEN SAP would be the cause of the remarked anti-tumor effect which has been demonstrated in the practice.

Based on Raziner’s studies 1992 and Lithander A.´s 1992 we conclude that it has a beneficial play part against liver carcinogenesis.

One of GREEN SAP components is used to prevent cases of chronic gastritis, stomach-duodenal ulcers, diabetes and wounds. This herb is approved by the pharmacopoeias of Bulgaria, France, Japan (seed), Indonesia, Korea, Philippines, Vietnam, Argentina and Paraguay.

This component reduces the lipid profile of the patients, this reduction not being affected by the loss of bilious acids (which present lipids in their contents) in the lees. Among the proposed mechanisms for the cholesterol reduction the most important is related to an interference in the reabsorption of the bilious acids, as well as an elimination of the mucilage in the intestinal reabsorption of the cholesterol, what promotes its elimination (Goodman y Gilman, 1991).

In other way, the topical GREEN SAP application, experimentally inhibits the initiation and progress of epidermic tumors, induced by benzopirens and 7,12 dimetilbenzoantracen with a 40 to 60 % of efficacy, based in Huang M. et al. 1994.

Besides the continuous administration of GREEN SAP, has a preventive effect on breast tumorgenesis, experimentally induced with 7,12 dimetilbenzoantracen with an efficacy next to 47 % (Singletary K. et al. 1991; Singletary K. et al. 1997).

Helvetian’s researchers from Nestle Research Center found out that extracts from this herb prevent DNA’s damages of cell cultures caused by aflatoxin a potent liver carcinogenic. Such activity would be determined principally by the action of two antioxidants (carnosol and carnosic acid) (Offord E. et al., 1997).

In an oncology level preliminary studies have been performed with GREEN SAP components either south-american and European in citotoxic tests, interactions being observed with tumor cell’s DNA (its pro-oxidation) and some favorable results in leukemia, what makes an investigation way promissory in this field (Arizona, M. et al., 1985; Jorbis B. et al., 1988; Mangelli E. et al., 1996).

Among the biological actions demonstrated in GREEN SAP can be mentioned in the digestive system the anti-ulcerous activity in Indometacine ulcer-induced models which mechanism of action would be based in a lower mobilization of intracellular calcium (Gamberini and Lapa A. 1992) and the liver-protective and colagogue action demonstrated by its flavonoids. The entireness of them demonstrated to improve between a 25 % and a 100 % the survival percentage of phalloidine intoxicated rats in a 20 mg/kg intravenous dosage.

The most active resulted hispiduline (Soickee H. and Leng Peschlow E., 1987).

The synergy among the herbs that compound GREEN SAP, have a marked anti-tumor effect and a high liver-protective effect.

Also GREEN SAP presents an stabilization effect on the membrane potentials, which would benefit the balance so that the cell does not switch its proliferation towards a malignant.

 

INVESTIGATION ABOUT THE FLAVONOIDS THAT COMPOSE GREEN SAP

 

The flavonoids are phenolics composed that are the part not energetic of human diet. They are found in vegetables, seeds, fruits, etc. They have the non oxidative and eliminative of free radicals activity. In lots of investigations has been demonstrated its antiinflamatory, antialergenic effect, and also a protective role against diseases like cancer.

These chemical substances can’t be produced by the human body, for this reason must be obtained by the food or in supplements.

The flavonoids contains in its chemical structure a variable number of hydroxil phenolics groups and excellents properties of iron quelation and others metals of transition, this gives them a great antioxidative capacity. For this, they take an esential role in the protection against process of oxidative hurt, having therapeutical effects in different patologies as cancer.

Their antirradicals free properties acts fundamentally to hydroxile and superoxyde radicals.

Between the flavonoids we found:  Citroflavonoids: QUERCITIN (the one that will be the center of our atention as its predominance in GREEN SAP. Hesperidine, naranjin and limoneno.

                                                         Isoflavonoids: Genistein and daidzein.

                                                         Proantocianidins.

                                                         Antocianidins.

                                                         Elagic acid.

                                                         Catequin.

                                                         Kaemferol.

 

QUERCITIN

 

Its antioxidative activity is because it is a great remover of free radicals, exercising a cytoprotective role in danger situations of cellular damage.

Its antitumoral activity is related with the antimutagenic action mechanism and antioxidative power that it has.

It has been used in antitumoral eschemes with sinthetics drugs showing a increase of this activity. Between this studies we account with:

 

1)     Quercitin with Cisplatin increase the efficacy of this against LXFL529 cells and lung cancer in humans and rats.

2)     Quercitin  with Adriamicin potence its activity in cases of MCF-7 breast resistant  cells.

3)     Quercitin with Busulfan increases to the double the activity of her in cases of leuchemia mieloide cronic.

 

Also in tumoral human cells cultures (colon, estomach and ovary) has demonstrated stop the proliferative process, afecting the cell in the cicle G1-S of transition phase.(29) (30)

 

Besides it has been demonstrated its activity at inmunological level, renforcing it in especial on gastrointestinal tract.

Quercitin’s antioxidative action shows sinergic effects with vitamine C. Ascorbic acid reduces the quericitin oxidation, so the combination with her allows the flavonoid maintain its fonctions antioxidatives for more time.

At liver level it has been described that quercitin has an hepatoprotective effect, preventing lipidic peroxidation, attenuates colagen deposits and hepatic fibrogenesys process.

 

PROTOANTOCIANIDINS

 

At central nervous system, the flavonoids protoantocianidics by its properties of being liposolubles and hydrosolubles, these can get through hematoencephalic barrier and this way protect brain cells, that they are sensibles to the lesions producec by free radicals.

Other property that present these flavonoids is to increase the efectiveness of natural killer cells of inmunological system.

 

TREATMENT STAGES.

It is a personalized treatment which depends on the evolution of each organism that receives the medicament. It is divided in 5 big stages:

1.    Assimilation: it concerns the good acceptation of the medicament by the patient, generally we must wait to acquaint this stage 15 days.

2.    Contention: it lasts in accordance to the disease, more or less 3 months. After this stage is finished the individual’s biochemistry must be performed and its evolution until this moment is studied.

3.    Effectiveness’ valuation of the product according to the obtained analyses: different variables are presented such as: A. Reduction of tumor’s size due to its necrosis, if  it is these case it is suggested a maintenance dose of 60 drops twice a day half an hour before meals. B. Partial reduction of the tumor or in case of metastases, its disappearance or reduction. It is suggested to keep the actual dosage and in the future according to the patient’s evolution take new analyses for evaluation performed. C. Actual improvement of the patient in these cases it is suggested 60 drops once a day in fast in the morning GREEN SAP.

4.    If the tumor keeps under control and the improvement is evident it is recommended 6 months with a dosage of 30 drops once a day in the morning.

5.    Complete remission of the pathology, patient with actual improvement. We advise at this stage in which the patient is in a good state of health, the annual ingestion of 30 drops in the morning, to avoid recurrence of the tumor or tumors or the appearance of metastases.

 

 

GREEN SAP’S USES AND TYPE OF ACTION

 

GREEN SAP is administered under the tongue, avoiding this way the pass through the liver, being absorbed directly.

Besides in case of not being able to administer it this way, can be administered orally, diluted in orange juice, this is explained by the synergism between the quercitin (flavonoid present in GREEN SAP) and vitamine C, that potences its effects. In cases of patients without oral way, it can be administered by nose-to-stomach catheter by syringe or by stomach-ostomy or jejune-ostomy, making a dilution of 1 cc of phisiologic serum .

 

GREEN SAP’S SIDE EFFECTS

 

About side effects of this product, we don’t have in our casuistic of more than 3.000 patients notices about any kind of allergenic reaction,  just be cutaneous or systemic, digestive, etc.

 

 

 

CONTRAINDICATIONS

 

As we don’t have any studies about teratogenicity of  the product, it’s not recommended its application in pregnants as in mothers in lactancy.

 

 

 

 

 

 

 

Inquiries of some patients treated with the medicament.

This is the result of the observation and experience in the handling of the medicament; from which results an anecdotic experience we would like to transmit.

When we refer to a clinic cure of a patient we mention his/her present state of health. We do not take into account classic clinic research time periods in oncology; because of the nature of our medication and our patients. This is a revision, a retrospective.

“We would like to settle down that we have in our possession the consent of the patients that appear in this work to have their clinic registers published, informed consent. Anyone who wants to see these patients’ approval as we have mentioned will have it sent.”


 

 

Malignant prostate pathology.

 

Malignant prostate pathology: Mr. Eber Paiva

Name:                  Eber Paiva

Age:                     67 years old

Country:               Uruguay

Reason of consultation:

10/5/2001              Consults because of polaquiury and disury. Has UAR done which                        makes him been catheterized. He is treated with pelvic anti-

inflammatories and does not improve. This symptomatology was present since six months ago. The episode of the UAR motivated his consultation.

Personal antecedents:            No personal antecedents to remark.

Family antecedents:   Mother deceased because of a rectum AC.

Present disease’s antecedents:

He begins six months ago with polaquiury and disury which needs the mentioned treatment to be performed. Rectum tactum performed, prostate compatible with a IV grade hypertrophy. (see page 17).

Biopsy by trans-rectum ultrasonography that shows well differentiated prostate adenocarcinoma. Gleason 5, PSA 14,94 (see page 18).

GREEN SAP initiated on November 3rd., 2001, 40 drops 3 times per day.

PSA after 30 days: 8,21.

11/23/2001: Computerized tomography (see page 23): Prostate size very increased and its density is heterogenic, which can correspond to a necrosis in its interior. It disfigures the blade’s floor but does not seem to infiltrate it.

It is decided to increase the medicament to 40 drops 4 times per day. He improves the urination disorders (urination stinging) and testicle pain.

Disease evolution:       On the 01/06/2002 has PSA tested which result is: 6.74 ng/ml. (see page 25). On the 08/22/2002 Total PSA 0.83 ng/ml. (see page 27). It is remarkable that the patient also received, as we advised conventional therapy, hormonal and radiant, being at the present moment in real improvement following with the ingestion of our medication.

                                    Released patient, ingests the medicament for one month yearly in a dosage of 30 drops per day.

Conclusions:                67 years old, with no personal antecedents to mark, suffers an urine acute retention. The biopsy by trans-rectal ultrasonography shows a Prostate Adenocarcinoma well differentiated Gleason 5, PSA 14.94. GREEN SAP treatment is initiated on November 3rd., 2001, 40 drops 3 times per day. He quickly improves his urinary disorders and testicle pain that grieved him.

                                    He reaches the remision and release thanks to the use of GREEN SAP, which has an acknowledged efficacy in Prostate cancer.

                                    GREEN SAP is a medicament of proved efficacy in this pathology, demonstrated along the years and the empiric experience. It is evident that GREEN SAP avoided more significant damages in the patient and we can say that it is a medicament for which this patient lives thankful for having eliminated his illness.




Malignant prostate pathology: Mr. Héctor Tanco.

Name:                         Héctor Tanco

Age:                            66 years old

Country:                      Argentina

Reason of consultation:

12/26/2000                    Consults because of polaquiury with no other symptoms. Normal urine.

Personal antecedents:            Hypertension, treated with hyposodic diet although he does not attach to it regularly.

                                    Smoker until 30 years ago. No alcohol. Apendicectomized and amigdalectomized, asthma until 22 years old.

Family antecedents:    None to remark.

Present disease antecedents:

                                    Begins with polaquiury. Studied with PSA showed figures of 84.5 on the 03/05/2001 which motivated a more exhausting study (see page 35).

                                    04/04/2001 - Has ultrasonography done which show images compatible with prostate of 38 mm. x 36 mm. and an approximate weight of 28 g., slightly post-urinary residue with n pathological significance, blade wall of normal thickness, with no endoluminal projections, joining free blade-urethers. Bilateral renal ultrasonography: both kidneys are of normal shape and size, with parenquimo-sinusal relation conserved. They are not observed neither signs of hydronefrosis nor images that could correspond to lithyasis.

                                    Prostate Biopsy Punction under trans-rectal ultrasonographic control. Images compatibles with: Prostate of 38x41x31 mm. which shows an approximately weight of 34 g. The specific prostate antigen for that weight would be 4 ng/ml. Cystic image in retro-uretheral central zone, seminal vesicles symmetric .

                                    Pathological Anatomy: showed a well differentiated Prostate Adenocarcinoma. Gleason Score 5 (3+2). It is a bilateral carcinoma, the compromise is similar in both sides and of a 50 %. Date of the result: 05/15/2001.

Total bone centellography: Date 06/06/2001 in the bone scan performed no pathologic hyper-concentration areas of the isotope are seen .

Abdominal and pelvic Computerized Axial Tomography: The liver conserves its habitual morphology and density, its structure is homogeneous, there is no dilatation of the bilious way, the bilious vesicle content is homogeneous by this method. Spleen, pancreas, kidneys and adrenal conserved. At the pelvic area an increased size of the prostate is observed with       of the blade floor, the blade shows its walls slightly thickened. No lymph nodes retro peritoneal iliac or inguinal are observed. 

Disease evolution:       A treatment with gosereline, 3,6 injectable, monthly, is installed, and bicalutamide 50 mg. per day. As a definitive pretreatment is installed B.A.T.

                                    We indicate 50 drops of the medicament, sublingually, every 6 hours.

                                    06/06/2001 A bone centellography is done, showing that in the bone scan performed no areas of pathological hyper-concentration of the isotope are seen.

                                    04/03/2002 Asymptomatic, increased to 60 drops every 6 hours.

                                    Normalization of his free PSA.

                                    Patient who begins his disease in stage T 2c N0 M0. He took the medicament during a year, at the present moment he is at clinic remission, taking 30 drops per day during one month, one month per year. Patient on release.

                                    66 years old, hypertension, treated with hypo-sodic diet, carrying a prostate differentiated adenocarcinoma, Gleason Score 5 (3+2), with similar compromise of both sides of a 50 % (05/15/2001).

                                    Treated with gosereline 3,6 injectable during a month and with bicalutamide 50 mg. per day. A total androgenic blockade is performed, definitive pretreatment.

                                    He receives the medicament 50 drops sublingually every 6 hours; he reaches the cure due to GREEN SAP which was the medicament he most received.

                                    There is normalization of the biochemical parameters which are beneath normal limits.

                                    The patient leads a life with an excellent quality thanks to the medicament.

                                    GREEN SAP has an excellent action against prostate cancer and has achieved that this patient leads a complete life and has eliminated his neoplasy thanks to this medicament. GREEN SAP has returned to him total functionality and changed his life, due to its efficacy empirically proved and of first level in prostate cancer.

                                    .



Malignant prostate pathology: Mr. Raúl Smith.

Name:                         Raúl Smith Belgrave

Age:                            77 years old

Country:                      Cuba

Reason of consultation:

                                    Night urine and weak urine flow.

Personal antecedents:

Mesenteric thrombosis in January,1995. He went under surgery and is evolutioning without difficulty.

Family antecedents:    With no antecedents to remark.

Present Disease Antecedents:

                                    Because of the night urine and weak urine flow was attended by an urologist who found at the rectal digital exam a prostate size increased and hardened of woody consistence, therefore indicating the following complementary exams which showed the following results:

                                    01/11/2002: Hemoglobin 134 g/l, Eritro 14 mm/h, Creatinine 98 mmol/l.

                                    Prostate ultrasonography: Bladder almost empty, anyway prostate size globally increased and heterogeneous, which measures 55x41. Superior hemi-abdomen ultrasonograph: fat liver, no nodular lesion, no other alterations.

                                    Bone gammagraphy: Nuclear bone scan where increased accumulation of the radio-pharmaco can be seen in the lumbar vertebral column (L5) and reduced accumulation in both sacroiliac joints.

                                    Prostate biopsy 01/11/2002: Moderately differentiated prostate adenocarcinoma, Gleason 6, PSA 88,1 ng/l. It was concluded that the patient presents a moderately differentiated prostate adenocarcinoma not metastasic and he was indicated to begin with Androcur 2 tablets per day. The month after having begun the treatment PSA is repeated 02/12/2002: from 88 ng/l to 21,4 ng/l.

                                    Besides the patient experiments a notable improvement related to the night urine previously mentioned.

Disease evolution:

                                    It was not possible to follow through the PSA as there are no reactives in the country. But the imagenologic studies were repeated on the 07/04/2002 and the gammagraphy showed the following inform:

                                    Nuclear bone scan shows larger accumulation of the radio-pharmaco on the fifth lumbar vertebra subjective of an increased osteoblastic activity at that level.

                                    It is suggested a conventional radiological study to discard bone degenerative process, in the rest of the skeleton no other pathological captures can be visualized.

                                    Now the patient refers to present only pain in the hip joint.

                                    12/09/2003 Another PSA is done and is of 12 ng/l and the hip joint pain has frankly improved, he goes on with the treatment with the medicament in a dosage of 40 drops 3 times per day.

                                    On the 02/26/2003 another PSA is done which is of 7,4 ng/l, the night urine has improved remarkably, he is in a good general state of health. He did not have loss of weight. He keeps a good appetite.

                                    03/07/2003 He is reevaluated by oncology and urology and is reported as clinically cured.

                                    All the complementary exams are within normal parameters. (see Some e-mails received page 159).

                                    Patient on real improvement.

Conclusions:                Patient of 77 years old proceeding from Cuba, with personal antecedents of mesenteric thrombosis in January 1995, who consults due to a low urinary syndrome, being explored with rectal tactum which showed prostate increased in size, hardened, of woody consistence. Prostate ultrasonography, bladder almost empty, though prostate globally increased in size, and heterogeneous, which measures 55 mm x 41 mm. By ultrasonography there is either no liver compromise nor other abdominal alterations.

Bone centellography with increased accumulation of the radio-pharmac in lumbar vertebral column (L5) and reduction of it in both sacroiliac joints. The  01/11/2002 biopsy showed Moderately Differentiated Prostate Adenocarcinoma, Gleason 6, PSA 88,1 ng/l. He was indicated Androcur, 2 tablets per day and the PSA lows to 21,4 ng/l.

On the 12/09/2003: PSA in 12 ng/l, frank hip joint pain improvement, receiving a dosage of 40 drops 3 times per day. Patient on urology and oncology release, with last PSA of 7,4 ng/l. Good general state, no weight loss and good appetite. All the complementary exams are within normal parameters. There is no doubt that the benefic effect of GREEN SAP on the prostate cancer, has manifested totally, conducting to the clinic cure of the patient, as well as his doctor daughter tells us by e-mail.

This patient achieved the cure of his pathology thanks to the use of GREEN SAP, that has a proven first level efficacy in prostate cancers, as well as in lots of others. It supports this testimony the fact that this patient’s daughter is a colleague who worked in the National Oncology Institute of Cuba and actually is working in LuandaAngola. Once again GREEN SAP contributes to the eradication of a malignant pathology and to the patient having a worthy life and disease free.

 


Glandular hyperplasia with atypical focuses with PIN III: Mr. Luis Mohana.

 Name:            Luis Mohana

Age:                            72 years old

Country:                      Argentina

Reason of consultation:

05/02/2002                   The patient’s wife consults, he presents prostate tumor.

Personal antecedents:

                                   No personal antecedents to remark.

Family antecedents:   None to remark.

Present disease antecedents:

Treated due to bladder polyps, with multiple explorations. In one of them a prostate increased in size is discovered, having the patient a normal PSA. In the first Pathological Anatomy can be seen various fragments of prostate tissue with glandular hyperplasia, ectasy, chronic inflammation and multiple areas of PIN III with acinar hyperplasia,  (see page 57). Results: low molecular weight queratine positive 95 % and (++). High molecular weight queratine positive in the area of atypical proliferation. PIN III (Diagnosis: glandular hyperplasia with micro-areas of PIN III).

Note: No total loss of basal layer is observed in these areas.

It is indicated control and treatment in Oncology Urology center in Buenos Aires. A biopsy is solicited 6 months from now on and PSA 3 months from now on. It is indicated to begin with the medicament with 30 drops 4 times per day sublingually.

Disease evolution:

06/05/2002 – Consults again with his wife. He refers asymptomatic, has a PSA to be done the 07/03/2002. The PSA levels are on increase but always within normal limits.

03/07/2002 PSA – 2,1 ng/ml

03/26/2002 PSA – 2,54 ng/ml

We keep in touch by e-mail or telephone. He accomplishes the treatment with the medicament precisely and the process keeps localized. As we do not see the patient we cannot have the perception that gives clinic exploration, anyway, at the present moment, the patient is within normal parameters.

07/10/2002 – Telephone communication with the patient who refers his 07/03/2002 PSA as of 3.09 ng/ml, that he is asymptomatic and his general state is good. He keeps on receiving 30 drops 4 times per day sublingually; we increase the dosage to 45 drops 4 times per day due to the slight increase of the PSA.

08/07/2002 A telephone communication with the patient was made, where he refers being asymptomatic, with good spirit, and performing all his daily activities. He considers that the intake of the drops has benefited him remarkably, opinion we share. Next control in March, 2003. Clinically stable patient. He goes on with the medicament with 45 drops 4 times per day.

03/25/2003 Telephone communication with the patient in what he communicates us he is in excellent state of health performing his daily activities and with no kind of problem. He send us via fax the last PSA made on the 03/14/2003 with a value of 3,56 ng/ml. (see page 59). Also he sends a pelvic ultrasonography with normal results (see page 60). Patient on release, at present on real improvement. It is indicated a maintenance dosage of 30 drops per day during a month, once a year.

Conclusions:                           Patient with malignant prostate pathology of 72 years old proceeding from Argentina, consulting his wife and referring to us a prostate tumoration. Treated due to bladder polyps, in one of them is discovered the prostate was increased in size, having a normal PSA.

                                   The pathological anatomy shows glandular hyperplasia with micro-areas of PIN III, and begins treatment with the medicament on May 3rd., 2002.

                                   Beginning with 30 drops, 4 times per day sublingually. Evolution towards an improvement, keeping always the PSA within normal values. Effect we attribute to the GREEN SAP. Patient who at present we can consider cured (not with the criteria of 5 years, international criteria) thanks to the use of GREEN SAP, which once again has shown its nobility as an anti-neoplasic medicament allowing the patient to be in a good state of health performing the daily activities that any person can do.

 


 


Malignant prostate pathology: Mr. Pablo Cordero.

Name:                         Pablo Cordero

Age:                            88 years old

Country:                      Panama

Reason of consultation:

05/25/2002                   Acute urine retention

Personal Antecedents:           

                                   Gonartritis; hypo-acusia.

Family antecedents:   None to remark.

Present disease antecedents:

                                   In January, 2002, due to an acute urine retention, after being examined he was given the diagnosis of prostate cancer, he had a bladder endoscopy made towards the end of March, resulting positive and was indicated Flutamide one tablet 3 times per day. He was suggested an orchectomy, but his family prefers alternative therapy. He looses weight. Anemic, with no pelvic pain, with bladder catheter. He underwent a prostate biopsy punction. Anatomy pathology Diagnosis: A. Prostate, right lobe (biopsy), moderately differentiated adenocarcinoma, Gleason 3+4=7 which compromises approximately 30 % of the sample, with no peri-neural invasion.

There’s a PIN III area of high grade, areas of lympho-vascular permeation are observed. B. Prostate, left lobe (biopsy), moderately differentiated adenocarcinoma Gleason 3+4=7 which compromises approximately 20 % of the sample.

            No peri-neural or vascular invasion is observed.

A month later bone centellography shows compromise, not defining in which bone.

Disease evolution:      They decide to use our medicament.

The patient feels well and the catheter was retired. In the 4th. month of treatment with the medicament he is urinating normally.

On February 11th., 2003, underwent a surgery due to intestinal occlusion caused by adherences of an old appendicitis surgery. He was grave and stayed in hospital for 36 days.

Also due to a pneumonia because of a hospital bacteria, but he is recovering satisfactorily.

He had a rectal exam done and a pelvic and abdominal computerized tomography. In the rectal exam a prostate increased in size but soft was found, as a bubble and not woody. He did not show pain at the tactum, the CAT showed a somehow big prostate. The surgeon informed that in the operation area the intestines were metastases free, only some necrosis of the thin intestine due to adherence was found.

He changes doctor and consults a urology oncologist, who did not know his case and found a prostate with the size of a plump.

The prostate was found to be of soft consistence as rubber and had a little protuberance also soft. He was surprised by the fact that previously he had been diagnosed as advanced prostate cancer. The doctor saw the biopsy and confessed that if it wasn’t for it he wouldn’t have believed it was the same patient.

A bottle of the medicament he was taking is shown to the doctor. He concluded that this medicament, which was the only thing he was taking, must have improved his cancer. Anyway he ordered some laboratory exams and “X” rays, he recommended to go on taking the medicament.

The patient is asymptomatic, in real improvement. (see Some E-mails received, page 159).

 


Conclusions on anti-tumor GREEN SAP action on malignant prostate neoplasies.

 Evidently, as for the collected experience, a benefic effect of GREEN SAP on prostate neoplasies is found, which is demonstrated by normalizing or reducing the PSA, causing a loss of size of the tumors evident either by rectal tactum or by trans-rectal ultrasonographies explorations, as well as on its consistence which goes from rocky to woody and from woody to a normal prostate consistence. The particular histological structure of the prostate can be in the genesis of this interaction which is hurtful to the tumor. Probably by a antiangiogenic mechanism the neo-vascularization of  the tumor is prevented, depriving it of essential nourishing factors for its development. This development has lost control, the cells have lost contact inhibition to proliferate.

GREEN SAP acts also at cellular level causing cytotoxicity and a cytostatic effect; occuring tumoral cell death not only when GREEN SAP is acting but  “a posteriori”, generating an accumulative effect evoluting to tumoral death induced by GREEN SAP.

This is maybe the reason why we find samples of prostatectomies with important intra-tumor necrosis and hemorrhages in their way to resolve or organizing; this observation would not correspond so much with the conventional hormonal treatment generally used.

It was also observed that GREEN SAP; prevents the creation of new tumor clones that escape to the body’s control and provoke early metastasis moreover on the bone substance, prostate metastases have avidity for bones.

Therefore GREEN SAP has a protective action on the bones preventing this body sector’s colonization by the disease, we observed osteoblastic lesions treated with GREEN SAP that set back and are eliminated by the organic depurator systems, provoking a removal and mobilization of the accumulated substance in the skeleton or particular areas of it.

The bone centellography exploration allows to appreciate the differences among treatments before and after the GREEN SAP.

The hormonal traditional therapy has the risk of provoking thrombotic pathology.

This is another effect we see that does not occur with GREEN SAP, when a conventional treatment plus GREEN SAP is faced, what leads to the patient’s benefit as it frees him of thrombosis of the lower limbs and other economy’s areas.

Many times this can be the event that provokes a lung thrombo-embolism, and this can lead to a very characteristic episode which can lead towards the patient’s death. Knowing the fact that lung thrombo-embolism is diagnosed by perfusion-inhalation centellography, in order to appreciate the lung area that ventilates and therefore the affected one, we can affirm that in conventional-GREEN SAP mixed treatments, we did not observed it so it does not occur in our casuistic.

 


Kidney cancer

 

Light cell kidney adenocarcinoma pathology with metastasis: Mr. Jorge Lindh

Name:             Jorge Lindh

Age:                            56 years old

Country:                      Sweden

Reason of consultation:

11/21/2001                    Left nefrectomized patient in 1998 by a malignant kidney pathology. He underwent surgery in Sweden, resulting a light cell adenocarcinoma.

Personal antecedents:

No antecedents to remark.

Family antecedents:   

We ignore them.

Present disease antecedents:

It was thought at the first place that the neoplasy had been taken definitively, a year later, after two checkinGREEN SAP that did not show any anomaly, shortly after the third checking, in July, 2001, he had a thorax additional tomography. At that moment metastasis in both lunGREEN SAP were discovered. Lymphatic metastasis in left and right lung which oppress both the tracheas and the esophagus. Later on it was discovered an additional metastasis in the left kidney post-surgery lay and behind the right clavicle. He consults about the possibility of treating himself with our medicament.

11/21/2001 The treatment is initiated with 30 drops 4 times per day of the medicament, for fifteen days, then 40 drops 4 times per day.

Disease evolution:

Patient who was treated only with our medicament by his own will.

01/27/2002 He expresses well being due to the intake of the medicament. He does not have swallowing difficulties because of the compression that the metastasis from both lung, on  esophagus and tracheas.

02/28/2002 The metastasis on the left kidney surgery lay has stopped its growth.

The metastasis behind right clavicle also stopped its growth.

The lunGREEN SAP metastasis which oppressed tracheas and esophagus only have grown 10,14 mm, he does not have swallowing difficulties.

03/14/2002 He comes to consult in Montevideo, subjectively and objectively well.

He maintained his weight. Normal kidney functionality. Marginal tumor growth, it is increased to 50 drops 4 times per day.

The patient improves his life quality, he can perform a normal life ambulatory, he goes on with 50 drops 4 times per day having his next control in May.

He is asymptomatic in real improvement and is released with a maintenance GREEN SAP dosage.

Conclusions:

Patient of 56 years old, left kidnectomized in 1998 due to a malignant kidney pathology (light cell kidney adenocarcinoma), surgery in Sweden. In July, 2001, there were metastasis discovered by thorax tomography, in both lunGREEN SAP. Lymphatic metastasis in left and right lung. Metastasis which oppress both the tracheas and the esophagus. Later on it was discovered an additional metastasis in the left kidney post-surgery lay and another one behind the right clavicle.

11/21/2001: He initiates the treatment with 30 drips 4 times per day. He begins with evident improvement, corroborated by exams. He received only GREEN SAP treatment, by his own will. He improves his swallowing capability. He improves his breathing capacity. Very good general state.

03/14/2002: He comes to Montevideo, subjectively and objectively fine. There are no doubts left about the beneficial action to a great level of GREEN SAP medicament, as the patient is in clinic cure and on release. It is doubtless that the medication has had a remarkable anti-tumor effect, with characteristics that equals the most ancient and experienced drugs by other colleagues. GREEN SAP action is not accidentally as we mentioned in GREEN SAP Action on kidney neoplasies . This action was observed throughout the years and the experience that is given by its use, which also fills with satisfaction both us and the people who use it.



Pathology: Light cell adenocarcinoma and hypernefroma: Mr. Jorge Suárez.

Name:                          Jorge Antonio Suárez

Age:                            51 years old

Country:                      Argentina

Reason of consultation:

12/27/2001                   Left kidnectomized in 1994 due to hypernefroma.

                                   Asymptomatic until March, 2001.

Personal antecedents:

                                   No personal antecedents to remark.

Family antecedents:

                                   No family antecedents to remark.

Present disease antecedents:

Asymptomatic patient until March, 2001 when he presents a left iliac fossa tumor, he has a biopsy done which shows a light cell carcinoma.

Clinically asymptomatic.

Computerized tomography: right supra-kidney gland metastasis. Nodular lesion in contact with the posterior side of the lower cava vein. Nodular lesions that compromise the psoas muscle.

He had a computerized tomography of the facial cranium structure done, which was normal.

Neck computerized tomography: normal.

Thorax computerized tomography: nodular image of soft parts density of approximately 15 mm in maximum left posterior intercostals diameter which would have to be evaluated following the antecedents.

Pelvic abdominal computerized tomography: it were explored the pelvic and abdominal regions, after the intake of oral contrast substance to dye the digestive tube and the injection of contrast substances intravenously.

Discrete diffuse hypo-density of the liver parenchyma compatible with slight infiltration. Nodular images compatible with metastasis in the right supra-kidney gland. The biggest of them of approximately 35 mm. It is also observed nodular lesion in contact with the lateral side of the lower cava vein immediately above the right kidney vein. Sequel of left kidnectomy, being identified the pancreas tail and the lower pole of the spleen at the kidney fosse. It is observed nodular lesion in the upper pole of the right kidney. The gall bladder does not show any alteration. The left supra-kidney gland is not identifiable. Nodular lesion with cystic and/or necrotic center coming from the front area of the left psoas muscle. It can also be observed nodular confluent lesions with soft parts density which involve the left iliac psoas muscle. It is also identified a nodular lesion in the right internal obturator muscle.

Comment: The described lesions in the thorax and specially in the abdominal-pelvic region are compatible in first place with metastasis.

 

Disease evolution:

He initiated the treatment with the medicament in November, 2001, with 45 drops 4 times per day. After a month he continued with 50 drops. Next month 60 drops 4 times per day.

04/03/2002: Clinically asymptomatic. Kidney carcinoma Stage IV. Tomographic improvement of his lesions in February, 2002.

He goes on with 60 drops every 6 hours sublingually.

08/28/2002: Patient stable, he keeps on asymptomatic and with good survival. He performs daily activities. He feeds well. He sleeps well. Conserved digestive transit. Urinary transit: no major alterations.

04/11/2003: In real improvement, on release with maintenance GREEN SAP dosage.

 

Conclusions:

Patient of 51 years old, left kidnectomized. Asymptomatic, until March, 2001. In March, 2001 presents a left iliac fosse tumor which shows in the biopsy Light Cell Carcinoma. He also presents in the computerized tomography a nodular image with soft parts density of 15 mm. of intercostals maximum diameter.

Lesions compatible with metastasis in the right supra-kidney gland.

He initiated treatment whit the medicament in November, 2001, quickly evolutioning both clinic and imagenologically.

The GREEN SAP’ mechanism of action on the kidney tumors and its metastasis manifested once more leading the patient to the clinic cure and his release. Maintaining a control dosage with the medicament.

This patient is in healthy state, what we attribute to the use of GREEN SAP, which has acted as we have been seen for years, in an excellent way. GREEN SAP is a therapeutic weapon of first level and our patients are our witnesses of the seriousness with what we face our work with them and we believe that this medicament is a fundamental contribution to the contemporary medicine. (see Conclusions GREEN SAP’ action on kidney neoplasies, page 89)

 

Kidney cancer: Mrs. Irma Renoldi

Name:             Irma Renoldi

Age:                            65 years old

Country:                      Argentina

Reason of consultation:

03/19/2002                   She consults due to retro-peritoneal tumoration.

Personal antecedents:

                                   Without personal antecedents to remark.

Family antecedents:

            None to remark.

Present disease antecedents:

She begins with lower limbs edema a month ago reason why she underwent exams. The abdominal ultrasonography and abdominal-pelvic and thoracic CAT show a left kidney mass. The CAT informs retroperitoneal mass that measures 5,1 cm. That seems to originate in the back valve of the left upper pole extending to the medial area getting in touch with the diaphragm and also with the left kidney vein. The bone centellogram does not show metastasis. The treatment with the medicament is initiated taking 40 drops 4 times per day.

Disease evolution:

06/05/2002 – Clinic and paraclinic improvement. Awaiting new paraclinic studies. Anyway the improvement of the patient’s life quality is impressive. She goes on with 40 drops 4 times per day.

08/21/2002 -  She comes to consult. She does not bring CAT but confirms us complete reducing of the tumor mass. Asymptomatic.

We maintain 40 drops 4 times per day sublingually. We maintain such dosage until December, 2002.

At the present moment, due to the complete reducing of the tumor mass and the excellent clinic and paraclinic state we release her with real improvement, maintaining basal dosage of the medicament during a month, once a year.

Conclusions:

Patient of 65 years old, who consults because of a retroperitoneal tumoration. The CAT shows retroperitoneal mass which measures 5,1 cm., that seems to originate in the back valve of the left upper pole, extending to the medial sector getting in touch with the diaphragm and also with the sub-renal gland. It also contacts the kidney vein.

She initiates the treatment taking 40 drops 4 times per day. GREEN SAP, due to the explained mechanisms in the kidney anti-tumor action, acted in a quick and effective way, achieving the patient’s clinic cure and her release, who presented a voluminous and related to other structures in the vicinity, kidney tumor.

GREEN SAP stopped the tumor kinetic, leading the patient towards a healthy state that more expensive medicaments and with more disgusting collateral effects and medicament interactions do not achieve in a indolent way, that is without suffering as our medicament does which has the back up of the cases in which it has achieved complete remissions, clinic cures and over all, what more interests us, an excellent life quality that allows the patient to develop from a physical point of view in a completely normal way, what psychologically benefits him in a superlative way, this being many times forgotten by the traditional medicine, but we keep in mind every day focusing the patient as a whole.

GREEN SAP deserves a stand up position among the medications which fight malignant diseases and make so without causing collateral effects, which many times in traditional medicine oblige to give up the treatment, which in a very high percentage of cases this does not happen to us, also establishing through GREEN SAP an actual friendship with the patient, what encourages him to go on and achieve the improvement as in this case, in which this medication was used.

 



Pathology: Wilms’ tumor: María Tabares

Name:                         María Alejandra Tabares

Age:                            4 years old

Country:                      Colombia

Reason of consultation:

02/12/2002                    A big mass is detected in left flank, which motivated its study with abdominal ultrasonography and posterior stenography. Where it was confirmed the presence of a big mass in left kidney with the possibility of being a Wilms tumor, reason why an urgent surgery was programmed.

Personal antecedents:
No personal antecedents to remark.

Family antecedents:

                                    No family antecedents to remark.

Present disease antecedents:

                                    Next Tuesday, 02/19/2002 she underwent extirpation surgery of left kidney with a Wilms’ tumor of 750 g of weight, which was sent to pathology for its analysis showing the following result:

                                    Microscopic description: In the histological cuts a malignant tumor lesion is identified formed by a blastomatose component, an epithelial one, forming tubular structures, and others mesenquimal-fusiforms. It is not observed anaplasy characteristic. The tumor compromises the kidney capsule but does not perforate it.

                                    In the not tumor kidney parenchyma there is tubular atrophy.

                                    It is not observed neither compromise of the vein nor the kidney arteries nor the urether.  

                                    It is a Wilms’ triphase tumor, with favorable histology, compromise of the kidney capsule without perforating it. Resection border lines vascular and urethral free of tumor. Following the results obtained from pathology, chemotherapy treatment was determined, with a protocol of 18 weeks with Vincristine, 0,05 mg/kg/d. Treatment followed until the week 10. Actinomicine D 0,045 mg/kg/d every 3 weeks until the week 18. Such treatment was initiated on February 22nd., 2002 and ended on June 22nd., 2002. During the chemotherapy treatment, control exams were performed, such as thorax Rx, hemograme, creatinine, etc. Very satisfactory results were obtained from surgery and chemotherapy.

                                    On October 25th., 2002, a new control abdominal scan was performed and the following results were obtained:

                                    Multiple cuts were made axially, and with helicoidal technique in abdomen, from lung bases to pubis sinfisis in simple phase and with 8 mm thickness cuts. The study was solicited without contrast mediums.

                                    Findings: Changes in left kidnectomy are identified. The left kidney fossa is empty and the tumor observed in the left kidney has been completely extirpated, the kidney fosse is occupied by thin intestine asas, although without contrast it is difficult to evaluate the retro peritoneum, in the present cuts there is no evidence of tumor recidivisms.

                                    It is surprising towards the left supra-renal gland the presence of a hypo-dense image of low density which could represent either a residual tumor or an adrenal gland lesion. There is no pleural drain or nodular images. The observation of the liver is normal, without metastasic disease. There is no evidence of gall via intra or extra liver.

                                    Coledoco and gall bladder normal.

                                    Spleen, pancreas, right supra-renal gland and right kidney without alterations. There is no evidence of masses or retro-crural or retro-peritoneal lymphadenomegalies.

                                    Cava vein and aorta: normal.

                                    No collections or ascitis liquid are observed.

                                    In the pelvis are identified the urinary bladder, rectum and annexes normal.

                                    There are no pelvic lymphadenomegalias.

                                    Radiologic conclusion:

                                    Kidnectomy with complete resection of the neoplasy observed in the previous study 02/13/2002.

                                    Hypo-dense lesion in left supra-kidney gland to consider residual tumor or metastasic disease. There is no evidence of metastasic disease in another abdominal place.

Disease evolution:

                                    On the past November 7th., 2002, surgery was performed, finding a new tumor en left supra-kidney gland with a necrosed part attached to the supra-kidney gland reason why its complete resection was made and the tumor was again sent to pathology for its evaluation.

                                    Sample: Left supra-kidney gland.

                                    Macroscopic description: product of the resection  of supra-kidney gland is received, which weighs 16 g and measures 5,5x3,8x1,2 cm. Supra-kidney gland is recognized, and in the periphery an hemorrhagic node is found, lobated, partially cystic and hemorrhagic which measures 1,8x1,6x1,6 cm, it is partially opened in the same container and separately they come several segments of tissue brownish colored, breakable consistence which weigh 1 g. Representative cuts are processed.

                                    Microscopic description:

                                    In the histological cuts supra-kidney gland is identified which presents in its capsule and fat that surrounds it, primitive tumor lesion, formed by an area of blastomatose aspect and others with tubular formations. The tumor has quite a mitotic activity. The material which comes separately corresponds to tumor fragments partially necrotic which surround striated muscle.

                                    Diagnosis:

                                    Left supra-kidney gland: Supra-kidney gland-ectomy. Recidivated Wilms’ tumor.

                                    The post-surgery recovering is very satisfactory, the girl is en excellent state of health in spirit and nutritionally. She weighs 16 kg. Reason why it is observed that the tumor did not have any metastasis in other places.

                                    12/08/2002 Treatment with the medicament is initiated taking 5 drops half an hour before meals.

                                    12/11/2002 She goes on with 5 drops half an hour before meals.

                                    12/13/2002 She goes on with 5 drips half an hour before meals.

She goes on taking the medicament until present. She is in excellent state of health, in spirit, and develops all the activities of a kid of her age. Asymptomatic, at the present moment is on release and considered with real improvement. An annual maintenance with GREEN SAP is done.

Conclusions:

Patient of 4 years old, proceeding from Colombia, to whom left kidney is extirpated on 02/19/2002 with a Wilms’ tumor of 750 g. of weight. Left supra-kidney recidivism which is extirpated on 11/07/2002.

She begins taking the medicament on 12/08/2002, achieving a quick optimization of her general state of health and imagenologic disappearance of any tumor image.  Reason why we consider her in real improvement, on release with periodic controls and a basal medicament dosage.

In the case of a girl we have to think in her tiny world, we have to take into account the cruelty of the disease that grieves her and we have to commit not to add more suffering although this was justified to improve her, as this can be something that marks all her life. GREEN SAP Drops, is an innocuous medication, without collateral effects and no interactions. Easy to take also by a 4 year-old girl, who does not reject it.

It is not traumatizing and its effect is so powerful as the conventional druGREEN SAP’ one, that is why we consider of such an importance the GREEN SAP treatment in children, being this an example that clarifies us about the tolerance and positive effect of the medication that ends with the patient in clinic cure and on release thanks to GREEN SAP.

We do not know if it can be said of another alternative medicament of similar or different characteristics, what this staff can say of GREEN SAP by its empiric experience and years of work, mitigating the pain and achieving cures where everything was taken for lost.

 


Conclusions on GREEN SAP action on Kidney Neoplasies.

GREEN SAP action on kidney neoplasms is highly specific, acting in a selective way on the tumor cell, with no adverse effects on the benign cells.

Basically has a pattern of action similar to the one seen on prostate. There would be an inhibition of tumor angio-genesis, depriving the tumor of nurturing factors, inhibition of the metastasic production by receptor blockage in different areas of the body and by direct litic action on the metastasic cell. Acting on the membrane potentials achieving a broad cell permeability, reason why the cellular apoptosis is produced.

GREEN SAP effect is very beneficial on lung metastasis, very frequent in kidney cancers. It acts by inhibiting the metastasis growth and reducing their number. Comparing thorax and upper abdominal CATs  before and after GREEN SAP use what was said is proved.

GREEN SAP does not affect neither the kidney function nor the azoemy, creatininemy, or creatinine clearance. It does not cause tubular damage. Its components act synergic and selectively o the tumor cell by the mechanisms already mentioned.

The medicament acts on the selected clones (the ones which will metastatize) and blocks the areas where they implant, such as: lung where lots of kidney cancers’ metastasis are seen.

GREEN SAP is an immunity stimulant, increasing the number of leucocytes specially granulocites, which benefits the organism to reject tumor pathology.

It stimulates the cilia sweeping in the lung what benefits the expulsion of strange materials from the lung, either cancerigen or pre-cancerigen.

It stimulates the hematosis, this is, the blood oxygenation in the lunGREEN SAP therefore increases the quantity of oxygen it can grasp and carry the hemoglobin by the body. A very benefic property as it reduces the risk of hypoxic complications due to the metastasis in kidney cancer.

Many times the tumor cells can be driven to zero kinetic, this is, to a quiescent state, of no reproduction, no proliferation, staying the tumors stables for years, without growing through all that time, without disappearing either but maintaining the patient asymptomatic and with an excellent life quality.

It is recommended once on release, and achieved the clinic cure, the intake one month per year of 30 drops daily, as a maintenance treatment. The basis of this is that if one cell escaped of zero kinetic, to proliferate and reinitiate the cancer process, there would be a “sweeping” by GREEN SAP action, or by the medicament metabolites which have been produced.

We conclude that GREEN SAP is a first line weapon in kidney cancer treatment, would it be with or without metastasis, being a natural medicament, innocuous and without collateral and adverse effects at the recommended dosages.


Malignant Ependimoma

 

Malignant Ependimoma Pathology: E. Benegas

Name:                         Eduardo Benegas

Age:                            5 years old

Country:                      Paraguay

Reason of consultation:

Endo-cranial hypertension, due to hydro-cephalia and a brain expansive mass situated in right ganglio-basal area with extension to cuadrigeminal area.

Personal antecedents:

                                   No special antecedents.

Family antecedents:

                                   Without family antecedents to remark.

Present disease antecedents:

It was urgently performed an external ventricular derivation and afterwards partial resection of the tumor that was informed as anaplasic glyoma.

Disease evolution:

He underwent plain dosage of radio and chemotherapy. A computerized tomography in October shows good evolution of his neoplasic lesion and his hydro-cephalia which was treated with internal ventriculo-peritoneal derivation.

In December, 2002, progressive neurological deterioration. Left hemi-paresia F.B.C. and control resonance shows extended ventricular recidivism.

On December 16th., 2002, he underwent new surgery and subtotal removal of the lesion.

It is desirable to know the inform referring to: New irradiation? Chemotherapy with temosolamide? Brachitherapy? Other alternative druGREEN SAP? Another procedure?

Our answer was: treatment with the medicament at the dosage of 10 drops 4 times per day, the following month we increase the dosage to 20 drops. This treatment was done at the same time that an strict vegetarian diet and temodal, indicated by Sao Paulo’s oncologists.

The present state of the boy (March 3rd., 2003) is optimum. Energy and vitality intact. Clinic and neurologic state impeccable. He will go on with the treatment with the medicament.

At the present moment he is in excellent state of health. Remission of his symptomatology reason why we opt to release him, due to his present improvement and go on with controls and maintenance dosage of the medicament.

Conclusions:

5 years old patient, proceeding from Paraguay, who consults due to endo-cranial hypertension following hydrocephalus and a brain expansive mass situated in the right ganglio-basal area with extension to cuadrigeminal region. It turned out to be a malignant ependimoma. He starts the treatment with the medicament in a dosage of 10 drops 4 times per day, the following month the dosage was increased to 20 drops. He received chemotherapy, radiotherapy and partial resection of the tumor which was informed as an anaplasic glyoma. The boy’s present state of health is excellent, without symptomatology with normal imagenology for the case, reason why he is on release, due to the excellent evolution and the patient’s state of health.

A basal dosage of the medicament is maintained.

It is out of question for us that GREEN SAP has accomplished a very important role in the cure of this patient. We have experience in Central Nervous System tumors, of the great efficacy this medication has.

This boy can have an equal life as that of the boys without his pathology, thanks to GREEN SAP, which was administered in a ruled and responsible way. There will always be incredulous people, but for them we have facts that prove that our medication is of the highest level proved throughout the years and that in the case of this boy has achieved what many would consider a miracle.

 



Malignant Ependimoma Pathology: Mauricio Ruiz.

 

Name:                         Mauricio José Ruiz

Age:                            8 years old and a half

Country:                      Paraguay

Reason of consultation:

In November, 1995, a tumor in the right hemisphere was detected, which extended from the front pole of the right temporal lobe (intra-ventricular portion) up to the middle line and back up to the occipital pole.

Anatomy-pathology: Ependimoma.

Personal antecedents:

                                   No personal antecedents to remark.

Family antecedents:

                                   No family antecedents to remrk.

Present disease antecedents:

In August, 2000, he suffers a recidivism in the same area and he undergoes surgery with total resection.

Anatomy-pathology: Malignant Ependimoma.

Post-surgery: Radio-surgery with 5940 cGy application in 33 sessions of 180 cGy.

In the third occasion, February, 2002, a nodular image is observed in the left frontal horn.

Treatment: Neuro-surgery.

Disease evolution:

He starts on April 25th., 2002, with 3 intakes per day of 25 drops, which were increased to 25 drops 4 times per day in July, 2002.

On 08/17/2002: He has a new magnetic resonance exam done and afterwards we are informed that the brain edema has reduced significantly what lead him to have reduced his corticoids dosage, which he received at maximum dosage. Baring in mind to retiring them totally but in very slowly.

Considering the tumor, it presents a slight improvement with reduction of the contrast impression in its borderlines. He is receiving the drops at the dosage mentioned previously and evidently tolerating them very well with no adverse reaction. His general spiritual state is good, with great vitality and a normal activity.

Towards the end of October, 2003: he will be finishing the 90 days period with a dosage of 25 drops 4 times per day.

The boy is going regularly to school, asymptomatic. (see Some e-mails received, page 159)

Conclusions:
                                  

It is about a 8 years old and a half patient, proceeding from Paraguay, who in November, 1995 was detected a right hemisphere tumor which extended from the front pole of the right frontal lobe (intra-ventricular portion) up to the half line and back up to the occipital pole.

It is about a malignant ependimoma which recidives in August, 2000 in the same place and has surgery done with total resection. Post-surgery, radio-surgery with application of 5.940 cGy. In February, 2002, an image in the left frontal horn is observed. It has surgery done. On April 25th., 2002, starts with 3 intakes per day of 25 drops, which was increased to 25 drops 4 times per day in July, 2002.

Imagenollogically he has improved notoriously. It is evident that GREEN SAP action crossing the hemato-encephalic barrier and acting through the various mechanisms with what it generally does and preferably in the central nervous system, has had a very favorable result.

The result in this patient with the use of GREEN SAP drops, has been excellent.

Since this patient begins the use of the medicament, he improved in a very remarkable way. With no doubt GREEN SAP has a prevalent action on Central Nervous System tumors what places it among the medicaments that we cannot leave out of question before initiating a treatment. This staff feels very rewarded by this boy notable evolution and there is no doubt we must attribute to GREEN SAP such an improvement in a very malignant pathology, of difficult treatment with conventional drugs that have been used, but we remark the curative role of GREEN SAP without interfering at any moment with any other different treatment. The treatment with our medicament has restored the happiness of life to this boy, without disgusting collateral effects, and we do not doubt that following with the treatment he will lead a worthy life, as we all deserve thanks to GREEN SAP.

 


Oligodendroglioma-glioblastoma Pathology: Sirvart Doganian.

 

Name:                         Sirvart Doganian de Topalian

Age:                            74 years old

Country:                      Brazil

Reason of consultation:

                                   Brain tumor

Personal antecedents:

                                   No personal antecedents to remark.

Family antecedents:

                                   No family antecedents to remark.

Present disease antecedents:

On 09/02/1999: she has a cranial CAT done which shows as a conclusion a left frontal expansive lesion. Front-parietal expansive process, whose nature is to be clarified.

On 06/15/1999: she has a magnetic nuclear resonance done which shows left frontal expansive lesion that presents heterogenic aspect and irregular contours, observing hyper-signal areas in T1 and hypo-signal in T2. Suggesting blood component, signs of peri-lesional edema, there is expansive effect characterized by erasing of the adjacent lines and compression of the left lateral ventricle, with slight deviation of the middle line structures. This lesion measures approximately 4 cm. Of diameter. The conclusion is that the magnetic nuclear resonance aspect is of a left frontal blastomatose process of probable glial origin.

09/26/1999: She has another cranial CAT done that does not show significant changes considering the previous ones.

On 09/28/1999: By per-surgery biopsy is diagnosed primary mixed brain malignant neoplasy, oligodendroglioma-glioblastoma.

On 12/23/1999: A new cranial computerized tomography is done which shows: Signs of left frontal craniotomy, hypo-atenuating area in left frontal area is observed, in the borders of the craniotomy, which after the intra-venous injection of yode contrast, produces annular highlighting. Recidivism? Accentuation of cortical lines and fissures and cerebella lines. Centro medial structures without deviation relating the middle line. Slight expansion of the supra-tentorial ventricular system. Post-surgery control.

On 01/17/2000: A cranial magnetic resonance is done, conclusion: left frontal lesion suggesting glial originated lesion, in relation to the previous exam of 09/15/1999 a reduction of the dimensions of the described lesion is observed.

Observation: Signs of right maxillary sinusopathy and bilateral sphenoidal.

On 05/26/2000: Encephalic magnetic resonance, conclusion: post-surgery control of left frontal neoplasy, post-surgery alterations with blood rests occupying the surgery remotion cavity. Extended alteration of the sign of the white substance of the brain hemispheres, of unspecific nature, maybe representing gliosis, de-mielinization associated to micro-angiopathies, not being possible to exclude post-actinic leuco-encephalopathy if the patient underwent radiotherapy. Gliosis focuses and/or ischemic lagoons, and/or peri-vascular spaces extended in lentiform nucleus, caudated, internal capsules and sub-insular regions. Cortico-subcortical encephalic volumetric reduction.

Disease evolution:

She begins to take GREEN SAP drops at a dosage of 40 drops, 6 times per day in August, 2000.

On 08/31/2000: An encephalic magnetic resonance is done which shows, conclusion: post-surgery control, blood rests occupying surgery remotion area with smaller dimensions in relation to the last exam with no evidences of local recidivism.

The rest of the findinGREEN SAP did not alter significantly from the last study.

On 01/30/2001: An encephalic magnetic resonance is done which shows: conclusions: Post-surgery control exam of left frontal neoplasy, in relation to the previous exam (from 08/31/2000) it is noted a reduction of the dimensions of the blood content and the contrast associated of the medium left frontal lesion and in correspondence to the surgery layer. Slight increase of the extension of the diffuse signal alteration in the white substance of the brain hemispheres, of unspecific significance. If there has been radiotherapy post-actinic leuco-encephalopathy has to be the first diagnose consideration.

On 04/27/2001: Encephalic magnetic resonance, in relation to the previous exam of 01/30/2001, there are evidences of partial absorption of the blood rests, which are situated in the surgery layer, as well as of the associated residual contrast; with other findinGREEN SAP practically unaltered.

No evidences of local neoplasic recidives have aroused.

On 09/04/2001: Cranial magnetic resonance, conclusions: Analysis: Signs of left frontal craniotomy, slight expansion of the supra-tentorial ventricles, without hypertensive characteristics, slight expansion of the IV ventricle, slight accentuation of cortical lines and fissures and of the basal cisterns. Excepting for lines in the left frontal region, which are partially fainted. Diffuse hypersignal in T2, and Flair in the white substance bilaterally compatible with leuko-encephalopathy.

Presence of magnetic susceptible articles in the craniotomy area which may give partly the adjacent structures image.

On 08/14/2002: Cranial magnetic resonance, showed: left frontal craniotomy, with presence of slight irregular areas of post-contrast highlighting, besides the surgery layer, less evident in the present study.

Magnetic susceptible artifacts adjacent to the craniotomy. Peri-vascular spaces extended. There persist extended areas of signal alteration, characterized by a high sign in T2 and Flair that does not present post-contrast highlighting, compromising the white substance of both brain hemispheres. Suggesting post-actinic alterations. The rest of the encephalic parenchyma with normal sign intensities. Crane-vertebral transition without abnormalities. Extended cortical lines. Big Silvian caesuras and basal cisterns. Dilatation of the supra-tentorial ventricular system, IV ventricle with normal form and dimensions.

Comparatively to the previous exam, reduction of the extension and intensity of the signals of the post-contrast highlighting areas was observed adjacent to the left frontal craniotomy.

Cranial magnetic resonance was made on 01/02/2003, which shows: left frontal post-surgery status. The comparative analysis of the present exam to that of the previous one no significant alterations are observed. Irregular contrast focus in the left frontal white substance which can correspond to a gliosis focus but does not discard recidivism signs. Increase of the encephalic liquid spaces. Signs of micro-leuko-angiopathy, peri-ventricular and in semi-oval centers.

We must remark that the patient received in all this period GREEN SAP drops as medicament, finding herself as it arises from the imagenologic results, stable since 2 years and a half ago with the intake of the medicament. Although the tumor extirpation was performed we think that this therapy alone does not justify the excellent evolution she had afterwards, reason why we consider her asymptomatic in real improvement, receiving maintenance dosage of the medicament.

Conclusions:

It is about a patient of 74 years old at present, with a brain malignant neoplasy of ominous prognosis. This neoplasy was extirpated, turning out to be a oligodendroglioma-glioblastoma, the patient in the 2000 begins to take the medicament, maintaining unchanged the imagenology and with a tendency to reduction. GREEN SAP evidently acted crossing the hemato-encephalic barrier as we stated in the central nervous system GREEN SAP anti-tumor action. This appears evident by the excellent result achieved as in the other cases already referred. This is why that a direct GREEN SAP action on the tumor is observed, although before we did not have the experience we nowadays have and was stated that GREEN SAP could not cross the hemato-encephalic barrier as well as many other medicaments.

Nowadays, with the acquired experience and the results achieved by the patients, we firmly think that GREEN SAP has a very well deserved position in the treatment of the Central Nervous System tumors, obtaining remissions, stabilizations and clinic cures. It is remarkable that no endo-cranial hypertension syndrome has produced, and this would be related to the mass effect taken away by the surgery, but also to the anti-inflammatory and stabilization effect of GREEN SAP.

This is a case that fills us with proud. The use of our medicament, which has already been proved by time and the empiric experience, has led a very difficult prognosis patient, even with the more modern conventional techniques, to a state of health. At the present moment she is in real improvement and can perform the tasks that other people of her age develop. GREEN SAP is a medicament of proven efficacy, even in so dangerous diseases and recommendable in oncology pathology. We can affirm this medicament is a so fortunate finding from the medical point of view that enables us to have such rewards as the one offered by this patient. This medicament is not an improvisation and hundreds of cases all around the world testify so. It creates hope where there is hopelessness, creates strength where the body and the soul weak and from the medical point of view achieves a percentage of cure that plenty justifies what we previously said.


 

 

General conclusions on the GREEN SAP anti-tuor action in the Central Nervous System.

The central nervous system tumors always have attracted physicians curiosity, as for their symptomatology, bad prognosis, therapeutic aggressiveness, and/or many times invalidating sequels.

From children to aged people, suffer from this pathology that by the other hand consist of lots of kinds and sub-kinds of tumors that is out of the case to mention.

Apart from the primary pathology of the central nervous system, there is its metastatic pathology, knowing that a high number of tumors metastatize in it and some of them with special avidity for this area.

GREEN SAP has a preponderant role in this kind of tumors’ therapeutic, having achieved complete remissions and clinic cures with the only use of the drops. Generally the tools used in these pathologies are surgery with total or partial extirpation and radiotherapy. This is because lots of chemotherapy drugs do not cross the hemato-encephalic barrier and cannot accomplish their duty. Sometimes as for example Metotrexate, they are directly placed intra-tecally. GREEN SAP cross easily the hemato-encephalic barrier, being able to act “in situ” on the tumor or tumors of the different intra-cranial structures. The fact that it is possible to place a drug in an inextensible cavity is already an advance in the direct treatment of the tumor or tumors. There is a certain avidity between the tumor cell and GREEN SAP, which provokes a bilateral lasting contact.

Due to potential differences GREEN SAP penetrates in the brain malignant process and perform the actions which in another part of this monograph we referred to.

At central nervous system, flavonoids protoantocianidins that compose GREEN SAP, by its properties of being liposolubles and hydrosolubles, may enter hematoencephalic barrier and this way  protect the cerebral cells, which are sensibles to lesions produced by free radicals.

The quick action of GREEN SAP necrotizing or destroying these tumors, makes that the mass effect they produce (by occupying a place in an inextensible cavity, such as the crane), that gives birth to a very varied set of symptoms and signs, known as endo-cranial hypertension syndrome, GREEN SAP achieves that this syndrome does not take place, or if it does, is very much slight than expected.

There would be an anti-inflammatory collateral action that would benefit the GREEN SAP action at this level. The action that performs at the vomit area, it is also interesting. But what is really interesting is that by reducing the intra-cranial mass, the pain due to compression and concomitant vascular dilatation relieves, which produces very intense and difficult to handle with conventional therapy headaches, what in emergency is generally deplective, anti-inflammatory and anti-comicial.

GREEN SAP “per se”, acts directly avoiding or minimizing the endo-cranial hypertension syndrome because of the reasons already mentioned.

 


Rectum cancer

 

Rectum cancer: Mr. Luis Peralta

Name:                         Luis Peralta

Age:                            61 years old

Country:                      Uruguay

Reason of consultation:

01/09/2002                   He consults because of vegetant tumoration in lower rectum.

Personal antecedents:

                                   No personal antecedents to remark.

Family antecedents:

                                   None to remark.

Present disease antecedents:

Diarrheic depositions since a year ago with comes and goes. Since 12/30/2001 presents recto-rraghia. He has a PAI done and does not present any lesion. In a rectum tactum it is detected tumoration in back and lateral side of rectum, movable, of 30 mm approximately. The CCV shows vegetant tumoration of lower rectum that infiltrates circumferentially the wall 10 cm. Away from the anus limit. The anatomy pathology result is expected.

On 01/09/2002 begins with the medicament at the dosage of 40 drops 4 times per day sublingually.

Disease evolution:

02/01/2002: Presents well differentiated adeno-carcinoma, infiltrative, of lower rectum. A front low resection is performed plus TCT plus Chemotherapy. A relative of his comes with data and clinical register, we indicate increase the medicament dosage to 50 drops 4 times per day sublingually.

07/24/2002: The patient comes to consult in good general state. He presents surgery scar without particularities. The abdomen is soft, depressible and painless, no viscero-megalies are palpable. He finished with concomitant radiotherapy and chemotherapy. Intestinal transit conserved. Professor Torres will see him in a month time. 30 drops 4 times per day are recommended. A control is requested in a month and a half time. Hyperproteic diet.

08/14/2002: The patient comes to consult and is stable, in hospital oncology control. He goes on with 30 drops 4 times per day sublingually.

At the present moment, in real improvement, on release, with a maintenance dosage of the medicament.

Conclusions:

It is about a patient of 61 years old proceeding from Uruguay, with an infiltrative well differentiated lower rectum adeno-carcinoma, he underwent a low front resection plus telecobalto-therapy plus chemotherapy.

On 01/09/2002: begins with the medicament at a dosage of 40 drops, 4 times per day sublingually, which afterwards is increased to 50 drops 4 times per day.

He achieves total improvement and we can see GREEN SAP action in a well differentiated lower rectum adeno-carcinoma.

With no doubt GREEN SAP with its action contributed to the no appearance of metastases and the clinic cure of the patient, who also was treated with conventional therapy, what shows GREEN SAP innocuousness, the high tolerance to it and the lack of collateral effects which led to the patient’s clinic cure. Remarking it is not a clinic cure up to 5 years from now on, as we stated at the beginning of this work, but the expression of the excellent state of health that the patient has at the present moment.

In this patient GREEN SAP action is of no doubt. The experience we have indicates us that in his pathology, is a medicament of first level, achieving complete remissions and a life status, so important in these patients, very superior, reason why there is no doubt for us that GREEN SAP has achieved to revert and control the oncology disease avoiding the dissemination as this work team’s experience throughout the years we worked with this medicament has seen.

 







Conclusions on GREEN SAP action on malignant neoplasies of colon and rectum.

GREEN SAP action on colo-rectum neoplasies is basically mediated by the already exposed mechanisms in other neoplasies. The colo-rectum malignant pathology develops due to many external carcinogens (due to diet) and internal ones (slow development of benign polyps into malignant neoplasies). GREEN SAP would have the faculty of taking the malignant cells into a reproductive zero phase avoiding and stopping carcinogenesis, maintaining the tumor or tumors in non proliferative phase and avoiding therefore the cancerization of this sectors.

Also there would be a property that acts on the vascular structures and leads to tumor necrosis with afterwards tumor expulsion, apart from the intracellular action acting directly on the DNA and disorganizing its bases provoking apoptosis.

GREEN SAP penetrates by the cellular membrane and afterwards by the nuclear membrane due to a membrane potentials alteration mechanism that permeates the malignant cell and makes it GREEN SAP’ target, which is transported up to the nucleus from the cytoplasm.

It provokes too a depuration of the toxins that are in the colon and rectum, leading to a “cleaning” of toxins that damage and help the carcinogenesis.

Its immune-modulating action prevents from infections and viral colonizations that could lead to the development of a neoplasy.

Because of everything previously exposed we are sure of GREEN SAP action (which besides improves the general state) as a useful alternative in the colon and rectum tumors treatment, either being the tumor present or having had it surgery extirpated.

GREEN SAP can act together with chemotherapy also in this pathology as it action is innocuous, with no medicament interactions and free of collateral effects.


Lung Cancer

 

Lung Cancer with Brain Metastasis: Mrs. Liliana Calzada

Name:                         Liliana Calzada

Age:                            48 years old

Country:                      Argentina

Reason of consultation:

07/20/2002                    We are sent Clinic Registers to evaluate the clinic case and begin the treatment.

Personal antecedents:

                                    Without personal antecedents to remark.

Family antecedents:   

                                    None to remark.

Present disease antecedents:

                                    Antecedent of right lung-ectomy due to esquamous carcinoma (01/24/2000) with adjuvant treatment (chemotherapy and radiotherapy), with good afterwards evolution. Then she begins with symptomatology suggestive of encephalic compromise reason why total macroscopic exams are performed on 04/20/2001. Presenting left back parietal encephalic mass. Neurological evolution was favorable in the post-surgery, presenting as an intercurrence surgery scar reason why the bone plaque was removed. In the MNR control presented local recidivism that underwent surgery in the left parietal sector where had been the first time. It was found dural infiltration by neoplasic cells. The dural fraction and the tumor recidivism were extirpated totally performing duramadre’s plastia. Good post-surgery evolution. She was derived again to oncology. The patient has received chemotherapy in 2 lines first CCCP plus VP 16 andn then carboplatine-vinorelbine, also RDT and chemotherapy in thorax and central nervous system. Because of this data we indicate 60 drops orally or sublingually every 6 hours.

Disease evolution:

                                    09/06/2002: Great improvement of his neurological symptomatology with large reduction of pathological image in the central nervous system. She goes on stable without progress of her disease until the present moment. She goes on with 60 drops sublingually every 6 hours.

                                    10/15/2002: Telephone communication with the patient where she informs us she presented convulsions. She had a CAT done which showed disappearance of the metastasis.

                                    11/11/2002: We had a telephone conversation with the patient where she informed us she goes on stable. We suggested her anti-convulsive treatment.

                                    02/15/2003: By telephone communication it is indicated to maintain the treatment as at the moment.

Conclusions:

                                    With no doubt GREEN SAP has benefited the patient who has a grave and of difficult treatment disease, avoiding convulsions (which she had) and achieving a remarkable improvement either in the primitive tumor as in the metastasis. GREEN SAP has a marked anti-neoplasic action in which the GREEN SAP medical staff has a practice of years. The medicament has been of remarkable efficacy in


Lung epydermoid cancer: Mr. Honorio Pereira.

Name:                         Honorio Serafín Pereira Silvera

Age:                            48 years old

Country:                      Uruguay

Reason of consultation:

                                    Progressive disnea.

Personal antecedents:

                                    Intense smoker.

Family antecedents:

                                    None to remark

Present disease antecedents:

                                    He is studied with a thorax computerized thomography on 07/23/1998.

                                    Inform: Immediately above and in front of the right hilium it is observed  a solid mass of approximately 5 cm. which blocks the upper lobar bronchium. Upper lobar athelectasy of that side. Adjacent caesural pleural enlargement. We do not see other lung lesions nor pleural leakage. Lymphadenomegalies latero-trachea right, lower and upper. Sub-carinal and of the pulmonary aortic window. Liver of normal size, shape and density. Supra-kidney glands, spleen, pancreas and kidneys without alterations. Rest of the study with no elements to remark.

                                    Fibro-bronchoscopy from the 11/26/1998: Clinic data: pathological right helium, vegetant process of right lobar bronchium.

                                    Anatomy Pathology: The examined sections show a malignant epithelial proliferation, with the morphology of a moderately differentiated epydermoid carcinoma.

Disease evolution:

                                    BPC  III B stage.

                                    Tele-cobalto therapy, plus chemotherapy is done (CDDP).

                                    Control thorax radiography of 09/01/1998: Marked improvement of the imagenology, disappearance of the right helium mass.

                                    Begins the 10/19/1998: Chemotherapy with cisplatine VP16.

12/04/1998: 5 series of Poli-chemotherapy are done, Cisplatine plus VP 16. Partial improvement.

In November, 1998: Begins with the treatment with our medicament, 30 drops 4 times per day. Total improvement.

The patient at the present moment (April, 2003) is asymptomatic, in real improvement. On release from September, 2000.

Conclusions:

It is about an intense smoker patient, with a lung epydermoid carcinoma, treated with conventional therapy, radiotherapy and chemotherapy with medium acceptable results.

He begins with our medicament afterwards, improving remarkably his general state remaining with a slight disnea but with a quick disappearance of his symptomatology reason why he is on release and considered patient in clinic cure.

This demonstrates the GREEN SAP action in the lung parenchyma and its metastasis.

The patient achieves real improvement thanks to the use of GREEN SAP as he was catalogued as incurable patient by conventional medicine. The patient returns to his original city and only uses GREEN SAP, achieving with this a real improvement that we can homologate to the clinic cures of conventional medicine (5 years). This demonstrates the potent GREEN SAP action on the lung parenchyma, depurating it of the toxins and attacking the neoplasic cell in a surprising way because of its avidity. This is a case that demonstrates once again the proved efficacy by GREEN SAP use, curing a disease of such a difficult prognosis, as Broncho-Lung carcinoma. It is remarkable that the patient develops a normal life, works and is another success of our medicament.

 


Conclusions on GREEN SAP Action on Lung-Bronchium Carcinomas and its Metastasis.

It is doubtless the beneficial action of GREEN SAP on LBC and on its metastasis. It acts by mechanisms already exposed but which are convenient to repeat now. GREEN SAP acts stimulating the cilia sweeping and therefore helping to depurate toxic substances that can settle in the bronchium-alveolar tree.

It has smoke depurating action, either from tobacco or other kind, reducing the tar and nicotine levels absorbed by the bronchium-lung system.

Due to its demonstrated anti-infection action it protects the lunGREEN SAP from repeated infections that by repeating can provoke a fertile ground to the LBC. Besides its immune-stimulating action acts synergic ally in this sense. In a attempt to establish a balance among the noxas that damage the lung and the “immune protectors” trying to promote the last ones so that no disease are produced.

When due to pleural colonization, exhudate or trasudate a pleural leakage is produced, a situation that avoids lung ventilation in different grades due to the leakage importance, GREEN SAP acts in that level provoking a liquid reabsorption, avoiding the trasudate and exhudate and changing the liquid viscosity making it more easily extractable by the evacuator toracocentesis.

This liquid can contain malignant cells or not, but is a complication that bothers the patient by favoring respiratory insufficiency.

As we already mentioned, by acting in the hematosis, GREEN SAP achieves that the hemoglobin transports more oxygen to the tissues and this is of vital importance in patients who have the ventilation compromised.

Referring the encephalic metastasis its action forms part of what we exposed for central nervous system, taking into account that most of the central nervous system tumors are metastatic ones and one of the metastatizers is the LBC.

It also acts on the supra-kidney metastasis by a citotoxic mechanism that we presume would be direct on a cellular level.

The LBC so difficult to treat, and potentially curable in early stages, classically with surgery and radio-chemotherapy, finds in GREEN SAP an invaluable tool, as its null toxicity, innocuousness and lack of collateral effects, apart from its high efficacy in the pathology we are referring to, with proved complete remissions and clinic cures, only by the use of GREEN SAP, makes it a first class medicament. The lung parenchyma answers favorably to GREEN SAP action, which reduces by a prostaglandin inhibitor mechanism the peri-tumor inflammation which is produced in the lung when a tumor is present.

It acts in the vascularization as in other tumors, but also acts in the macro-vasculature, “filtrating” the selected clones that want to implant in the distance to develop carcinogenesis and therefore metastasis. GREEN SAP would act, as by an adhesion mechanism it would block the crossing over of these cells towards the circulation. By circulating attached to GREEN SAP the cells loose their capability of stopping in other organ and therefore develop the carcinogenesis. Of course that the other mechanisms already mentioned in GREEN SAP anticancerigen action also act. For everything here exposed GREEN SAP is of great usefulness and efficacy in LBC treatment of different kinds, with or without metastasis.

 


Pancreatic Cancer

 

Pancreatic cancer: Mrs. Herminia Andarnello

Name:                         Herminia Andarnello

Age:                            66 years old

Country:                      Argentina

Reason of consultation:

07/29/2001                    She consults due to progressive epigastric plenitude sensation. She notes abdominal tumefaction. She presented itchiness and sub-icterical colour.

Personal antecedents:

                                    Without personal antecedents to remark.

Family antecedents:

                                    None to remark.

Present disease antecedents:

                                    She has an ultrasonography done on 07/20/2001 that shows liver increased in size. Heterogeneous parenchyma due to multiple solid nodular images from 25 to 63 mm. that compromise both lobules.

                                    Pancreas in cephalic region. Nodular solid image hipo-ecoic heterogeneous of 33x29 mm. It presents two internal micro-calcifications, pancreas body and tail normal

                                    Retro-peritoneum: nodular solid image, hipo-ecoic of 18 mm. of diameter situated in peri-pancreatic region (lymphadenopathy). Direct Bilirrubine 1.9, Total 9.8

                                    Transaminases: GOT 82, GPT 48

Disease evolution:

                                    11/07/2001: She begun with the medicament with 30 drops 4 times per day on 08/17/2001 until now. From the clinic point of view conserved appetite, she does not feel significant annoyances, neither itchiness nor jaundice, she maintained the same weight from the start when she had lost much. The ultrasonography of 10/11/2001 shows necrosis area in liver nodule. She goes on with 30 drops 4 times per day sublingually.

                                    02/06/2002: The patient comes to consult. She has normal appetite. She does not present epigastric pain. Neither jaundice nor itchiness. She does not bring new para-clinic. It is decided to increase the dosage of the medicament to 50 drops 4 times per day. It is expected to receive more actualised para-clinic.

                                    08/14/2002: A relative communicates and informs us that the patient takes the medicament periodically and is clinically stable. She did not more para-clinic studies because she herself asked so (the patient). She never stopped taking the medicament and now we recommend to increase the dosage to 60 drops 4 times per day.

                                    She passes away in September, 2002, due to her pathology, remarking the excellent survival she presented and the graveness of the disease she was suffering from.

Conclusions:

                                    Pancreatic cancer is a pathology of high lethality and short survival once diagnosed. Of this patient more than the survival, in time terms, we remark the life quality she maintained until the end of her disease. Generally the patients suffering from pancreatic cancer lead a very impaired survival, with a marked general repercussion and pains in the solar plexum that many times lead to the use of radiotherapy as a painkiller, with the results that many times this has. GREEN SAP acted in the pancreatic cell level minimizing the suffering due to its painkiller effect, offering the patient a worthy and useful survival.

                                    In this patient it shows us another aspect of its action. By a direct and endorphin liberating action, it eased the intense pain the patient suffered from, leading her to the acalmy. It achieved that in an ominous and grave disease, such as pancreatic cancer, which besides, causes multiple sufferinGREEN SAP, our patient had a worthy survival, without pain, with a normal intestinal movilization, without bilio-hematic derivation, having a survival that it is not frequent in pancreatic cancer. This she owes to GREEN SAP.

 


 

 

 


Conclusions on GREEN SAP Action on Pancreatic tumours

Pancreatic tumours can be from the hexogen or the endogen pancreas, by this we refer

To the cells that can be affected by a neoplasm. Those of hexogen secretion, for example: pancreas head tumour, or those of endogen secretion (insulinoma), it is not the purpose of this monograph to make a medicine treaty, this is why we will not stop in the classification of pancreatic tumours, but in the effect that GREEN SAP has on them.

GREEN SAP acts moderating the pancreatic secretion would this be endogen or hexogen, it has direct citolitic action on the pancreatic neoplasic cells, by reducing the tutor vascularization and affect the cancerous DNA provoking disturbs that make the tumour cell die.

It is very important the painkiller effect that GREEN SAP has and that is manifested in this kind of neoplasies very markedly. Generally pancreatic tumours, specially the hexogen pancreatic ones compromise due to their situation the solar plexus, causing pains that turn out to be really untreatable even with plain dosage morphine.

GREEN SAP, by inhibiting the secretion of inflammation mediator substances and of prostaglandins, easies the great pain these pathologies cause.

Also as it has an immune-stimulant effect, delays the neoplasic caquexy so characteristic of this tumours. Generally it delays the appearance of liver metastasis and the tumour adhesion to neighbour big veins, which makes them many times inextirpable, nevertheless GREEN SAP by a direct mechanism on the tumour cell, maintains the extirpation levels and many times the patient can achieve a radical surgery (body-cephalic duodeno-pancreatectomy), or a palliative one (colecisto-yeyunostomy) (stomach-yeyunostomy) that improve the patient’s quality life, apart from prolonging it and avoiding the bilio-hematic derivation so common in the pancreas head tumours.

In endogen tumours by the mechanisms already known, it acts and avoids that substances like insuline (insulinoma) are secreted, or like in the gastrinoma which produces a gastrine aberrant secretion.

 


Thyroid Cancer

 

Thyroid Cancer: Mrs. María Pilani

 

Name:                         María Julia Pilani

Age:                            46 years old

Country:                      Uruguay

Reason of consultation:

03/13/2002                    She underwent surgery in May, 2000 due to a thyroid nodule, having a total thyrioidectomy done, lateral neck ganglionar depletion. Anatomy pathology: Medullar thyroid carcinoma. Carotid ganglions with massive substitution. Para-clavicle ganglions with massive substitution.

Personal antecedents:

                                    Without antecedents to remark.

Family antecedents:

                                    Intense smokers parents

Present disease antecedents:

                                    08/15/2000: Reviewing the patient’s clinical registers, specially the surgery description and its anatomy pathology, and the result of the centellogram with MIBI which does not show capture of the radio tracer at the thyroid logia it is necessary to make a neck ultrasonography to evaluate if with it a glandular residue can be found, not able to be found centellographically. If no thyroid residue can be found and considering the histological type of the tumour to treat no yodum capturer it is considered unnecessary the administration of the high dosage of therapeutic yodum. Although the patient has the centellography study with yodum coordinated as a complementary study to evaluate the possibility of residual thyroid tissue, not observed with the previous study (reason why the patient is without hormonal treatment), it is believed of convenience to reinitiate hormonal therapy and make a dosification of calcitonine as tumour indicator and from the centellography point of view make a DMSA penta-valent (radio tracer used in these cases to observe lesion extension).

Disease evolution:

                                    01/16/2002: She has surgery done due to lymphadenopathies in the same place.

                                    02/18/2002: Parathormone intact 32,8 pg/ml

                                    03/13/2002: She begins with our medicament. She starts with 40 drops every 8 hours.

                                    04/20/2002: She goes on with the medicament 40 drops every 8 hours, with good result. The calcitonine is reduced, the do not bring the exam, control in 3 months from now.

                                    07/17/2002: She goes on under control, receives 40 drops 4 times per day, control in 3 months from now.

                                    09/11/2002: Unchanged general state with the received treatment.

Conclusions:

                                    This case was included in this monograph in order to show the GREEN SAP anti-tumour action on thyroid. Although we lost contact with the patient and the pursuit is not complete. By the data we have we know about the GREEN SAP beneficial effect on the patient and the hormones that were measured. Take a look on the para-clinic studies. It was about a Thyroid Medullar Carcinoma with carotid ganglions with massive substitution and para-clavicle with massive substitution. She started on 03/13/2002 with our medicament, 40 drops every 8 hours, stabilizing the hormones (parathormone). GREEN SAP also has a hormonal action and this is what notoriously benefit this patient, enabling her a normal life although her advanced disease, the tumour type and the organ in which the neoplasm was placed.

                                    This benefit, that notoriously improved the patient’s life quality as we have been proving throughout the time, as it is a high efficacy medicament, has been of great benefit for this patient.

                                    The use of the medicament favoured her in several medical ways and this is GREEN SAP’ accomplish, as the staff who work with this medication for years has demonstrated to be of proved efficacy.




Conclusions on GREEN SAP Action on Thyroid tumours.

Thyroid tumours, would they be papillar, follicular, medullar or anaplasic, generally

Cause a generous extirpation, being according to the tumour, total or sub-total

thyroidectomy.

Generally the follicular and papillar tumours are of slow evolution, whereas the

anaplasic is a great malignancy tumour that causes oncology urgencies due to tracheal

compression, what motivates immediate surgery. In the great majority yodum

radiotherapy is used, radioactive that is of great efficacy if there are residues of the gland left. GREEN SAP acts as moderator of the residual thyroid secretion in case there was any, also preventing the appearance of metastasis in the distance or intra-thyroid, this made by an endocrine action what makes us think in a hormone mediated action, in which GREEN SAP would act as hormone-like allowing to maintain acceptable levels of thyroid and parathyroid hormones, knowing that many times during surgery the para-thyroids are accidentally withdrawn needing the patient to receive the hormone in an hexogen way, the same as when there are extended or total thyroidectomies  he must receive the thyroid hormones by external ingestion. The GREEN SAP mechanism of action on the tumour, if this is present, is by a mixed action, anti-angiogenic and direct citotoxic, altering the tumour DNA bases, as it does in other kind of tumours. From this it derives that some patients prefer not to undergo surgery but make a non conventional medicine treatment instead, in this case GREEN SAP, achieving success, obtaining in many cases, the tumour lisis, maintaining always a control with thyroid biochemical profile and serial neck ultrasonographies, in order to avoid the tumour reappearance or the metastasis that can appear in the neck or in the distance.


Vulva-vaginal Carcinoma with
Metastasis

Pathology: Vulva-vaginal Carcinoma plus Solid Basal-cellular Carcinoma: Mrs. Terezinha de Oliveira.

Name:                         Terezinha de Oliveira

Age:                            59 years old

Country:                      Brazil

Reason of Consultation:

Ulcerated skin lesions, in nose, coccyx, right hand and right maxillary.

Personal antecedents:

                                    Without personal antecedents to remark.

Family Antecedents:

                                   Without personal antecedents of relevance.

Present disease antecedents:

                                   She initiates radiotherapy on 03/03/2001, after a rescue surgery.

                                   04/02/2001: With no signs of disease, only slight actinic sequels.

Disease evolution:

06/20/2001: She consults us because of ulcerated skin lesions, in nose, coccyx, right hand and right maxillary.

Inform of hand sample: solid Basal-Cellular Carcinoma with deep margin compromised. It is about a patient with skin Type 1 (Fitzpatrick Classification) with chronic solar exposure which showed solar elastosis, actinic melanosis, solar leuko-dermias, actinic queratosis, some basal-cellular carcinomas. The basic treatment during this period was: solar protection, creams based in alfa hidroxi-acids, crio-cauterization of the queratosis with liquid nitrogen spray, surgery extirpation of the basal-cellular or subjective lesions.

In reference to the radiant treatment performed due to her vulva-vaginal carcinoma, it was performed in the first place, a rescue surgery treatment and afterwards radiant treatment practiced with photons of particle lineal accelerator in 10 MB for total pelvis, applying the dosage of 5040 cGy in 180 cGy fractions. The brachi-therapy of low range dosage was applied with the use of vaginal cylinders of 2,5 cm. Of diameter. 176  - 179 – mg of 137 Cs charges, with a dosage exposure of 4793 cGy in the vagina surface in the upper third. Treatment administered between 02/08/2001 and 03/03/2001.

Rectal and cisto-rectal mucous reaction which were medicated.

On 06/26/2001: She begins the treatment with GREEN SAP drops and gel. Dosage: 30 drops 4 times per day. Gel in the compromised areas twice a day.

On 11/25/2001: The dermal lesions we have already mentioned, disappear.

At the present is in a real improvement, on release with a maintenance dosage of the medicament.

Conclusions:

It is about a 59 years old patient proceeding from Brazil, suffering from a Vulva-vaginal Carcinoma treated with chemotherapy until the 11/23/2000. Afterwards she has a rescue surgery performed due to recidivism and radiotherapy with posterior brachi-therapy.

On 04/02/2001 there are already no signs of the disease.

On 06/20/2001 she consults us due to ulcerated skin lesions, in nose, coccyx, right hand and right maxillary which correspond to solid basal-cellular carcinoma with compromised deep margin.

She begins the treatment in June, 2001 with GREEN SAP drops and gel, on November 25th., 2001 having the lesions disappeared.

This demonstrates us the GREEN SAP highly beneficial action on skin carcinomas would they be of high or low malignancy grade.

Although her vulva-vaginal carcinoma was not treated with GREEN SAP, the medicament also plays a preponderant role in the cure of this neoplasies.

The skin neoplasies were cured with GREEN SAP as it was demonstrated and the patient herself let us know so. The medicament is very useful in skin cancers, from the more indolent to the more grave ones which can cause death. But GREEN SAP once more acted through multiple mechanisms, achieving the cure of this patient’s skin disease, as we have proved with many other patients.

The vulva-vaginal cancer also could have been treated with GREEN SAP, which has an excellent effect at this level, acting by different mechanisms that are explained in “Conclusions on GREEN SAP action on vulva-vaginal cancer” (page 197), as well as we have proved in numerous cases with this disease.

 


Conclusions on GREEN SAP Action on vulva-vaginal neoplasms.

GREEN SAP acts in these neoplasies by a direct effect as it has already been mentioned and besides it has a very important role from the immune point of view, preventing the pre-cancerous lesions of this sector of the organism.

Generally a tumour extirpation is performed and afterwards tele-cobalto-therapy or brachi-therapy. Many times the patients come after having the conventional therapy done and the vascularization is not good. Therefore GREEN SAP contributes to improve the general state, improves the appetite and the physical activity, which allows a better quality life and a longer survival. There are cases of patients treated only with GREEN SAP who achieve a complete remission and clinic cure, but used after the conventional therapy its action does not interact with the other treatments, due to its proved innocuousness and lack of adverse interactions and disgusting collateral effects make it an important tool and of first class in these tumours treatment. For all this it is recommendable the use of GREEN SAP in these pathologies, with serial controls, biochemical and ginecologic ones, and adjustment of the drops dosage to take until the arrival to a maintenance dosage.

To summarize, GREEN SAP acts in these neoplasies by the mechanism already exposed, direct citotoxic action, inhibition of the neo-vascularization, increase of the immunity, anti-infectious activity and an anabolizant action that leads to the ground improvement and therefore of the general state.


Conclusions on GREEN SAP Action on skin neoplasms.

GREEN SAP acts on skin neoplasies by a repair mechanism of the lesion or the lesion layer if this was extirpate. It is used orally so it acts systemically arriving to the lesion and acting on it causing citolisis, increasing the immunity which is impaired and provoking by immune-modulating effect an anti-neoplasic action.

The Gel is also used concomitantly which penetrates through the skin layers in order to act directly on the tumour focus and allowing a long-lasting skin repair. The Gel penetrates easily the different skin layers and easily reaches the cancerigen focus, eliminating it through the same effects as systemically, the difference being the way through which it reaches the neoplasm. It acts on the tumour provoking the desaferentization of the neo-vasculature disordering the nuclear DNA, acting on its bases and by a direct citotoxic action penetrating the tumour cellular membrane, altering the membrane potentials, this is why GREEN SAP has a deserved place among skin carcinomas treatments, from the more malignant to the more indolent ones, generally achieving a clinic cure, taking into account the stage in which the tumour treatment was faced and also taking into account the existence or not of metastasis on which it also acts by the same mechanisms that acts on the primary tumour.

 


FINAL CONCLUSIONS ABOUT GREEN SAP

GREEN SAP drops has demonstrated anti-tumour action, either “in vitro” and “in vivo”, in animals and humans. Improving life quality, and by a direct effect on the tumour. By saying improving life quality, it improves the appetite in anorexic patients, reduces pain, helps to heal and moreover for the review of international literature its components have a series of effects among which we find the reducing of the tumour size what is the major objective. It improves the immunity strengthening the patient. It has anti-bacterial activity what is also useful in case of opportunist pathogens.

It lacks secondary effects. It is innocuous and has no contraindications.

It can be used with the traditional anti-neoplasic therapies without interfering in no way with them.

The components are safe, known and of long use in non traditional medicine, what guarantees its quality to join and form a compound that unifies the best properties of them all.

GREEN SAP drops has had success in veterinary and human medicine as the cases that we have presented guarantee.

They are result of the observation, essay and practice of its components.

It is expected they are part of the therapeutic arsenal to treat neoplasic processes, in a near future, benefiting the people suffering from this disease, which is of a multifactor origin.

The topic use of GREEN SAP has resulted in cheloids and psoriasis, skin diseases which practically can not be reverted with conventional therapy, is it by their recidivisms or by not achieving to eradicate them during the first treatment.

ONCONAT GEL has showed to be active in both diseases and its results are “a priori” very encouraging as in many cases it achieves the cure of the mentioned pathologies which generally do not recur with the ONCONAT GEL; making it with surgery, liquid nitrogen, etc. (in the case of cheloids) for example.

In our experience either in pathology and in skin the results have been very good. Would it be combining conventional therapy with GREEN SAP or using GREEN SAP alone in the treatment of the current pathology. This casuistic has been done privately and we expect some time be able to introduce GREEN SAP in the hospital background, with no doubts of the benefits this could have.

Therefore, GREEN SAP is a new tool to fight this disease of difficult resolution, as is cancer, which is invalidating, with expensive treatments and many times inefficient, with disgusting collateral effects. This is why the use of this natural therapy is hopeful to achieve a better answer to the treatment and an upper quality of survival.

 


OPINION OF SOME HEALTH PROFESSIONALS WHO HAVE EXPERIMENTED THE USE OF THE MEDICAMENT IN THEIR PATIENTS.

 

Dra. Araceli Tashjian

Rheumathology post-graduate

NCP 70898

Uruguay

 

Present.

I’m sending to you my opinion about the use of our new product made of original herb extract of our country: GOTAS GREEN SAP.

Because of its excellent qualities I have treated different types of tumor and in different stages of the disease, with the best results: less tumor mass, less volume of metastases, a good tolerance to chemotherapy and radiotherapy, and decrease the pain.

The product is non toxic for that reason it can be indicated in adults and in pediatric patients, showing good tolerance.

Besides it can be taken at the same time with conventional treatments, because there is no medicament interaction.

For all these, I find GOTAS GREEN SAP an optimum natural alternative treatment, to be used in oncology patients.

I remain at your orders and receive my regards,

Dra. Araceli Tashjian

 

Dra. María del Carmen García

Dermatology post-graduate

NCP 56241

Uruguay

With my best regards,

I am writing to you in order to make some comments about the new anti-cancerigen medicament based on natural extracts from autochthon herbs of our territory, GREEN SAP Drops.

 

Upon the observation of the collected data of the cases treated with this medicament, about patients suffering from different types of cancer in different evolutive stages, I can transmit you that they show: considering their own comments on their subjective symptomathology,  that within a few weeks of beginning the treatment, the great majority of them already feel relieved from their pain taking into account they need less quantity of conventional analgesia to cope with it, with greater motility, more energy to do their activities, with more appetite, more vitality, with a generalized well being; and considering de objectivity of such improvements, in a great number of cases, depending on the precocity of the beginning of the treatment in some of them, a visualization through the battery of complementary exams made, of a reduction of the tumor size and in some cases of their complete disappearance.

 

For what, resuming, we can tell that GREEN SAP Drops is capable of offering the oncology patient, almost all of them, a well being and relief of the symptomathology, which is the first goal to accomplish with the medical act in the cases where there is no other prognosis alternative, and in the cases of earlier states capable of a cure, a real possibility of a natural therapy, without the secondary effects or the aggressiveness of the conventional oncology therapy (although it can perfectly be used at the same time), which offers a new hope for these patients.

 

We remain at your order for any further question you want to ask, truly yours,

 

 

Dra. María del Carmen García

 

Dr. Joaquín Velarde

General Physician

Perú

 

GREEN SAP is an extraordinary formula with which I could notice that the patients that have begun to be administered to, immediately show fundamental signs of improvement, I should consider that one of the aims that has to be accomplished in the treatment of neoplasic diseases is pain control, which is unbearable, not only for the patient, but for the family also and for the physician, with GREEN SAP the pain subject is controlled with great velocity and effectiveness.

In precise cases where the patient is hopeless as conventional medicine can not solve the problem, with GREEN SAP medicament really we can not still think this way, as the fight against the neoplasm can be initiated at any phase of this pathology; by this I mean that I noticed that it is never too late to initiate GREEN SAP treatment.

GREEN SAP is a reliable formula for the treatment of any kind of Neoplasm, within the desperation it opens the window of hope, treating neoplasies with this formula is no more the constant deception to which many of us are used to.

 

Dr. Joaquín Velarde

 


Dr. Miguel Aristy

 

Internist and Neurologist

Dominican Republic

 

Personally, I do not have any final cure statistics. I do have radiographies, for example, from the brain where a multiform glioblatoma evolution is being shown. Apart from that I have 30 clinic reports with considerable improvements and many others, not being patients of mine.

A particular example was one of a woman with an uterus cancer, with liver and bone metastasis. She had the uterus extirpated and underwent radiotherapy. She had to quit her job because she vomited everyday and could not even swallow the saliva. In only 3 days this woman was incorporated to her job. I still do not have the proof of total elimination, but if proofs value, I have all the world’s ones.

Supposing that a placebo could act this way, then I would use placebo, because it allowed me to offer the cancer patients a comfortable life.

Anyway I refer them to Uruguay, where they have much more clinic experience than me, specially because I do not have 6 months in using the product.

I say good-bye, not without telling you that the suggestion can be maintained for sometime, not forever, and if 3 or 4 months that my patients have of treatment, have allowed them a breath-take in reference to sleep, pain. Summarizing, life quality, these products, only just for that have validity.

A hug,

 

Dr. Miguel Aristy

Internist physician and Neurologist

 

 

Dr. Carlos Eduardo Medina

 

Physician specialized in Neural Therapy and Clinic Homeopathy

Colombia   

 

A cordial hug.

In reference to my observations on GREEN SAP Drops, they can be resumed as follows: I have seen that the less they produce is a life quality improvement in the cancer patients. When they are definitively terminals, they help a lot they can make their final step in peace and without pain. In some of them the improvement starts in a few days, increasing the appetite and reducing the pain, sometimes in an admirable way. In some others, I have seen the detention of the tumour growth and the process stays “frozen”… Summarizing I could say that it is a therapeutic element very important that acting in an unspecific way on the immune system achieves to improve the life quality of the cancer patient, increasing his survival, relieving his annoyances associated to his kind of tumour, stopping the tumour growth. It is also very notorious its protective action against the side effects of the radiation and chemotherapy. I believe that within a biological scheme of facing the cancer patient, GREEN SAP Drops must occupy an important place due to its clear anti-tumour action and because of the lack of secondary effects.

 

Carlos Eduardo Medina Arenas M.D.

 


Some E-Mails received from patients treated with GREEN SAP

 

From: diskcarimbos@terra.com.br

Sent: Tuesday, October 01, 2002 8:47 PM

 

I would like to inform you (Mr. Pacheco) had some tumours (melanoma) in the brain. One of them was of 1,8 cm. and others small. From the point of view of the doctors that treat my father, he had 3 months maximum of life. But anyway my father had from 25 to 30 radiotherapy sessions done in his brain and before that had a chemotherapy session. My father begun the radiotherapy and at the same time the use of GREEN SAP Drops. We are in October and 3 to 4 months have already passed since the beginning of this treatment. We performed a battery of exams, tommography, radiography, blood exam and many others, it was demonstrated that my father does not have any tumour in any other part of the body, but only in his brain, and that this biggest brain tumour did not grow, that is, my father’s disease is stabilized. He has great weakness in his leGREEN SAP and already had thrombosis, but it is under control. He does not feel headaches, and we are hopeful that this tumour would have stopped growing, as from the doctors’ point of view if it was growing, my father would not have had more than 3 months of life. This is more or less my father’s clinic situation. I ask you to send me some answer so that we can go on with the treatment which has never stopped. I am grateful!

 

Data: Saturday, April 28th., 2001

PATIENT’S DATA         

 

Name: Mirna

Surname: Galarza

Contact: Son

Contact’s name: Daniel

City: Reconquista

Country: Argentina

Telephone: 03482-421200

Address: San Martín 1456

Clinic story: She started with anaemia. The cause was looked for without results. She had done: Ultrasonography- serial radiography- Blood exams- Proteinogramme- Colon-enema (diverticulas and some polyp were found). The only thing that continues abnormal is the eritrosedimentation value (it reached 100 mm/h). (can be due to the osteoporosis? or due to a rheuma or arthrosis process?. She does not feel any annoyance except for the joint pains, she did not loose any weight.

 

Clinic Diagnosis: By now and by phone, osteoporosis.

 

Anatomy-pathology Diagnosis:

 

Surgery: No

 

Kind of surgery:

 

Chemotherapy: No

 

Scheme:

 

Radiotherapy: No

 

Dosage:

 

Tolerance to medicaments: Good

 

From: Hugo Daniel Montyn

Sent: Wednesday, July 25, 2001 9:09 AM

 

Claudio, how are you, the new order to purchase 5 bottles is already done. I tell you my mother is doing a normal life with very little joint pain and she will be beginning the 15 daily drops intake. I hope the delivery will be fast as she has only one bottle left. Thank you very much.

Daniel

Reconquista. Santa Fe. Argentina

 

 

From: Daniela Eguiazabal

Sent: Sunday, July 14, 2002 11:40 AM

Subject: Elsa Julia Frattesi

 

My mother is 61 years old and she has Parkinson since 15 years ago. Three years ago she was diagnosed bone-necrosis in her right knee which has left her almost unable to move by her own means. At the beginning of the year she started with genital haemorrhages (as if she was menstruating) and a fibroma was detected, they began treating her to stop the haemorrhages but after a couple of months they repeated again that was why they decided to perform a biopsy to analyse the causes. Dr. Copolecchia (ginecologist) was in charge of practising the biopsy and it was him who detected the uterus horn lesion. After confirming the diagnosis with the pathology results he contacted us with Dra. Brosio (oncologist) who told us that the lesion’s grade of advance avoided they could make a surgery and extirpate the damaged part and that the treatment we should follow by now was radiotherapy. This new situation caused us a lot of affliction and we started to look for alternative solutions and there was how marvellous comments about the drops reached us. We consulted the web site and are very anxious to begin the treatment with the drops as we trust they will be able to help us to overcome this new challenge life gives us.

Well, we are looking forward to hearing from you soon.

HuGREEN SAP.

Elsa, Daniela and Pamela.

 

From: Daniela Eguiazabal

Sent: Tuesday, July 16, 2002 12:21 AM

 

First of all we would like to thank you for your soon reply, as we are really very interested in our mum beginning as soon as possible with this treatment.

Tomorrow we will have the computerized tomography result and the thorax and pelvis radiography which she had done last week, but we can advance you some dta of her general state.

She takes her Parkinson medication every three hours, but sadly as she is in the limit dosage, the druGREEN SAP are not sufficient to maintain the improvement until next dose. When the medication is “low” her general situation is characterized by very intense muscle pains, loss of muscular tone, stiffness, slow movements and anguish states and reluctance which oblige her to stay laid down until next dose makes effect. While the medication is “high”, although she keeps on having motility problems, she is able to develop her daily routine in a better way and her spirit tends to improve.

At the present moment she is overweight, but the last clinic exams (urine, blood, blood pressure, etc.) show results within normal parameters. It must be mentioned that within her diet it is not recommended protein intake, at least during the day, as it blocks druGREEN SAP effect; additionally she does not present difficulties in the ingestion of any kind of food, although she must control quantities as she has a hiatus hernia, which causes her reflux when she feels too plenty. She has some intestinal troubles, that is why every night she takes a digestive herbal tea and a spoonful of Vaseline, which lets her regulate the situation.

Her spirit suffer from some ups and down, but she is supported by her family and the psychiatrist who sees her for more than 2 years now, that is why observing her we notice she is confronting this situation quite well.

We hope this information would be useful to you to define mum’s treatment, and as soon as we have the previously mentioned studies’ results, we will be in touch with you.

We ask you please to let us know if we already are in conditions to start the treatment or it is necessary to send you more information. If we are in conditions to start, please let us know the drops’ cost and the fastest way to access them.

We say good-bye and thank you for the aid you are giving to us.

 

Elsa, Pamela and Daniela

 

From: Daniela Eguiazabal

Sent: Friday, August 09, 2002 5:26 PM

Subject: Medicament’s delivery

 

Hi, we just wanted to inform you that we received without any kind of problem the drops and mum has already begun with the treatment following the instructions you sent us by mail. As it was to be supposed, some doubts aroused which we hope you will be able to answer us.

1)       How do we have to store the bottles that are not being used?

2)       Can she take the drops with her Parkinson medication?

3)       Is it necessary that half an hour after taking the drops she eats anything?

Well, these are the inquiries that aroused by the moment, we say good-bye and we hope we will be able to send good news soon.

HuGREEN SAP.

 

Pamela and Daniela.

 

From: Daniela Eguiazabal

Sent: Monday, January 06, 2003 7:20 PM

Subject: Good news from Elsa Frattesi

 

Hi to everybody,

 

It’s us again to tell you that luckily mum already finished the ray applications and the studies showed that the tumour has reduced and become fibrosed. There are also good news about her bladder, luckily it is not damaged and it was possible to retire the catheter she used since 5 months ago.

Luckily the clinic general situation is very good as well as her spirit and the doctors are very happy with the obtained results.

For all this we would like you please to tell us how do we have to follow the drops treatment, do we have to administrate the drops the same way (4 times per day 45 drops)? Until when does she have to take the drops?

This Friday my mum is travelling to the coast to enjoy some deserved holidays in the beach and if you consider it is necessary for her to go on with the treatment we would  need you to prepare urgently for us six bottles which will be taken from your office in Montevideo as the last time.

Well, we kindly say good-bye and hope you can answer us as soon as possible.

 

Pamela and Daniela Eguiazabal.

 

From: Delaigue, Hernan HM

Sent: Thursday, December 21, 2000 5:37 PM

Subject: Delivery confirmation

 

Mr. A Manuel,

 

Hi, well as you mentioned in the attached e-mail, I have not heard of the medicament’s mail until this morning, so as to withdraw it from my city’s mail box.

So once in my hands I will let you know.

Have a merry Christmas and a happy new year.

 

Hernán Delaigue R.

 

From: gotitas.com

Sent: Wednesday, December 20, 2000 4:59 PM

To: Delaigue.Hernan.HM@bhp.com

 

Dear Mr. Hernán Delaigue,

 

Due to the absence of mails from you, we are worried about the arrival of the medicament up to your home, as we are in a more than prudential time for this delivery to be in your hands, in case it has not arrived, we ask you please to communicate with the customs or with your country’s accelerate mail system. As soon as you have some news please let us know so that we can download in our registers such information, also if it is already in your hands.

We are sending you a big hug from Uruguay, remaining at your order as always.

 

For gotitas.com

  1. Manuel

 

From: Delaigue, Hernan HM

Sent: Thursday, January 03, 2002 6:28 PM

Subject: Cheloid treatment

 

Sirs,

 

I am writing to you in order to tell you that the cheloid treatment recommended by you applying the drops, was totally eliminated, only remaining a scar. The cheloid my son had behind his ear produced by a surgery had produced itchiness, inflammation and an always irritated area.

This is why I thank you for the attention and recommendations when I asked for them.

I hope you have had a merry Christmas and wishing you all the best for this new year, and hope you can reach many other persons who need an improvement.

 

Sincerely yours,

 

Hernán Delaigue R.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Saturday, June 22, 2002 9:36 AM

 

Dr. Bernardo Udaquiola,

Mauricio Ruiz’s case

 

I thank you for your attention of immediate answer to my e-mail, but I would like to make some corrections of some mistakes made in the writing of the previous one and are referred to:

  1. The tumour in the first opportunity (November, 1995) manifested in: “right hemisphere, extending from the front pole of the right temporal lobe (intra-ventricular portion) to the middle line” and back to the occipital pole”, from the inform of the neuro-surgery. A total extirpation is performed. Anatomy-pathology: ependimoma.
  2. In the second opportunity (August, 2000) it is about a recidivism. In the same area and he undergoes a surgery with total extirpation. Anatomy-pathology: malignant ependimoma. Post-surgery radio-surgery with 5940 cGy application in 33 sessions of 180 cGy.
  3. In the third opportunity (February, 2002) a nodular image is observed in the left frontal horn. Treatment: neuro-surgery.

All the content is correct except for the indication of the brain side in which the tumour was situated in each case as I exposed in the previous e-mail.

I beg you notify me of this mail reception. I will be expecting any need of explanation and we expect with interest your recommendations and the possibility of the use of GREEN SAP.

GreetinGREEN SAP.

 

Hugo Ruiz

 

From: Hugo Ramon Ruiz Fleitas

Sent: Monday, June 24, 2002 5:23 PM

Subject: Mauricio Ruiz’s case

 

Dra. Araceli Tashjian Ramirez,

 

Allow me to thank you from now on the interest in answering my consultations referring to my son Mauricio’s case. Due to some mistakes made in the first e-mail sent, I rectified them through another one I sent on Saturday 22nd. of the current month. To be more clear about it, I consult you:

  1. Being a boy (8 and a half years old) the proposed GREEN SAP dosages are normally tolerated?; and also is there in your registers antecedents of brain tumours’ treatment, in our case it is an “ependimoma”?  Which were the results?
  2. As I have exposed to you previously, in this moments we are in an observation process of the reaction the tumour shall present to the “radio-surgery” treatment performed in March of the current year. The first controls show tumour cells necrosis, what even produces an important oedema surrounding the tumour, provoking headaches. It is expected an answer to a “corticoid” based treatment and in case of slight reaction we could undergo a new surgery. Do you believe it could be co-adjuvant to the treatment and afterwards preventive the use of GREEN SAP?.
  3. We are very interested with no doubt in the use of GREEN SAP drops, we will confirm you afterwards our delivery as you suggest or by another person means who travel frequently to Uruguay. Even for the moment, after your answer to the present mail, we could already be using the medicament available by some friends who already use it in Asunción. Referring to the proposed diet, we have already adopted part of it and we will be adjusting it according to your recommendations.

Kindly yours,

 

Hugo R. Ruiz Fleitas

 

From: Hugo Ramon Ruiz Fleitas

Sent: Tuesday, June 25, 2002 5:13 PM

Subject: Mauricio Ruiz’s case (2)

 

Dra. M. del C. García,

 

Thankful for the soon reply to my requests and helping for a better acknowledge of the referred patient I inform you that Mauricio has at this moment 34 k. and is recovering from the oedema that surrounds the tumour which was target of radio-surgery on March 25, of the current year. It causes him headaches he is being treated with corticoid (2 mg every 6 hours) and now and then he throws up.

We are awaiting for his MR periodic controls to decide eventually a surgery to extirpate the tumour in necrosis process; if the patient does not react to the treatment previously mentioned.

I will keep you informed. I expect your comments.

GreetinGREEN SAP.

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Friday, June 28, 2002 10:46 AM

Subject: Mauricio Ruiz’s case (3)

 

Dra. M. del C. García,

 

I repeat my thankfulness for the deference of soon reply to my consults. Following the first instructions received in the previous e-mail and as I commented, thank to the availability from another patient of yours who have in Asuncion a GREEN SAP bottle for his use and so as not to loose time we have already initiated Mauricio’s treatment from Tuesday 25th. of the current month with 45 drops 4 times per day. With the complementary information I sent you afterwards (patient’s weight 34 kl) you instructed me on a new dosage: 25 drops three times per day; we will plan for the rest of the first month and I will keep you informed so as to accompany the treatment. Our purchase of bottles is on the way. GreetinGREEN SAP.

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Thursday, July 25, 2002 7:08 PM

Subject: Mauricio Ruiz’s case. Evolution

 

Dra. M. del C. García,

 

We have received your e-mail and will be waiting the arrival of your “drops” delivery.

In reference to Mauricio’s evolution, as I previously informed you he underwent on March 25th., 2002 a radio-surgery and from the end of May he suffered from strong headaches. He was hospitalised from May, 31st. to June, 12th., afterwards from June, 25th., we started using the “drops”, following received instructions, but was interrupted from the 29th. of the same month due to an intensification of the headaches, he had very strong vomits and  was hospitalised from June, 30th. to July, 5th., being strong medicated based in corticoid. For all this we have effectively and uninterruptedly administrated the “drops” to him from July, 2nd. Mauricio had a magnetic resonance control done on July, 19th., and the doctor’s comment says: “ it is observed a reduction in the peri-lesional oedema and a reduction in the administrated contrast’s capture”.

I can tell you that the patient is in very good mood, good appetite, with no headaches since we came out from hospital, but with lots of cares so as not to expose him to eventual infections, due to his corticoid based treatment, which would reduce his defences (as for the doctor’s expression). With this comments, we understand that the administrations of the “drops” are contributing to his good recover and we expect your indications to go on with the treatment. GreetinGREEN SAP.

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Friday, July 26, 2002 7:15 PM

Subject: Drops arrival

 

Dra. M. del C. García,

 

I thank you for the soon reply to our request of bottles of “drops”. Certainly, today at 17:00 of Paraguay we received the bottles you sent so as to administer them to Mauricio. Yesterday I sent you comments referred to the patient’s evolution and as we are accomplished the first month of medication, I await by this same mean your recommendations to go on with the “drops” supply. I repeat my thankfulness, and kindly yours,

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Friday, September 13, 2002 6:52 Pm

 

Dearest Dra. Ma. del C. García,

 

I appreciate your interest referring to Mauricio’s evolution as well as the information about the GREEN SAP Paraguay’s representative. I must make it clear, however, that I did not have any trouble with your drops delivery in previous opportunity.

Certainly on August 27th. Mauricio had a new MR exam, and afterwards we were informed that the “brain oedema” has reduced significantly what led to determine to reduce his “corticoid” dosage (which he received in a maximum dosage) in order to retiring it totally but slowly. Referring to the tumour it presents a slight improvement, with reduction of the contrast impression in its borders. We expect this is part of a process in order to the disappearance. His next control will be done at the end of October.

He is receiving the drops in the previously indicated dosage and evidently he tolerates it very well, with no adverse reaction. His spirit is good, with great vitality, with normal activity. He is clinically stable, with no disturbance.

I would like to consult you the following: I consider important that you could see the MR images we have been performing (for example the 3 or 4 last ones), so as to have a clear idea of the lesion’s evolution. This is why I could send you by courier the radiographies, but we would have to have them back to continue the controls. In case you want so, to which address I should send them? And how much would be the cost of re-sending of the radiographies? I repeat my thanks for the interest manifested and awaiting your comments, I say good-bye.

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Friday, September 13, 2002 6:59 PM

Subject: Previous e-mail complement

 

Appreciated Dra. Ma. del C. García,

 

Complementing my e-mail referring to Mauricio’s evolution, I transcribe as follows Dr. Antico’s comments referring to Mauricio’s evolution through the MR images. GreetinGREEN SAP.

 

Hugo Ruiz.

 

From: Antico Julio

 

Dear Mr. Ruiz,

 

I received Mauricio’s studies, observing in the images a reduction of the peri-lesional oedema and of the lesion’s mass effect which produces a smaller deviation of the middle line structures. Referring to the tumour itself, there is a slight reduction of the contrast’s capture in its borders. Resuming I believe that there is a slight improvement in the evolution and that confirms my decision of progressive reduction of the corticoid until its complete retire.

I beg you to maintain me informed of the evolution. I consider a new MR control  in two months time.

Sincerely yours,

 

Dr. Julio Antico

Neuro-surgery

Radio-surgery chief

Leksell Gamma Knife FLENI

Montañeses 2325 (1428)

Buenos Aires – Argentina

TE: +5411 5777-3200 intern 2931

E-mail: jantico@fleni.org.ar

 

From: Hugo Ramon Ruiz Fleitas

Sent: Tuesday, December 24, 2002 9:23 AM

Subject: Comments on Mauricio

 

Attention: Araceli Tashjian

 

Appreciated Dra. Araceli,

 

I appreciate the attention from “drops” getting interested in Mauricio’s state of health. He is in good state with normal activity enjoying the school holidays. In the next days we will be asking for the “drops” delivery.

I express in my family’s name our sincere wishes of a merry Christmas and a better year 2003, to you and all the Drops’ staff. GreetinGREEN SAP.

 

Hugo Ruiz F.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Wednesday, March 12, 2003 6:39 PM

Subject: Comments on Mauricio’s health

 

Mr. Drops,

 

I want to comment you that Mauricio is following as always his treatment with GREEN SAP Drops, at the indicated dosage. However I must comment you that in a recent image control study (02/20/2002), magnetic resonance, it was again detected the presence of a lesion in right parietal area and last 03/07 underwent a surgery and the tumour was totally extirpated. Apparently it would be again an ependimoma, we await the anatomy-pathology study results.

In the next days we will be asking for a new deliver of GREEN SAP Drops.

GreetinGREEN SAP. Thanks.

 

Hugo Ruiz.

 

From: Hugo Ramon Ruiz Fleitas

Sent: Thursday, March 13, 2003 7:21 Pm

Subject: Comments on Mauricio’s health – Anatomy Pathology

 

Mr. Drops,

Attention: Dra. Araceli Tashjian

 

Answering to your e-mail I transcribe you part of the anatomy-pathology inform corresponding to Mauricio’s extirpated tumour on March, 7th. of the current month, which says:

“… we would tend to ..re-classify this tumour according to this more recent evidence as of grade 2 or cellular…”, according to the most recent publications (which classify them in: of non atypical usual histology or grade 1, cellular or grade 2 and anaplasic or grade 3).

Reference: OD Wiestler and M. Rosenblum. Ependimoma. In WHO Classification of tumours. Blue Book. IARC, Lyon, 2000.

Yours,

 

Hugo Ruiz.

 

From: Jorge Lindh

Sent: Monday, November 19, 2001 3:39 PM

Subject: Drops prepared

 

Dear Sirs,

 

My name is Jorge Lindh, Argentinean living in Sweden.

In July, 1998 I underwent a surgery in which I was extirpated the left kidney, cancer damaged. Such cancer resulted after the analysis performed, to be (translated from Swedish) “light cells adeno-carcinoma”. It was believed at the beginning that the cancer had been definitively eliminated. A year later – after two controls which did not show any anomaly -  in July, 2001, shortly after the control was done, I was appointed at the hospital to have an additional thorax tomography done. In that occasion they discovered metastasis out of both lunGREEN SAP – according to my hospital record, lymphatic metastasis in left and right lung that compress both the trachea and the oesophagus. Later on it an additional metastasis in a vein was discovered in the area of the extirpated left kidney and one behind right clavicle.

This is my present situation. Throughout my sister who lives in Buenos Aires, I knew about you and thought I should contact Renilur.

I travelled from Sweden specially to buy your product. I arrived a couple of days ago and will be until November, 27th., date of my departure. My interest is to buy drops that would last me four months, and then buy more and have they sent to me in Sweden via diplomat mail as I am a local employee of the Argentinean Embassy in Stockholm -  it would also be possible to travel to Buenos Aires again in four months and buy new dosages.

I will call you tomorrow, Tuesday.

I will be looking forward to hearing from you, sincerely yours,

 

Jorge Lindh e-mail: jorgelind@hotmail.com or sueca@sinectis.com.ar

 

From: Jorge Lindh

Sent: Sunday, January 27, 2002 11:55 AM

 

Dear Leonel,

 

After something more than two months that we have met in Montevideo, I am arriving to the date I will have a new tomography here in Sweden. This will happen on February, 6th., and by the 13 of the same month I will have the results. I will immediately transmit them to you.

From my point of view, I can tell you that I’ve feeling better since I begun with the drops. The annoyance I had to swallow due to the metastasis in both lunGREEN SAP compressed the oesophagus and trachea, has disappeared. Now I swallow as if there was no any “obstruction” blocking the food passage. This is a subjective appreciation. We will see the truth with next 6 day’s proves.

 

On the other hand, it was nice to receive a mail from a “disgraced mate”, I’m referring to Mr. Jorge Suarez who also is treating himself with the drops. It seems to me it is very useful to create a kind of users net to exchange experiences. Jorge’s contact was a right initiative from you.

Another favour, please tell about this mail to Dr. Harriague, as I promised him to keep in touch.

A big hug and thanks from now for your help.

 

Jorge Lindh

 

From: Jorge Lindh

Sent: Thursday, February 28, 2002 6:18 PM

 

Hello Gladys,

 

I apologize for the delay but I was away for a few days. Last Monday I received the results of the exams I had been done.

  1. Last computerized tomography I was done before this one was o June 5th., 2001.
  2. I started taking the GREEN SAP drops to the end of November, after the visit I made to Montevideo.
  3. There have been more or less three months of treatment with the drops, which  means that between the beginning of June and the end of November there is a period of almost six months “without treatment”.
  4. I was informed last Monday that in reference to the metastasis in the area where my left kidney was extirpated, it has stopped growing. The metastasis behind the right clavicle also stopped growing. The two metastasis in both lunGREEN SAP, which compressed the trachea and oesophagus, only have grown some 10-14 mm. I can assure that the slight annoyance I had to swallow has totally disappeared.
  5. It has to be taken into account that it could be speculated with that actually a regression of the metastasis has occurred, due to the difference of time between the previous tests and these ones. From now on we will have a safer pattern as for next tomography, in six months time, I will have a GREEN SAP treatment for a similar period.
  6. On March, 9th. I will be arriving at Buenos Aires and it is my intention to visit you in Montevideo. Once at Buenos Aires I will send you a mail to establish day and hour.
  7. I have a question to ask. Aren’t there any GREEN SAP drops in a bigger capacity container?  It would be good, for example, to take from Montevideo bottles of half a litre or a litre, easier to manipulate in the luggage in my return to Sweden. I will have to buy a six months stock. The bottle I use now only lasts me a week, with the dosage of 40 drops every six hours.
  8. I take with me the actualised clinic record (in Swedish) although we can translate it willing full when we see each other.

A hug for you all.

 

Jorge Lindh

 

From: Jorge Lindh

Sent: Tuesday, March 12, 2002 7:27 PM

Subject: confirm consultation

 

Dear Gladys,

 

Thanks for your reply. I confirm I will be with you on Thursday at 15 hours. At the same address than last time, in Pocitos? Thankful for your help.

Sincerely yours,

 

Jorge Lindh

 

From: RENILUR S.A.

 

Very dearest Mr. Jorge Lindh:

 

On Thursday 14th. of the current month at 14 or 15 hours is what I could arrange with Dr. Harriague.

What time do you arrive? Confirm us which is the more convenient.

GreetinGREEN SAP.

 

For gotitas.com

Gladys Gómez

 

From: Jorge Lindh

Sent: Tuesday, August 27, 2002 5:17 PM

Subject: News

 

Mr. Leonel,

 

Just yesterday I received the results of the tomography and tests in general.

From our last meeting in March six months have passed without any problems or major annoyances. The dosages have been respected religiously and I think that the treatment has resulted by the following:

In my yesterday interview with the doctor I was informed that the abdominal metastasis has totally stopped growing. The same occurred with the ones at the right clavicle, it totally stopped growing. (since last February tomography). In reference to the both lung metastasis, which compressed the trachea and oesophagus, he told me they were collapsed, that they were left without “food” and have been reduced. I did not say anything and the doctor by himself asked me if I went on “taking those pills or whatever I brought from Uruguay”. I answered him affirmatively and he told me that he didn’t know much about it but to keep on taking them. (referring to the GREEN SAP). I found this doctor’s reaction strange as Swedish doctors are traditionally reluctant to all kind of alternative medicine -  although naturally there are some exceptions.

Leonel, a big hug for you all – with the good news – and I hope to see you soon (I estimate towards the end of September).

GreetinGREEN SAP to you all.

 

Jorge

 

From: Jose Medina

Sent: Friday, December 28, 2001 7:02 PM

Subject: Good News

 

Hi! I write to you to tell you how my father was doing. To refresh your memory, he was diagnosed in Puerto Rico Right lung cancer type 4 with liver and adrenal metastasis. He went to Chicago (Zion, Illinois) to the Cancer Treatment Centre of America (Midwestern Regional Hospital in Zion) and there he was indicated that his cancer was type 3 and didn’t come out of  the lung. He begun taking the drops approximately 2 weeks before starting the treatment in Chicago. They begun giving him the first chemotherapy session (July, 27th.) but had a very strong reaction so he had new exams done and resulted there was no tumour improvement. On the contrary, they grew in size reason why they were afraid it would collapse. Then they decided to irradiate him. He had 32 sessions of radiotherapy (until October, 11th.) for 15 minutes daily. He returned to Puerto Rico that same day. He interrupted the drops during the chemotherapy due to a severe infection in the mouth which didn’t allow him to swallow any kind of liquid or solid. Nevertheless, he was taking the drops throughout the radiation period. He returned to Chicago on December, 10th., for some follow-up exams. These revealed that the cancer has been controlled in a strange but positive way. At this moment he isn’t receiving any kind of cancer treatment and goes on taking the drops. He has to return to Chicago in three months, then in six, then in a year and so on for revision.

We are hopeful that the drops have achieved some way or the other my father’s recover and therefore we are very grateful. We will soon make the next order as he is running of them. I would like to know which would be the amount of drops that have to be taken in this situation. I will thank your reply.

I wish to tell you that I referred your drops at Rincon Town and know of about two more persons who have bought them. We will keep in touch.

Go on saving lives as you did with my father’s.

GreetinGREEN SAP from Puerto Rico,

 

Mayrin Sanchez

 

From: Hernan

Sent: Friday, August 31, 2001 3:07 PM

Subject: Information

 

I have a relative of mine with lung cancer, I was visiting your web site in Internet and I would like to know if the prices of the products that appear there (for example GREEN SAP Drops 50 ml) are still the same. I live in Santa Fe city, Argentina, and if confirming my e-mail, I would be also confirming its purchase, today if possible. I believe the most convenient way of payment, in this case, is by Western Union.

I am looking forward to hearing from you soon.

Kindly yours,

 

Hernán Mena.

 

From: Hernan

Sent: Wednesday, September 12, 2001 8:54 PM

Subject: Complementary information.

 

Hello! Just today’s afternoon we were able to contact your medicament. There was a mistake in the address, maybe when the transport or the package was done, but luckily after some “come and go” it arrived at its original address.

I have some questions to ask that are not very clear for me, when I visit Internet and consult the drops’ dosage.

  • Which are the elements or products that contain “teobromine”?
  • In some part it says that the drops cannot be mixed with vitamin B17 intake… is it only that kind of vitamin, or does it embrace all B vitamins (such as, B6 or B12) ??

We think that after resolving these inquiries, my father would agree to begin the treatment correctly and for the period of the time the disease requires.

Kindly yours,

 

Hernan Mena

 

From: Hernan

Sent: Friday, November 23, 2001 2:31 PM

Subject: Information

 

Hello!

According to the last e-mail received, I would need to make a request for 3 (Three) more 50 ml. Bottles. I would like to know if there are any changes in the product’s prices and to know to whom the deposit by Western Union is directed to (as we have done before).

From now, thank you very much and I await for your soon reply.

GreetinGREEN SAP.

 

Hernan Mena.

 

From: Hernan

Sent: Friday, February 07, 2002 2:31 PM

Subject: Re: News

 

First of all, thank you for being concerned about my father’s health. At this moment I am at Carlos Paz city, Cordoba province, due to work, but I understand thinGREEN SAP are going quite well, every treatment was finished, being it drops, chemotherapy and radiotherapy, so there would be a new study to perform and compare the results with the previous ones. Any news that could emerge from this, I would make you know immediately… Thanks again…

 

Hernan Mena.

 

From: Hernan

Sent: Monday, November 18, 2002 3:54 PM

Subject: Bad news

 

Sirs from Drops.com,

 

In August, 2001, I contacted you in order to receive information about your product, since I had my father with lung cancer. Well, I hope this short introduction can situate you in the case.

The treatment, at that moment, was made strictly, as apart from the Drops, the medical treatment was never quitted (chemotherapy and radiotherapy), complementing it with the famous “gorgojos” and a strict diet too.

Now, a week ago, new analyses were performed, and in a head tomography a new inconvenient arouses: according to the doctor, there is a “Brain Dissemination”, that is, as for the very little I understand the subject, it is about the left part of the brain’s inflammation, that manifests in partial and temporal memory loss, apart from the motor problems in upper and lower joints.

Also according to the doctor, this problem is maybe more grave than the previous one, as, quoting, he said to us“ it is the beginning of the end”…

All this previous description has only one reason: consult you if there are any chances to make a new treatment with the Drops. In the Internet web site does not appear any case similar to this one, this is why I am writing to you again so as to please inform me.

From now, all my family and I are deeply thankful…

 

Hernán Mena.

 

From: Hernán Mena

Sent: Friday, March 21, 2003 5:30 PM

Subject: Inform and consultation

 

Dear Sirs from Drops,

 

Next I transcribe you two informs of the evolutive process of my father’s disease, with its respective dates.

 

Inform: Encephalic CAT

Date: 11/15/2002

The encephala was studied by axial and sequential tomographic cuts parallel to the meatal orbital line. The study was reinforced by 1 cc/kg weight endo-venous contrast administration.

 

Small hypo-dense images represent oedema.

This oedema regions supra and infra tentorial are generated by neo-formed elements, which stand out after administrating the iodated reinforcement.

There are two small lesions in posterior fosse, one in the left cerebella’s hemisphere and the other one in the cerebella’s vermis (slice 02 with contrast). In the supra-tentorial level there is a big lesion in the left temporal lobe and others in the left occipital area, right optical thalamus, left lateral frontal, middle supra-ventricular parietal, right middle supra-ventricular parietal and left polar frontal.

Resuming: Multiple secondary lesions.

 

Inform: Cranial C.A.T.

Date: 02/12/2003

 

Procedure:

Cranial C.A.T. was performed, making axial cuts of 5x10 mm thickness consecutive intervals of 5 and 8 mm parallel to the orbito-meatal line and post-administration of hydro-soluble tri-iodated E.V. contrast substance.

 

Interpretation:

Present C.A.T. was compared to previous C.A.T. brought by the patient observing more than 50% reduction of the visualized lesions in left frontal, left occipital and left cerebella’s hemispheric and cerebella’s vermis areas.

The rest of the lesions are not visualized in this opportunity but there is a hyper-dense area of 7 mm diameter in right frontal sub-cortical area, not observed in the previous study, with no signs of oedema. Dot-form images of calcium density are observed, left para-ventricular, not observed in previous C.A.T., in some cases it can be due to post-treatment densitometric change.

 

Conclusion:

Marked reduction (more than 50 %) of the visualized lesions in left frontal, left cerebella’s hemispheric, cerebella vermis and left occipital areas. In this opportunity dot-form lesions are visualized, calcium, left para-ventricular, not observed in previous C.A.T., and an hyper-dense area without oedema, not typically proliferative, right frontal sub-cortical, repair lesions? Incipient secondary lesions?

 

In reference to the textual transcribed informs, the fundamental consult is if he has to go on with the present treatment (60 drops – 4 times per day) or if he has to make any dose changes. Besides we would like to know if he has to go on with the strict diet that is recommended on the web site or he can slowly incorporate some up to now “forbidden” food and/or drink.

From now, all my family’s members infinitely thank you for the interest and cooperation offered in this case and we are sure that my father’s quality of life has depended and depends not only on our faith and hope, but also on your valuable help. THANK YOU VERY MUCH.

I am looking forward to hearing from you soon, kindly yours,

 

Hernán Mena.

 

From: Hernán Mena

Sent: Tuesday, April 01, 2003 4:26 PM

Subject: Information

 

Sirs from Drops,

 

Having consulted with my family your proposal of having my fathers’ disease case appearing in your web site, I communicate you that we do not have any kind of trouble in doing so.

By the way, I inform you the change in my e-mail address. The new address is:

Herstafe03@arnet.com.ar

I again say to you in my family’s and myself name, THANK YOU VERY MUCH.

 

Hernán Mena.

 

From: Ricardo Abraham Topalian Doganian

Sent: Sunday, October 22, 2000 10:06 AM

Subject: Ricardo from San Pablo

 

Dear Leonel,

I am “bothering” you again with questions. I would like to know from you if it is primordial for me to send you the magnetic resonance my mother had done in the end of August, if it good for the doctor to see it, because I found a place where scan those thinGREEN SAP (radiographies and so on) and they themselves send them by Internet. If your answer is yes, I’ll be sending it on that same day. Another question I would like to ask is: 1) Do I go on with the prescribed dose: 45 drops, 4 times per day? 2) I want you to have the time schedule of the medicaments she takes in order to know if there is any interference between the drops and the medicaments the doctor indicated her:

04:00    45 drops with a little water

06:30    Tegretol (carbamazepine) 300 mg and Higroton (clortalidone) 50 mg. At this time she has breakfast.

10:00    45 drops with a little water

11:30    Sometimes, around this hour she feels a little hungry and eats a fruit or bread

13:00    She has lunch

14:30    Tegretol 300 mg

16:00    45 drops with a little water

17:30    She has some tea or eats something to “entertain” her stomach

19:00    She has dinner

22:00    45 drops with a little water

22:30    Tegretol 300 mg and a Lorax (lorazepam) 1 mg

Do you think the schedule is fine or should I change anything?

Leonel, thanks for everything and I await for your reply. A hug,

 

Ricardo Topalian

 

Dear Leonel,

 

Since my last message I did not contact you again, receive my apology. I couldn’t get a place where I could scan the exams and send them to you, but from that day until now my mother had 3 (three) cranial magnetic resonances performed and luckily the cancer has not returned. The last one was last April, 27th. and nothing appeared, in the laboratory’s opinion: “in reference to previous exam of 01/31/2001, there are evidences of partial reabsorption of the blood residues in the surgery layer, as of the residual associated contrast, with the other findinGREEN SAP practically unchanged; there are no evidences aroused of local neoplasic residue”. Luckily she seems to go on quite well; she is  at the present moment in Novo Hamburgo (near Porto Alegre), spending some time with my brother. She travelled by plane with no problem, the only thing I notice is that as the day passes by she looses strength in the leGREEN SAP and finds it very difficult to walk, although there is always somebody helping her because she is not well from her balance. Apart from informing you of the situation, I would like to ask you if I go on giving her the same amount of drops: 45 each time, 4 times per day. I go on like this or do I have to change anything? Thanks for everything and I await for your kind reply. A hug,

 

Ricardo Topalián

 

Dear Leonel,

 

Thank you for answering me so soon. I will do whatever it takes to send you the exams. I would only like to ask if the 40 morning drops must be given at 4 in the morning or at 10 in the morning, keeping the fast period 2 hours before and 2 hours after the drops. A hug,

 

Ricardo A. Topalián

 

From: Ricardo Abraham Topalian Doganian

Sent: Wednesday, March 20, 2003 3:27 PM

Subject: Answer medical staff

 

Br. Cristina Eliópulo,

 

Thanks for answering me so soon, I will keep you informed on the subject and of course you can give my e-mail to that couple. Sincerely yours,

 

Ricardo A. Topalián

P.S.: please, don’t treat me as an old man, I’m not so old.

 

From: Ricardo Abraham Topalian Doganian

Sent: Sunday, May 26, 2002 7:40 PM

Subject: Ricardo from San Pablo

 

Dearest friends,

 

I am getting in touch with you at this opportunity in order to clear out one doubt. My mother is taking the drops since August, 2000 and luckily the cancer has not manifested again, and, unluckily, it seems like my mother-in-law has presented some trouble in her liver and the doctor sent her to an oncologist because it can be a tumour. She has to make some exams yet and afterwards has to go to see the oncologist so as to know what she has and we would like to know if in case it was the same she could take the drops for that kind of cancer. When I have more information I send you another message.

I already thank you for your reply,

 

Ricardo A. Topalián

 

From: Ricardo Abraham Topalian Doganian

Sent: Saturday, August 31, 2002 5:58 PM

Subject: Ricardo from San Pablo

 

Dear Dr. M. del C. García,

 

I’m getting in touch with you again in order to inform you that my mother had a magnetic resonance done in August (she has to have one every six months for control), and the result could not be better: there is no evident alteration comparing to the previous exam.

Kindly yours,

 

Ricardo A. Topalián

 

From: Hilda Smith Vivas

Sent: Saturday, July 13, 2002 12:06 PM

Subject: Information required

 

I’m a Cuban doctor and my father presents a prostate carcinoma in an advanced stage. I am working in Angola by my own means and I read in Internet about this product you have. I beg you send me more information, way to use it and price.

I’m looking forward to hearing from you soon, kindly yours,

 

Dra. Hilda Smith Vivas.

 

From: Hilda Smith Vivas

Sent: Monday, July 15, 2002 3:26 PM

Subject: Thanks for the information

 

First of all my greatest greetinGREEN SAP for the attention you gave me as I am in a desperate situation with my father’s problem.

I have great interest that my father receives the medicament, that’s why I need to know the ways of payment for it.

I am working on my own in Luanda, Angola, so that I can support my family economically.

With the new migratory laws for Cuban doctors currant from last September it is forbidden to me to return to my country, I only knew about my father’s disease in December and I am desperate to see him again and to have him recovered.

My e-mail in Luanda is hildita@ebonet.net, I am the one who will cover all the expenses from here. At my daughter’s and son-in-law they will receive and administer the treatment, their e-mail is Kelly@infomed.sld.cu, they are also doctors, today I knew of a gammagraphy with a radio-pharmaco concentration in L5, he was indicated radiographic studies to precise if it is due to metastasis osteo-blastic lesion or due to degenerative changes, also that it is a moderately differentiated adenocarcinoma grade 6 of H.

I need to know the ways to make a bank transference, agency name and data, account number, etc.

Our address in Cuba is:

Kelly Santos Smith

Edificio E 51, apto. 21, zona 11. Alamar. Habana City. Cuba.

I immensely thank all of you for this hope of life you give me and desire you the best successes of all the world.

In Cuba I worked as Radiologist in the Oncology National Institute but as for merely economic reasons I went out of the country, now it is forbidden to me to come even to visit due to my father’s disease and you have returned hope to me for a longer survival and, most important of all, a useful life, without suffer.

I forwarded the message I received to my daughter and son-in-law, so they will be updated of the situation.

I repeat my thanks for your solidarity an comprehension and I anxiously await the transference data.

Lots of greetinGREEN SAP and my best wishes for you all. Thank you very much and God bless you all.

I await your reply,

 

Dra. Hilda Smith Vivas.

 

From: Hilda Smith Vivas

Sent: Tuesday, July 16, 2002 8:59 PM

Subject: New explanation

 

First of all my kind greetinGREEN SAP to you all.

I need to know urgently if the drops have expiration time, because I’m interested in making a purchase to guarantee at least 1 year of treatment.

I came to know today that there have been some problems with the relation between Cuba and Uruguay what terrorised me and in case I have to guarantee the medicament to my father.

If it is possible to buy a year’s supply, please send me the answer urgently in order to make the transference, as well as the cost including all the taxes.

I apologize for my despair, but I am worse every day, frightened of anything that can happen, I also wanted to tell you that if the state doesn’t allow the medicament entrance to Cuba, please let me know so then I would receive it here in Luanda, Angola and would make it arrive by other means.

I apologize for my anxiety, but I repeat, I am frightened that any problem could emerge. I repeat my thanks for to excellent comprehension and help.

My best wishes for you all.

Most kindly and with love, awaiting for your reply,

 

Dra. Hilda Smith.

 

From: Hilda Smith Vivas

Sent: Friday, July 19, 2002 9:48 AM

Subject: Dra. Hilda

 

First of all my greetinGREEN SAP for you all and thanks for the soon and excellent attention you gave to me.

Yesterday, more calmly, I checked with other colleagues your web site and I found a testimony of an old lady with bone-muscle-joint pains she was successful to solve with the product.

My mother suffers intensely from those pains, she is 83 years old, she has hypertension and an important cardiac insufficiency, osteoporosis and a monostotic Paget in L5. She is suffering too much pain in her body and I don’t know what to do.

I beg you to tell me if she can use the GREEN SAP treatment and how, as if it is possible I would like to buy it for her too.

I’m very thankful and awaiting your indications, kindly yours,

 

Dra. Hilda Smith Vivas.

 

From: Hilda Smith Vivas

Sent: Friday, August 09, 2002 8:29 AM

Subject: Dra. Hilda Smith Vivas.

 

My greetinGREEN SAP for you all and my wishes of a good health and prosperity although the situation going on. The present mail is to inform you that my father has had a new PSA done with figures of 11.87. The previous exam was situated in 88.

The bone survey revealed generalized arthrosic changes and increased bone density in the lumbar segment of the vertebral spine. We will keep you informed of his evolution as well as my mother’s. Kindly yours,

 

Dra. Hilda.

 

From: Hilda Smith Vivas

Sent: Wednesday, October 30, 2002 7:30 PM

Subject: Dra. Hilda Smith Vivas.

 

My greetinGREEN SAP fro you all and thanks for the quick attention.

As soon as I am informed of next ultrasonography’s result, we will send you the result.

With great love to you all, my cordial greetinGREEN SAP,

 

Hilda.

 

From: Hilda Smith Vivas

Sent: Thursday, November 07, 2002 7:33 PM

Subject: Dra. Hilda Smith Vivas.

 

My greetinGREEN SAP and wishes of good health and success.

My father had a trans-rectal ultrasonography done and the prostate has a volume of 50 cc., with reduce in its ecogenicity in its peripheral portion, which is thickened.

They recommended a new biopsy.

The PSA was situated a few days ago in 11,87.

He has already accomplished the 4 months with the dosage of 60 drops 4 times per day, he goes on with the acidity and presents two daily diarrheic depositions.

My mother hasn’t resolved her joint pains with the treatment, so she suspended it as you had recommended me, but it came to be that she is an habitual constipated and has a functional mega-colon, she tells me she had restarted taking them, because while she was using them, she could defecate daily and with no effort, she suffers from constipation up to 10 days without defecating.

I don’t know if you already had this data that it is useful in chronic constipation.

I’m looking forward to your orientations about my father, kindly yours,

 

Hilda.

 

From: Hilda Smith Vivas

Sent: Thursday, February 20, 2003 3:29 PM

Subject: GreetinGREEN SAP from Dra. Hilda

 

First of all my greatest greetinGREEN SAP and thankfulness for your concerns about my father’s situation, which is quite fine.

I didn’t write to you before, because we don’t have the P.S.A.’s result yet, performed after the radiotherapy.

As I informed you, he was indicated 30 radiotherapy sessions which ended on day 9 of the current month, they immediately performed a new P.S.A., last one was in 8,11 but we will have to wait until several patients are in the row to have it done due to difficulties with the reactives.

His physical situation is quite good, he feels fine although he presents an increased polaquiuria, apparently a radiotherapy sequel, which had to be interrupted 2 weeks because he suffered from some burnts.

The pains he previously presented, specially in the lumbar region and right hip, have y reduced markedly, the appetite is increasing and he goes on with the drops treatment, as you recommended us.

As soon as I have got some news, I will inform you.

Thanks for your attention.

Kindly yours,

 

Hilda.

 

From: Hilda Smith Vivas

Sent: Monday, March 10, 2003 8:41 AM

Subject: Dra. Hilda Smith Vivas

 

My greetinGREEN SAP for you all.

I will tell you I’m very happy and thankful to you because my father was declared clinically cured.

He had the Androcur suspended for 2 months and was indicated to have a new PSA done, the last one after the radiotherapy was of 7,2 still high, but they associate it with the radiant treatment, that is why they recommended him to repeat it after 2 months.

He goes on with the drops treatment 40 drops, 3 times per day.

I wish to know what do you recommend me to do in reference to the treatment.

Kindly yours,

 

Dra. Hilda.

 

From: Hilda Smith Vivas

Sent: Thursday, April 03, 2003 2:58 PM

Subject: From Dra. Hilda Smith.

 

Subject: Clinic record resume

Francisco Raul Smith Belgrave

 

Male patient of 77 years old with mesenteric thrombosis antecedent in January, 1995 he underwent surgery and is evolutioning without difficulty. In December of last year he started with night urine and weak urine flow reason why he was attended by an Urologist who observed by rectal digital examen an increased in size and hardened prostate of woody consistence due to what he indicated the following complementary exams which showed the following results:
01/11/2002

Hemoglobine                 134 g/l

Eritro                            14 mm/h

Creatinine                     98 mmol/l

Prostate U/S                 Almost empty bladder, nevertheless increased in size prostate globally and heterogeneous, which measures 55/41/41

Upper hemi-abdomen U/S          Fatty liver, no nodular lesion, no other alterations

Bone gamma-graphy                 Nuclear bone scan where an increased RF accumulation is observed in lumbar vertebral spine (L5) and reducing of it in both sacroiliac joints.

Prostate biopsy: 01/11/2002       Moderately differentiated prostate adenocarcinoma, Gleason 6

PSA                                         88.1 ng/l

 

It is concluded that the patient presents a moderately differentiated prostate  adenocarcinoma no metastasic and was indicated to start with Androcur 2 daily tablets. A month after having begun the treatment the PSA is repeated 02/12/2002 it is observed an important reduction from 88 ng/l to 21.4 ng/l.

Besides the patient experiments a remarkably improvement in reference to the night urine previously mentioned.

It wasn’t possible to follow up through a PSA as there are no reactives in the country but the imagenologic study was repeated on 07/04/2002 and the gammagraphy had the following inform: Nuclear bone scan that shows bigger RF accumulation in 5th. lumbar vertebra suggesting an increased osteo-blastic activity at the place, we suggest conventional radiological study to dismiss bone degenerative process in the rest of the skeleton there are no other pathologic accumulations.

Now the patient only refers to present pain in the hip joint.

On 12/09/2003 a new P.S.A. is done and is in 12 ng/l and there is a frank improvement of the pain in the hip joint.

He goes on with the drops treatment at a dosage of 40 drops 3 times per day.

On February, 26th., he has a new P.S.A. done which is in 7,4 ng/l, la night urine has improved markedly, he keeps a good general state, he hasn’t lost weight and good appetite.

On March, 7th., he is again evaluated by Oncology and Urology and is reported as clinically cured.

All the complementary exams are within normal parameters.

This is summarizing my father’s situation, for which I am extremely grateful.

Kindly yours,

 

Dra. Hilda Smith.

 

From: valiacordero@hotmail.com

Sent: Monday, May 27, 2002 6:36 AM

Subject: Patient’s Data

 

Name: Pablo

Surname: Cordero

Date of birth:

E-mail: valiacordero@hotmail.com

Contact: Daughter

Contact’s name: Valia Cordero

City: Panama

Country: Panama

Telephone number: (507)227-4382

Address: Calle 1a. Perejil, Edificio Carmencita Apto. 5

Clinic register:  My father is 88 years old and was until short time ago a healthy man who very seldom was ill, active and seems to be much younger. He has ear troubles, frequent sickness or dizziness and knee arthritis and in recent months trouble with urine retention. In January of this year he was diagnosed prostate cancer.

He had a  bladder endoscopy done at the end of March becoming positive and was indicated “Flutamide” one tablet 3 times per day. The doctor has programmed a surgery to extirpate him the testicles this Tuesday, 28th. but now that we have seen the web site about GREEN SAP product we want to suspend this surgery and take this medicament because we actually want him to have the opportunity to cure better than only palliative measures.

Present condition: He looses weight and is anaemic, he doesn’t have pelvic pains, occasionally presents spasmodic bladder pains, he has a catheter to urinate.

How many bottles does he need for about two months? How many drops and with which frequency must he take them per day? What can you tell me about this new treatment in this particular case? Please don’t be late to answer me and thank you very much from now for your attention.

Valia Cordero

Clinic diagnosis: Bladder endoscopy: increased PSA – prostate with irregular in consistence and badly defined right lobe. A needle biopsy was taken from both lobes.

Anatomy Pathology diagnosis: Pathologist inform: DIAGNOSIS:

A: PROSTATE, RIGHT LOBE (BIOPSY):

-          Moderately differentiated adenocarcinoma Gleason 3+4=7 which affects approximately 30% of the sample, there is no peri-neural invasion.

-          There is a high grade PIN focus.

-          Lympho vascular permeation focus are observed.

B: PROSTATE, LEFT LOBE (BIOPSY):

-          Moderately differentiated adenocarcinoma Gleason 3+4=7 which affects approximately 20% of the sample.

-          No peri-neural or vascular invasion is observed.

 

This biopsy’s results as I previously mentioned were done on March, 23rd. A month later a centellogram was performed and bone metastasis were found but I don’t know which grade.

Surgery: No

Kind of surgery:

Chemotherapy: Yes

Radiotherapy: No

Dosage:

Tolerance to medicament: Good

 

From: Valia Cordero

Sent: Wednesday, April 02, 2003 11:50 PM

Subject: Good news

 

Dear Dra. García,

 

My greetinGREEN SAP for you and the medical adviser staff from Drops.

The reason of this mail is to inform you my father’s state of health, Pablo Cordero, who began treating himself with Siqueiras Drops since last year. In this second opportunity he took 30 bottles that we got through Dr. Freddy Henríquez and at the present moment we are undergoing new dealinGREEN SAP with the Beneficence Lottery Director, institution which is helping us economically to buy the drops.

My father underwent surgery on February, 11th., due to an intestinal occlusion caused by the adherences of an old appendicitis surgery. He was very sick and stayed hospitalised for 36 days, also due to a pneumonia because of the infection with a  hospital bacteria but he is recovering satisfactorily.

Within this urgency he was done a rectal exam and a CAT. In the rectal exam they found an increased in size but soft prostate, the doctor mentioned that soft as a bubble and not rocky. He didn’t show pain to the tact. The computerized tomography showed a somewhat big prostate. The surgeon that attended my father informed us that in the surgery area the intestines were free of cancer which was what they feared. As I mentioned before, they only found part of the intestine (thin) necrosed by the adherences.

Yesterday we took my father to an Oncologist-Urologist physician who didn’t know about his case and he actually found that my father had the prostate with a size of a plump. He also found that the prostate was of a soft consistence as rubber and had a small protuberance also soft. He was surprised that he had previously been diagnosed with an advanced prostate cancer. Of course we also had given him the biopsy laboratory result which verified that diagnosis. He told us that if it weren’t for the biopsy he wouldn’t have believed it was the same patient we were talking about.

Dr. Monterrey, to whom we showed a GREEN SAP drops’ bottle, concluded that this medicament that was the only thing he had taken, must have improved him from the cancer. Nevertheless, he ordered several laboratory exams and X rays. He told us that he would have liked to examined him at first so as he by himself could have detected  the change in his improvement. He recommended us to go on giving him the drops. He was also interested, not only in his prostate state but also in his general appearance as he looks and feels like being fine although his recent disease of intestinal occlusion. I left him a diskette record of the drops web site.

We are all very happy and encouraged by the perspective that my father is cured or being cured of the cancer and that we could recommend others this treatment.

We hope to continue with the drops if God lets us and that my father uses this given time to go on acquiring his Creator knowledge and establishes a precious friendship relation with Him as God’s purpose by giving life’s gift to us is that we search him and get to really know him.

I say good-by to you,

 

Valia Cordero

 

From: Victor manuel tabares Trujillo

Sent: Saturday, November 30, 2002 2:14 AM

Subject: Case wilms tumour recidivism

 

Appreciated doctors,

Kind greetinGREEN SAP.

 

My  name is Victor Manuel Tabares Trujillo, father of María Alejandra Tabares the girl who uncle Luis Gerardo Tabares refers to who has already had communicated with you, and he informed to me about the medicaments you are promoting for oncology treatments, interested in what you offer and with the spirit of giving a better life quality to my daughter during this process apart from finding other alternatives for solving this problem I would like to present you the girl’s case so as you can advise me in the case.

 

María Alejandra is 4 years old, last February, 12th., 2002 was detected a big mass in the left abdominal flank, she had radiological analyses done such as abdominal ultrasonography and after that a scan, where it was confirmed the presence of a big mass in left kidney with the possibility of being a Wilms Tumour, reason why an urgent surgery was programmed. Next Tuesday February, 19th., 2002, it was performed an extirpation surgery of the left kidney with a Wilms Tumour of 750 g. of weight which was sent to pathology for its analysis showing the following result:

 

Surgical pathology inform:

 

Microscopic description: In the histological cuts a malignant tumour lesion is identified, formed by a blastomatose component, a epithelial one forming tubular structures and a fusiform mesenquimal one. No anaplasic characteristic are observed. The tumour compromises the kidney capsule but doesn’t perforate it. In the non tumour kidney parenchyma there is tubular atrophy. No compromise of the kidney vein or artery is observed, neither of the urether.

Diagnosis: Nefrectomy of left kidney

Tri-phase Wilms Tumour with favourable histology

Kidney capsule compromise without perforating it

Vascular and urethral borders of extirpation free from tumour

 

According to the results obtained from pathology it was determined the CHEMOTHERAPY treatment with a protocol of 18 weeks with VINCRISTINE 0,05 mg/kg/d treatment followed until week 10, ACTINOMICINE D 0,045 mg/kg/d every three weeks until week 18. Such treatment started on February 22nd., 2002 and ended on June 22nd., 2002.

During the CHEMOTHERAPY treatment control exams were performed such as thorax radiographies, hemogrames, creatinine, etc. obtaining very satisfactory results, which indicated a very good surgery and chemotherapy result.

Last October, 25th. a new abdominal control scan was done, and there were obtained the following results:

 

ABDOMINAL CAT

 

TECHNIQUE

Multiple cuts in axial plan and with helicoidal technique were performed in the abdomen, from lung basis to the pubis sinfisis, in simple phase and with 8 mm. Thickness cuts. The study was asked without contrast medias.

 

FINDINGREEN SAP:

Left nefrectomy changes are identified. The left kidney fosse is empty and the tumour observed in the left kidney was completely extirpated. The kidney fosse is occupied by thin intestine asas. Although it is difficult to evaluate the retro-peritoneum without contrast, in the present cuts there is no evidence of tumour recidivism. It catches the eye towards the left supra-kidney gland, an hypodense image, of low density, which could represent residual tumour or else an adrenal gland lesion. There is no pleural leakage or nodular images.

What can be observed of the liver is of normal characteristics, with no evidence of metastasic disease. There is no evidence of the gall via, intra or extra liver. Coledoco and gall bladder normal. Spleen, pancreas, right supra-kidney gland and right kidney without alterations. There is no evidence of masses or retro-crural or retro-peritoneal adenomegalies. Cava vein and aorta normal. No collections or ascitis liquid are observed. In the pelvis, bladder, rectum and annexes are identified and normal. There are no pelvic adenomegalies.

 

RADIOLOGIC CONCLUSIONS

-          NEFRECTOMY WITH COMPLETE EXTIRPATION OF THE NEOPLASY OBSERVED IN THE PREVIOUS STUDY (13/02/2002)

-          HYPODENSE LESION IN LEFT SUPRA-KIDNEY GLAND, RESIDUAL TUMOUR OR METASTASIC DISEASE TO CONSIDER.

-          THERE IS NO EVIDENCE OF METASTASIC DISEASE IN ANOTHER PLACE OF THE ABDOMEN.

Due to this exam results it was determined a new laparotomy to determine the finding with precision.

Last November, 7th., 2002 the surgery was done finding a new tumour in the left supra-kidney gland of not very good aspect for the doctors who participated in the surgery, it presented a necrosed part adhered to the supra-kidney gland so they extirpated it completely, and the tumour was sent again to pathology for its evaluation.

 

The pathologic evaluation showed the following result:

 

SURGICAL PATHOLOGY INFORM

 

SAMPLE

Left supra-kidney gland

 

MACROSCOPIC DESCRIPTION

 

It is received the product of extirpation of supra-kidney gland which weighs 16 grms. And measures 5,5x3,8x1,2 cms. Supra-kidney gland can be recognized and in the peripheries there is an hemorrhagic, lobated, partially cystic nodule which measures 1,8x1,6x1,6 cms., which is partially opened, in the same container and separately several brownish coloured tissue fragments come, friable consistence which weigh 1 grm. Representative cuts are processed.

 

MICROSCOPIC DESCRIPTION.

 

In the histological cuts supra-kidney gland is identified which presents in its capsule and fat that surrounds it primitive tumour lesion, formed by an area of blastomatose aspect and others with tubular structures. THE TUMOUR HAS QUITE A MITOTIC ACTIVITY. The material that comes separately corresponds to tumour fragments partially necrotic, which surround striate muscle.

 

DIAGNOSIS

 

Left supra-kidney gland SUPRA-KIDNECTOMY

WILMS TUMOUR RECIDIVISM

 

The post-surgery recovery is very satisfactory, the girl is in excellent state of health spiritually and nutritionally, she weighs 16 kGREEN SAP, as it can be observed the tumour was focused with no evidence of metastasis in another place.

 

Due to the results obtained from pathology it was determined a new chemotherapy treatment adopting a more aggressive protocol of 24 weeks as it is shown as follows.

 

CHEMOTHERAPY PROTOCOL FOR WILMS TUMOUR STAGES II TO IV WITH DIFUSE ANAPLASY

 

Weeks 

AAA                     

x

BBB

CCC

DDD

EEE

x     

 

A = Doxorubicine

B= Ciclofosfamide

C= Etoposide

D= Vincristine

E= Vincristine

 

This chemotherapy treatment will be reinforced with radiotherapy in the middle of the process.

Last Saturday, November 23rd. the chemotherapy was started as the protocol determined.

I want to know the product you offer and in which way it can help the girl in her recovery and minimize the collateral effects of the treatment.

For the attention you pay to these inquiries we will be infinitely grateful and with the conviction that God will go on blessing you.

Kindly yours,

 

VICTOR MANUEL TABARES TRUJILLO (FATHER)

LUZ MARINA MURIEL (MOTHER)

MARIA ALEJANDRA TABARES MURIEL (SICK BABY)

imvicta@hotmail.com

Santiago de Cali, Colombia

 

From: victor manuel tabares Trujillo

Sent: Friday, February 14th., 2003, 12:00 AM

 

Appreciated doctors,

 

I would like to thank you from my heart for having paid attention to my daughter’s case, which has had a successful evolution during all this process she is going through.

I tell you that my girl is in a state of health that I would describe as enviable, after a whole intense chemotherapy treatment the girls is in excellent spiritual and nutritional state (from the beginning of the treatment she has put on 2 kGREEN SAP.) and I wish to clear out that apart from the chemotherapy medicaments the girls only was treated with the GREEN SAP Drops and with the Wilms Tumour specific medicament that Dr. Medina sent us.

The results obtained are excellent, thanks to God and to you, reason why we want to share with you the evolution of the treatment we are following until now, so I attach the Clinic record diary of the girl.

The girl’s physician Dr. Fabio Dario Pereira is very interested in communicate with you to share your experiences with the medicament and authorized me to give you his e-mail address, so that you can have a direct contact and beneficiate more children who are suffering from this disease, the e-mail is fpereira@andinet.com, God let you contact.

I again want to thank you for all, and wish you that God blesses you and the labour you develop in the treatment of this disease.

Yours,

 

Eng. Victor Manuel Tabares T.

 

From: victor manuel tabares Trujillo

Sent: Friday, April 04, 2003 1:30 AM

 

Appreciated doctors,

 

Kinds greetinGREEN SAP.

Following your solicitation, I am next sending you all the Clinic Record Diary of my daughter from the very moment in which the problem was detected.

María Alejandra is 4 years old, last February, 12th., 2002 was detected a big mass in the left abdominal flank, she had radiological analyses done such as abdominal ultrasonography and after that a scan, where it was confirmed the presence of a big mass in left kidney with the possibility of being a Wilms Tumour, reason why an urgent surgery was programmed. Next Tuesday February, 19th., 2002, it was performed an extirpation surgery of the left kidney with a Wilms Tumour of 750 g. of weight which was sent to pathology for its analysis showing the following result:

 

Surgical pathology inform:

 

Microscopic description: In the histological cuts a malignant tumour lesion is identified, formed by a blastomatose component, a epithelial one forming tubular structures and a fusiform mesenquimal one. No anaplasic characteristic are observed. The tumour compromises the kidney capsule but doesn’t perforate it. In the non tumour kidney parenchyma there is tubular atrophy. No compromise of the kidney vein or artery is observed, neither of the urether.

Diagnosis: Nefrectomy of left kidney

Tri-phase Wilms Tumour with favourable histology

Kidney capsule compromise without perforating it

Vascular and urethral borders of extirpation free from tumour

 

According to the results obtained from pathology it was determined the CHEMOTHERAPY treatment with a protocol of 18 weeks with VINCRISTINE 0,05 mg/kg/d treatment followed until week 10, ACTINOMICINE D 0,045 mg/kg/d every three weeks until week 18. Such treatment started on February 22nd., 2002 and ended on June 22nd., 2002.

During the CHEMOTHERAPY treatment control exams were performed such as thorax radiographies, hemogrames, creatinine, etc. obtaining very satisfactory results, which indicated a very good surgery and chemotherapy result.

Last October, 25th. a new abdominal control scan was done, and there were obtained the following results:

 

ABDOMINAL CAT

 

TECHNIQUE

Multiple cuts in axial plan and with helicoidal technique were performed in the abdomen, from lung basis to the pubis sinfisis, in simple phase and with 8 mm. Thickness cuts. The study was asked without contrast medias.

 

FINDINGREEN SAP:

Left nefrectomy changes are identified. The left kidney fosse is empty and the tumour observed in the left kidney was completely extirpated. The kidney fosse is occupied by thin intestine asas. Although it is difficult to evaluate the retro-peritoneum without contrast, in the present cuts there is no evidence of tumour recidivism. It catches the eye towards the left supra-kidney gland, an hypodense image, of low density, which could represent residual tumour or else an adrenal gland lesion. There is no pleural leakage or nodular images.

What can be observed of the liver is of normal characteristics, with no evidence of metastasic disease. There is no evidence of the gall via, intra or extra liver. Coledoco and gall bladder normal. Spleen, pancreas, right supra-kidney gland and right kidney without alterations. There is no evidence of masses or retro-crural or retro-peritoneal adenomegalies. Cava vein and aorta normal. No collections or ascitis liquid are observed. In the pelvis, bladder, rectum and annexes are identified and normal. There are no pelvic adenomegalies.

 

RADIOLOGIC CONCLUSIONS

-          NEFRECTOMY WITH COMPLETE EXTIRPATION OF THE NEOPLASY OBSERVED IN THE PREVIOUS STUDY (13/02/2002)

-          HYPODENSE LESION IN LEFT SUPRA-KIDNEY GLAND, RESIDUAL TUMOUR OR METASTASIC DISEASE TO CONSIDER.

-          THERE IS NO EVIDENCE OF METASTASIC DISEASE IN ANOTHER PLACE OF THE ABDOMEN.

Due to this exam results it was determined a new laparotomy to determine the finding with precision.

Last November, 7th., 2002 the surgery was done finding a new tumour in the left supra-kidney gland of not very good aspect for the doctors who participated in the surgery, it presented a necrosed part adhered to the supra-kidney gland so they extirpated it completely, and the tumour was sent again to pathology for its evaluation.

 

The pathologic evaluation showed the following result:

 

SURGICAL PATHOLOGY INFORM

 

SAMPLE

Left supra-kidney gland

 

MACROSCOPIC DESCRIPTION

 

It is received the product of extirpation of supra-kidney gland which weighs 16 grms. And measures 5,5x3,8x1,2 cms. Supra-kidney gland can be recognized and in the peripheries there is an hemorrhagic, lobated, partially cystic nodule which measures 1,8x1,6x1,6 cms., which is partially opened, in the same container and separately several brownish coloured tissue fragments come, friable consistence which weigh 1 grm. Representative cuts are processed.

 

MICROSCOPIC DESCRIPTION.

 

In the histological cuts supra-kidney gland is identified which presents in its capsule and fat that surrounds it primitive tumour lesion, formed by an area of blastomatose aspect and others with tubular structures. THE TUMOUR HAS QUITE A MITOTIC ACTIVITY. The material that comes separately corresponds to tumour fragments partially necrotic, which surround striate muscle.

 

DIAGNOSIS

 

Left supra-kidney gland SUPRA-KIDNECTOMY

WILMS TUMOUR RECIDIVISM

 

The post-surgery recovery is very satisfactory, the girl is in excellent state of health spiritually and nutritionally, she weighs 16 kGREEN SAP, as it can be observed the tumour was focused with no evidence of metastasis in another place.

 

Due to the results obtained from pathology it was determined a new chemotherapy treatment adopting a more aggressive protocol of 24 weeks as it is shown as follows.

 

CHEMOTHERAPY PROTOCOL FOR WILMS TUMOUR STAGES II TO IV WITH DIFUSE ANAPLASY

 

Weeks 

AAA                     

x

BBB

CCC

DDD

EEE

x     

 

A = Doxorubicine

B= Ciclofosfamide

C= Etoposide

D= Vincristine

E= Vincristine

 

This chemotherapy treatment will be reinforced with radiotherapy in the middle of the process.

Last Saturday, November 23rd. the chemotherapy was started as the protocol determined.

CLINICAL RECORD DIARY

 

Maria Alejandra Tabares T.

 

* November 7th., 2002  -  Left supra-kidnectomy.

 

* November 23rd., 2002            - CHEMOTHERAPY (Adriblastine-Razoxane-Ondansetron-Dexametasone), she presented muscle pains, in the chest, general sickness, she threw out three times in the breakfast of  November 24th., 25th. and 26th.

 

* November 29th., 2002            - CHEMOTHERAPY (Vincristine 1mg.) presented pain in chest, teeth, knees, she was treated with Acetaminofen and Tramadol in order to reduce it, which persisted for four days she consulted the oncologist and the Vincristine dose was reduced to 0,7 mg.

 

*December 7th., 2002   - Ambulatory     SURGERY for installation of sub-clavial central catheter, the procedure lasted an hour.

 

*December 8th., 2002   - Treatment with HOMEOPATHIC medicament GREEN SAP DROPS is initiated. 5 drops half an hour before the meals and pepitas for Wilms Tumour.

 

*December 11th., 2002 - HOSPITALISATION for Intense Chemotherapy (Ciclofosfamide, Etoposide, Ondansetron, Dexametasone, Hidratation), goes on with Homeopathic treatment.

 

*December 12th., 2002 - Hospitalised (Ciclofosfamide, Etoposide, Ondansetron, Vincristine, Dexametasone, Hidratation), she presented sickness due to previous day’s chemotherapy, irritable, short appetite, threw out 3 times, started to loose hair, she goes on with Homeopathic treatment.

 

*December 13th., 2002 -  Hospitalised (Ciclofosfamide, Etoposide, Ondansetron, Dexametasone, Hidratation), presents good mood, good appetite, without sickness, she goes on with homeopathic treatment.

 

*December 14th., 2002 - Hospitalised (Etoposide, Ondansetron, Dexametasone, Hidratation), very good mood, good appetite, without sickness, she spent a very good day, she goes on with Homeopathic treatment.

 

*December 15th., 2002 - Hospitalised (Etoposide, Ondansetron, Dexametasone, Hidratation), she spent a very good day, visit of the oncologist and she is on release.

 

*December 19th., 2002 - Hemograme, Hemoglobine (10,3), Platelets recount (360.000), weight increase from 15 kGREEN SAP. To 16 kGREEN SAP., very good appetite, good general state.

 

* December 21st., 2002 - CHEMOTHERAPY (Vincristine 0,7 mg.), without collateral effects, she goes on with Homeopathic treatment.

*December 28th., 2002 - CHEMOTHERAPY (Vincristine 0,7 mg.), without collateral effects, the endo-venous medicament is placed in right hand, she goes on with Homeopathic treatment.

 

*December 29th. and 30th., 2002          - She presented possible knee pain which is not confirmed, as it could be spoiling.

 

*January 4th., 2003                  - CHEMOTHERAPY (Adriablastine- Razoxane-Ondansetron-Dexametasone-Vincristine 0,7 mg.). She didn’t present neither collateral effects nor complications, chemo placed in right hand’s vein.

 

*January 11th., 2003     - CHEMOTHERAPY (Vincristine 0,7 mg.), she goes on with Homeopathic treatment, placed in left hand, without collateral effects.

 

* January 20th., 2003    - HOSPITALISATION for Intense Chemotherapy (Ciclofosfamide, Etoposide, Vincristine, Ondansetron, Dexametasone, Hidratation), goes on with Homeopathic treatment. She didn’t present collateral effects. Hemograme with platelet recount. Good result HGB 9,73 g/dl, PPLT 342 K/ul.

 

*January 21st., 2003                 - Hospitalised (Ciclofosfamide, Etoposide, Ondansetron, Dexametasone, Hidratation), she goes on with homeopathic treatment. She was a little irritable, good appetite.

 

*January 22nd., 2003    - Hospitalised (Ciclofosfamide, Etoposide, Ondansetron, Dexametasone, Hidratation), she goes on with homeopathic treatment. Without collateral effects, good mood, good appetite, irritability due to confinement not the medicaments.

 

*January 23rd., 2003                 - Hospitalised (Etoposide, Ondansetron, Dexametasone, Hidratation), she goes on with homeopathic treatment. Good mood, good appetite.

 

*January 24th., 2003     - Hospitalised (Etoposide, Ondansetron, Dexametasone, Hidratation), she goes on with homeopathic treatment.

 

* February 1st., 2003    - CHEMOTHERAPY (Vincristine 0,7 mg.), she goes on with Homeopathic treatment. Hemograme post-hospitalisation HGB 10.30 g/dl, PLT 324 K/ul. Without collateral effects. It was only detected in the girl some difficulty to talk, words stick to her, it seems as if it is an effect of the VINCRISTINE.

 

* February 8th., 2003    - CHEMOTHERAPY (Vincristine 0,7 mg.), she goes on with Homeopathic treatment. Without collateral effects, her weight was checked observing an increase of almost two kilograms since her last control, before the December’s hospitalisation.

 

*February 15th., 2003   - CHEMOTHERAPY (Adriablastine- Razoxane-Ondansetron-Dexametasone-Vincristine 0,7 mg- Hidratation). She goes on with Homeopathic treatment, without collateral effects.

 

*February 24th., 2003   - CHEMOTHERAPY (Etoposide, Ciclofosfamide, Ondansetron, Dexametasone, Hidratation). She goes on with Homeopathic treatment, without collateral effects.

 

*February 25th., 2003   - CHEMOTHERAPY (Etoposide, Ciclofosfamide, Ondansetron, Dexametasone, Hidratation). She presented some sickness with vomit and discourage. She goes on with Homeopathic treatment.

 

*February 26th., 2003   - CHEMOTHERAPY (Etoposide, Ciclofosfamide, Ondansetron, Dexametasone, Hidratation). Collateral effects disappear, good mood, good appetite, she goes on with Homeopathic treatment.

 

*February 27th., 2003   - CHEMOTHERAPY (Etoposide, Ondansetron, Dexametasone, Hidratation). Without collateral effects, good mood, good appetite, she goes on with Homeopathic treatment.

 

*February 28th., 2003   - CHEMOTHERAPY (Etoposide, Ondansetron, Dexametasone,

 


HYGIENIC-DIETETIC RECOMMENDATIONS - Special for patients being treated with GREEN SAP:

 

GREEN SAP medical adviser team makes the following hygienic-dietetic recommendations addressed to the patients, applying them obviously to each pathology, state of health and nutritional state of each patient.

 

What follows is an hygienic-dietetic guide-line for patients with intestinal fuction conserved, without any other complication, as they need other recommendations.

  • Maintain a reasonable corporal weight (it can be evaluated following the corporal mass index, relative weight measure which is calculated by dividing the weight in kilogrammes by the square of the height in metres, it must be between 18.5 and 25 kgm2).
  • Make quick walks one hour per day or similar exercise, adecuating it to his/her performance status.
  • Choose diets predominantely based on vegetables (fruit and vegetables), legumen, and minimum refined food.
  • Receive daily 400-800 grammes (5 or more varied vegetable and fruit portions) through the whole year.
  • Receive daily 600-800 grammes (more than 7 portions of cereals, legumes, roots and tubercules). Choose minimum processed food. Limit the consumption of refined sugar.
  • Limit the consumption of alcoholic beverages (no more than two glassed per day).
  • Limit the consumption of red meet, to one portion of less than 80 grammes per day.
  • Limit the consumption of fat food (specially those of animal origin).
  • Limit the consumption of salt, and salty food.
  • It is recommended not to take elaborated  B Vitamin tablets, injectables or any other medicinal presentation. For its potential negative effect it can have on the neoplasie. What doesn’t mean it isn’t possible to take the B Vitamin which is contained in natural food, which can be taken without fear.

 

GUIDING DIET

 

Breakfast and tea: Each time light tea with two spoonful of sugar. Two cookies or 10 buiscuits. Two thin slices of fatless cheese.

Lunch and dinner: Each time chicken breast without skin or fatless red meat filet, a small dish of common white rice, or corn floor. Two grated or baked apples, peeled.

Intakes between foods: Two slices of fatless ham or two cookies or its equivalent. Three baked meringues. If you feel hungry you can add a portion of gelly.

Mineral water without gas used separated from the food (though you can have lunch or dinner with a small glass).

 

ESOPHAGUS CANCER

 

Fractioned diet, soft (creams, gellies, ice-creams, mashed food, blended).

Small quantity and frequent intake (6 times per day).

Chew well, eat slowly.

Drink water with food.

Elevate the upper and back part of the bed while resting so as to avoid stomach-esophagic reflux.

Avoid tobacco-stress, hot liquids (tea, coffe, mate).


 

STOMACH CANCER

 

Frequent food, small quantity (creams, gellies, ice-creams, white meat whitout skin, garlic, up to 80 grammes of non smoked red meat).

Avoid stimulants (caffeine, tobacco, alcohol).

Drink liquids between food, not during them different to esophagus.

Eat slowly, trying the diet to be soft.

 

LIVER-GALL AND PANCREATIC CANCER

 

Inform the patient that the gall increase can produce diarrheas.

For this reason they must be excluded or strictly reduced at the beginning and reincorporated in times to be defined due to evolution the potent stimulating motility and/or secretion factors such as fat, lactose, big volumes, insoluble fibre, cold liquids, hyper-osmolar solutions, (mono and di-sacarid excess). Also exclude at the beginning coffe, mate, and other strong infusions (alcohol, spicy seasoning, acid food).

Fats are restricted up to 20% of the total calories or less than 20% with steatorrea or high caloric value. Lactose is discarded and afterwards is reincorporated diluted following situation and previous routine.

The intake of food must be fractioned in 6 or more intakes of small amount, it is reduced the total quantity of fibre, preferring pectine; they are modified by cooking and mechanic methods (smash, blend, grate). Sacarose’s use must be controlled and irritants and cold preparations are contraindicated.

Plenty of water must be consumed during the day, avoid its use during the food, allow the loss of gas and don’t consume it cold, add salt in normal quantities. All food will be fatless. The allowed food will be amplifying, incorporating only one each time and observing if it makes any inadequated effect. You will take into account the number and characteristic of depositions to help to decide if the regime can be amplified. All vegetables will be used without skini and seed, and prepared in a way that their fibre may be “softened”. Control sugars and sweets.

 

ANAL CANCER

 

Avoid constipation.

Increased fibre, it is advised to add to the normal intake (10 grammes-1000 kcal.) an extra amount of up to 20 grammes. This intake is achieved only by using supplements or additioned food, less quantities can improve the situation if the mean a sensible increase in relation to the previous intake. Anyway the increase is performed gradually to guarantee the intestinal adaptation, it is promoted the inclusion of insoluble fibre to increase the fecal mass moreover the soluble fibre also improves in the same way as it is used by the bacterian flora.

Increased liquids, two to three litres per day added to what usually is consumed in the natural composition of the main food. It can be chosen water of fruit juices, eventually mate or another infusions. It is preferred sugarless, cold temperature, to stimulate peristaltism, and without gas to avoid distension for excessive use.

Natural lubricants, oil and honey promote the fecal mass to slip, if the nutritional state is normal, it is advised to increase the total fat up to 30% of the caloric value and include honey as part of the simple sugars allowed.

Probiotic addinGREEN SAP, for replacement of the bacterian flora, yogurs are indicated preferably bio-yogur resistant to the stomach ph.

Increase the organic acid, contained in the majority of fruits and vegetables.

Food distribution, it is advised 4 basic foods and 2 minor ones, promoting the adding of a minor food in fast, which stimulates the stomach-duoden-yeyuno-colonic reflex. Choose a preparation of maximum stimulation such as cold fruit juices adding honey or boiled or natural fruit.

 

COLON AND RECTUM CANCER

 

Avoid certain foods and beverages which have gas and their effect is to distend theh abdomen and produce flatulency.

Chew correctly the aliments as well as swallow well.

The intakes must be received in fixed time schedules, feed slowly.

It is recommended to take skinless chicken, baked fish, garlic, minimum red meat.

Avoid food which produce fermentation such as legumes, vegetables in excess, etc.

Some medicaments’ absorption can be altered.

Avoid excess of weight.

In right colostomies, or transverse nearby duoden, avoid raw or pasty vegetables, whole bread, stimulant beverages.

Some people tolerate badly milk, or fruit juices.

Preferred food: water without gas, rice, vermicelli, grout, fatless ham, fresh cheese without fermentation, peeled fruit. Fatless milk and yoghourts. Green cooked legumes.

Avoid stimulant gas beverages, cereals, sausages, pate, fat cheese (goat’s), dry fruits and laxants (altogether). Plain milk, legumes rich in fibre.

 

BRONCHO-LUNG CANCER

 

It is recommended to drink plenty of liquid without gas (at least 2 litres), white meat (chicken, fatless fish), up to 80 grammes of red meat.

Eat fruit, cooked vegetables and tubercules as wanted.

If it is possible, intake of garlic.

Two spoonful of honey per day.

Don’t take alcoholic drinks.

Don’t eat fried food.

Try to perfom respiratory exercises to improve blood oxygenation.

 

BREAST CANCER

 

Similar diet to normal, or healthy.

As a recommendation, minimum intake of red meat on the frying pan with the less quantity of oil as possible.

EgGREEN SAP intake, preferably cooked, not fried.

Consume at least one litre of fatless milk per day.

Drink at least two litres of water without gas per day.

Eat raw fresh fruit, vegetables, and tubercules as wanted.

 

 

CENTRAL NERVOUS SYSTEM CANCER

 

It is recommended to intake liquids without gas.

Food: cooked vegetables, fresh fruit, gellies, iced creams, if there is good swallowing. White fatless meat (chicken, fish) 250 grammes per intake. Minimum of red meat, preferably cooked, one 150 grammes portion per week. Eat garlic following tolerance. Don’t use very refined sugar as edulcorant.

Saltless diet. Season food with lemmon.

Cereals at least two portions per day.


 

KIDNEY, BLADDER AND PROSTATE CANCER

 

Plenty consumption of liquids (3 litres per day).

Eliminate alcohol, coffe, tea and other irritants.

Fresh fruit and vegetables as wanted.

At least 125 grammes cereals per day.

Eat garlic if possible.

White fatless meat, red meat up to 80 grammes.


 

BIBLIOGRAFIA:

 

 

(1) De Oliveira SQ, Dal-Pizzol F, Gosmann G, Guillaume D, Moreira JC, Schenkel EP. 
 
Antioxidant activity of Baccharis articulate extracts: isolation of a new compound with antioxidant  activity.  Free Radic Res. 2003 May;37(5):555-9.

 

(2) Zanon SM, Ceriatti FS, Rovera M, Sabini LJ, Ramos BA. Search for antiviral activity of certain medicinal plants from Cordoba, Argentina. Rev Latinoam Microbiol. 1999 Apr-Jun;41(2):59-62.

 

(3) Gamberini M., Skorupa L.A., Souccar C. & Lapa A., Inhibition of gastric secretion by a water extract from Baccharis triptera, Mart, Escola Paulista de Medicina Departamento de Farmacologia INFAR, Sao Paulo, Brasil, 1992.

(4) Palacios et al. 1986.

 

(5) Mongelli E. et al., 1997

 

(6) Desmarchelier C.& Ciccia G., 1998.

 

(7) Soicke H. & Leng Peschlow E., 1987.

 

(8) Arisawa M. et al., 1985; Jarbis B. et al., 1988; Mongelli E. et al., 1996.

 

(9) Simoes C. et al., 1986.

 

(10)  Steiner M, Priel I, Giat J, Levy J, Sharoni Y, Danilenko M.  Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Nutr Cancer. 2001;41(1-2):135-44.

 

(11) Offord EA, Mace K, Ruffieux C, Malnoe A, Pfeifer AM. Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis.
1995 Sep;16(9):2057-62.

 

(12) Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD, Conney AH. Inhibition of skin tumorigenesis by rosemary and its
constituents carnosol and ursolic acid.
Cancer Res. 1994 Feb 1;54(3):701-8.

 

(13) Galvez M, Martin-Cordero C, Lopez-Lazaro M, Cortes  F, Ayuso MJ.   Cytotoxic  Effect of Plantago spp. on cancer cell lines.J Ethnopharmacol. 2003 Oct;88(2-3):125-30.

 

(14) Hiang LC, Chiang W, Chang MY, Lin CC. In vitro cytotoxic, antiviral and immunomodulatory effects of Plantago major and Plantago asiatica. Am J Chin Med.
2003;31(2):225-34.

 

(15) Lin LT, Liu LT, Chiang LC, Lin CC.  In vitro anti-hepatoma activity of fifteen natural medicines from Canada. Phytother Res. 2002 Aug;16(5):440-4.

 

(16) Ruffa MJ, Ferraro G, Wagner ML, Calcagno ML, Campos RH, Cavallaro L. Cytotoxic effect of Argentine medicinal plant  extracts on human hepatocellular carcinoma cell line. J Ethnopharmacol. 2002 Mar;79(3):335-9.

 

(17)  Gomez-Flores R, Calderon CL, Scheibel LW, Tamez-Guerra P, Rodriguez-Padilla C, Tamez-Guerra R, Weber RJ.  Immunoenhancing properties of Plantago
major leaf extract. Phytother Res. 2000 Dec;14(8):617-22.

 

(18) Ikawati Z, Wahyuono S, Maeyama K.  Screening of several Indonesian medicinal plants for their inhibitory effect on histamine release from RBL-2H3 cells. J Ethnopharmacol. 2001 May;75(2-3):249-56.

 

(19) Gomez-Flores R, Calderon CL, Scheibel LW, Tamez-Guerra P, Rodriguez-Padilla C, Tamez-Guerra R, Weber RJ.  Immunoenhancing properties of Plantago major leaf extract. Phytother Res. 2000 Dec;14(8):617-22.

 

(20) Lithander A. Intracellular fluid of waybread (Plantago major) as a prophylactic for mammary cancer in mice.Tumour Biol. 1992;13(3):138-41.

 

(21) Karpilovskaia ED, Gorban' GP, Pliss MB, Zakharenko LN, Gulich MP. [Inhibiting effect of the polyphenolic complex from Plantago major (plantastine) on the carcinogenic effect of  endogenously synthesized nitrosodimethylamine. Farmakol Toksikol. 1989 Jul-Aug;52(4):64-7. Russian.

 

(22) Chiang LC, Chiang W, Chang MY, Ng LT, Lin CC. Antiviral activity of Plantago major extracts and related compounds in vitro. Antiviral Res. 2002 Jul;55(1):53-62.

 

(23) Goodman y Gilman, 1991.

 

(24) Singletary K et al. 1991.

 

(25) Singletary K et al. 1997.

 

(26) Offord E. et al, 1997.

 

(27) Arizona, M. et al., 1985; Jorbis B. et al., 1988, Mangelli E. et al., 1996.

 

(28) Cremaschi et al, J. Neuroimmunol, 2000, 110: 57.

 

(29) Suolinna E. et al.: Quercetin, and artificial regulator of the high aerobic glycolisis of tumour cells. J. National Cancer Inst. 53: 1515-19 (1974).

 

(30) Ip C. and Ganther H.: Combination of blocking agents and suppressing agents in cancer prevention. Carcinogenesis. 12: 1193-96 (1991).